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Abstract 
 
Joshua A. Harrill 
 
Effect of Pyrethroid Insecticides on Gene Expression in the Mammalian Central Nervous 
System 
 
(Under the direction of Kevin M. Crofton, Ph.D.) 
 
 Pyrethroids interfere with nervous system function by increasing neuronal 
excitability.  Increased excitability underlies the toxicity observed at the whole organism 
level following an acute pyrethroid exposure.  However, changes in neuronal excitability also 
trigger de novo gene expression which may impact neuronal function.  This aspect of 
pyrethroid toxicity has not been extensively examined.  The present studies test the 
hypothesis that in vivo pyrethroid exposures, at doses surrounding the threshold for 
neurobehavioral effects, result in changes in gene expression in the rat cortex.  In the first 
aim, adult rats were orally dosed with deltamethrin (DLT: 0.3, 1, 3 mg/kg), permethrin 
(PERM: 1, 10, 100 mg/kg) or vehicle.  Frontal cortex was collected at 6 hr and global 
transcriptional profiles were generated.  Dose-dependent changes in gene expression were 
identified using penalized linear and isotonic regressions.  A set of altered transcripts were 
then confirmed by qRT-PCR.  In addition, rats were dosed with either DLT (3 mg/kg), 
PERM (100 mg/kg) or vehicle and cortical tissue collected at 1,3,6 and 9 hr.  Expression of 
transcripts examined by qRT-PCR in the dose-response studies were investigated in this time 
course cohort.  Functional category analysis identified ‘branching morphogenesis’ as a 
biological process potentially sensitive to pyrethroids.  This prediction was confirmed in an 
 iii 
in vitro model of neuronal morphogenesis.  The time course of expression for Camk1g was 
further examined by qRT-PCR and Western blot.  Expression of the Camk1g1 mRNA splice 
variant changed in response to pyrethroids with no detectable change in Camk1g1 protein.  
The second aim determined if Type I and Type II pyrethroids produce similar effects on gene 
transcription in the cortex.  Rats were dosed with vehicle or either a Type I or Type II 
pyrethroid at doses that produce the same effect on an apical behavior.  Cortex was sampled 
at 3 and 6 hr and global transcriptional profiles were generated.  Qualitatively similar but 
quantitatively different patterns of expression between Type I and Type II pyrethroids were 
observed that is consistent with increases in neuronal excitability.  These data contribute to a 
comprehensive mode-of-action model for pyrethroids. 
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 2 
I. Overview 
 
 Pyrethroids are neurotoxicants that disrupt nervous system function by interacting 
with membrane bound ion channels in neuronal plasma membranes.   Pyrethroid induced 
alterations in ion channel function result in changes in neuronal firing patterns.  These altered 
firing patterns underlie the acute symptoms of pyrethroid intoxication observed in vivo.  At 
the molecular level, changes in the frequency or pattern of neuronal firing results in 
transcriptional induction or repression of activity-regulated genes.  Changes in the expression 
of activity-regulated genes are an immediate response of neurons to excitatory or inhibitory 
stimuli and may lead to adaptive changes in the form or function of mature and developing 
neurons.  Transient changes in gene expression can result in longer-lasting alterations in 
neuronal function that persist even when the excitatory stimulus (such as pharmacological 
excitotoxicants, i.e. a pyrethroid) is eliminated from the target tissue.  To date, there is a 
paucity of data concerning alterations in gene expression and adaptive changes in neuronal 
form or function that occur downstream of the pharmacological action of pyrethroids at the 
neuronal membrane.   
 The present research was designed to test the hypothesis that in vivo pyrethroid 
exposures alter activity-regulated gene expression in neurons of the central nervous 
system.  There were two specific aims in this research project.   Specific Aim 1 determined 
whether gene transcription in the rat cortex is affected by pyrethroids in vivo, at doses 
that do not produce profound symptoms of pyrethroid poisoning. The goals of this 
specific aim included: 1) identifying genes that are transcriptionally induced or repressed by 
acute pyrethroid exposure, 2) characterization of the time course of gene expression 
following acute exposures, and 3) comparison of the similarities and differences in dose-
 3 
dependent gene expression patterns between a model Type I and Type II pyrethroid.  A 
corollary hypothesis that pyrethroid exposures result in alterations in neuronal 
morphogenesis was also tested in light of the findings from the first phase of 
experimentation.  Furthermore, a gene candidate believed to be driven by the 
pharmacological actions of pyrethroids at the neuronal membrane and linked to pyrethroid 
effects on neurite branching morphogenesis was further examined in the second chapter of 
this work.  Specific Aim 2 tested whether acute exposure to equipotent doses of multiple 
Type I and Type II pyrethroids in vivo resulted in similar alterations in gene expression 
patterns: i.e., is there a structure-activity relationship for the transcriptional effects of 
pyrethroids? The goals under this specific aim included:  1) identification of suites of up- 
and down-regulated genes for each of six pyrethroids tested in an acute time course model, 2) 
cross compound enrichment analysis and qRT-PCR analysis of genes altered by the 
individual pyrethroids, and 3) exploration of gene networks commonly affected by the 
pyrethroid test panel.   
The present data contribute to the development of a comprehensive mode-of-action 
model for the pyrethroids and provide insight into an aspect of pyrethroid neurotoxicology 
that to date remain poorly characterized. 
II. Pyrethroid usage 
 
 Pyrethroids are a class of insecticides used in both agricultural and domestic 
applications including crop protection, household pest control, public health (i.e. head louse 
treatment), protection of textiles and in the control of contagious disease vectors, such as 
mosquitoes (Heudorf & Angerer 2001; Yanez et al. 2002).  Usage of pyrethroids has 
increased in recent years due to the phase out of other insecticides such as organophosphates 
 4 
and organochlorines (Amweg et al. 2005).  Pyrethroids are now offered in a variety of 
commercial formulations available to ordinary consumers for use in the home.  It is now 
estimated that approximately 80-90% percent of households in the United States use 
pesticides with pyrethroids comprising a considerable percentage of total use (Whyatt et al. 
2003).   
 Increasing usage of pyrethroids, both in agricultural and domestic sectors, yields an 
increased likelihood of human exposure.  Pyrethroids and pyrethroid metabolites have been 
detected in the blood of pregnant urban mothers, the urine of pesticide applicators, 
agricultural soil run-off, residential carpet dust, and, perhaps most importantly, in wipe 
samples from child-care centers (Leng et al. 1997; Whyatt et al. 2003; Colt et al. 2004; 
Weston et al. 2004; Tulve et al. 2006).   The Food Quality Protection Act of 1996 mandates 
that the United States Environmental Protection Agency reexamine the established tolerances 
for various pesticide usages and, where necessary, consider the cumulative risk posed by 
exposure to multiple pesticides with same mechanism-of-action.  As result, a variety of 
research efforts have been focused on examining the molecular mechanisms of pyrethroid 
toxicity and addressing data gaps critical to the establishment of a comprehensive mode-of-
action model for these compounds (Soderlund et al. 2002). 
III. Pyrethroid toxicity 
 
 Pyrethroids are neurotoxicants that pharmacologically alter the function of voltage-
sensitive (and perhaps ligand-gated) ion channels located in the plasma membrane of neurons 
(Narahashi et al. 1996; Ray 2001; Soderlund et al. 2002).  Figure 1.1 outlines the 
hypothesized  mode-of-action for the acute effects of pyrethroids.  Classically, pyrethroids 
have been divided into two types, Type I and Type II, based on chemical structure (Figure 
 5 
1.2) and the acute poisoning syndromes observed in non-target species at near-lethal dose 
levels (Vijverberg and Van den Bercken 1990; Soderlund et al. 2002).  Structurally, 
pyrethroids are esters of cyclopropane carboxylic acids linked to aromatic alcohols through a 
central ester bond (Kaneko and Miyamoto 2001).  The difference in chemical structure 
between the two pyrethroid types is that Type II pyrethroids have an α-cyano group added to 
the alcohol moiety (Figure 1.2, arrow); Type I pyrethroids lack this group (Coats 1990).  At 
high doses, the signs of acute Type I pyrethroid poisoning in the rat progress from episodes 
of aggressive sparring behavior and increased sensitivity to external stimuli to fine tremors 
followed by whole body tremors and prostration.  This is known at the T-syndrome of 
pyrethroid poisoning.  Type II pyrethroids produce a CS-syndrome characterized by 
increased pawing and burrowing behavior followed by profuse salivation, course whole body 
tremor and a ‘sinuous writhing’ motion known as choreoathetosis (Verschoyle and Aldridge 
1980; Lawrence and Casida 1982).  Acute disruption of neuronal firing within the nervous 
system is the underlying cause of both the Type I and Type II poisoning syndromes 
(Soderlund et al. 2002; Ray and Fry 2006).  However, at this time the precise molecular 
mechanisms that underlie the divergent signs of poisoning across the two pyrethroid types 
are unknown.   
 Pharmacokinetic studies indicate that pyrethroids selectively partition into nervous 
system tissue from the blood due to their high lipophilicity (Ladowski 2002; Mirfazaelian et 
al. 2006).  Accumulation of target tissue concentrations following oral exposure is rapid: i.e. 
brain concentrations of deltamethrin peak ~3 hr and elimination half-lives of pyrethroids 
range from approximately 10 – 30 hr  (Ruzo et al. 1978; Anadon et al. 1991; Anadon et al. 
1996; Anadon et al. 2006; Mirfazaelian et al. 2006).  Metabolism of pyrethroids occurs via 
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oxidative cleavage of the central ester bond followed by hydroxylation of aromatic moieties 
(or vice versa) followed by phase II conjugation of hydroxylated products and elimination 
from the body (Soderlund et al. 2002).  Cleavage of the central ester bound is the critical 
event in the deactivation of pyrethroids.  Onset of the acute symptoms of pyrethroid 
poisoning correlate well with the accumulation of these compounds in nervous system tissue, 
and recover upon elimination of pyrethroid from the target tissues (Gray et al. 1980; Gray 
and Rickard 1982; Rickard and Brodie 1985; Kim et al. 2007).   
 There is no concrete evidence that pyrethroids produce significant toxicities apart 
from their actions in the nervous system.  Some pyrethroids have been shown to have 
genotoxic effects in in vitro carcinogenesis assays (Villarini et al. 1998; Naravaneni and 
Jamil 2005; Undeger and Basaran 2005; Patel et al. 2006).  However several two-year 
carcinogenicity studies in rats and mice provide little evidence of increased cancer incidence 
following chronic pyrethroid exposure (Parker et al. 1983; Cabral et al. 1990; Cabral and 
Galendo 1990).  The International Agency for Research in Cancer (IARC) has concluded that 
there is insufficient evidence to classify pyrethroids as carcinogens (IARC 1991a, 1991b, 
1991c).  Nerve degeneration or the development of gross lesions either in the central or 
peripheral nervous system was not reported in studies of chronic pyrethroid exposures, 
however pyrethroid effects on neuronal microstructure (i.e. dendritic branching, number of 
synaptic contacts, myelination, etc.,) have not been examined.   
 Early research in the 1970’s that characterized the T- and CS- syndromes was all 
conducted at extremely high (i.e. lethal) dose-levels.  At administered doses below those that 
induce frank signs of poisoning, pyrethroids affect a number of neurobehavioral endpoints.  
Reviews of these behavioral effects is available in Soderlund et al. (2002) and Wolansky and 
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Harrill (2008).  Much like the acute signs of pyrethroid poisoning, induction of these acute 
behavioral effects is rapid, occurring within minutes to hours following oral exposure.  
Currently, motor activity is the most extensively characterized behavioral endpoint affected 
by pyrethroids.  All pyrethroids, regardless of type, produce a decrease in ambulatory motor 
activity (Wolansky et al. 2006).  Motor activity is an apical behavior shown to be a reliable 
and sensitive endpoint for measuring the neurotoxicological effects of pyrethroids (Crofton 
and Reiter 1984; Crofton and Reiter 1988; Crofton et al. 1991; Wolansky et al. 2006; 
Wolansky and Harrill, 2008).  Administered doses required to reach the threshold for effects 
on motor activity range from ~0.5 to ~120 mg/kg (depending upon the compound) and are 
1.5 to 2 orders of magnitude less than reported LD50’s (Wolansky et al. 2006).  Effects on 
motor function (and other behavioral endpoints) following acute pyrethroid exposures are 
transient.  Full recovery to control performance levels is observed in a matter of hours 
following an acute dose (Crofton and Reiter 1984; Peele and Crofton 1987; McDaniel and 
Moser, 1993).   
 There is a paucity of data regarding repeated low-level pyrethroid exposures on 
neurobehavioral endpoints.  The available data argue both for and against the development of 
deficits in nervous system function and cognition.  A thirty day repeated exposure to 6 mg/kg 
cismethrin and 2 mg/kg deltamethrin did not detect any cumulative effects on ambulatory 
motor activity in adult rats (Crofton and Reiter 1984).  Likewise, Hornychova et al. (1995) 
did not detect any cumulative effects of supermethrin on learning and memory.  On the other 
hand, Glowa (1986) demonstrated that a repeated exposure to 3 mg/kg deltamethrin (once a 
day for ten days) reduces daily pre-exposure response rates in an operant responding task and 
that response rates fail to return to controls levels after cessation of repeated dosing.  
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Additional studies are needed to clarify the effects of repeated pyrethroid exposures on 
nervous system function and cognition. 
 The actions of pyrethroids at the nerve membrane likely produce biological responses 
secondary to the neurotoxic effects observed in acute behavioral tests, one of which likely 
being changes in gene expression.  In neurons, depolarizing excitatory stimuli activate 
intracellular signaling pathways that can trigger waves of de novo gene expression in the 
nucleus which can in turn lead to changes in the form or function of the cell (Bradley and 
Finkbeiner 2002; Clayton 2002; Adams and Dudek 2005).  Transcription-mediated changes 
in neuronal function in response to excitatory stimulus may be beneficial, such as the 
induction of late-phase long term potentiation, a molecular correlate of learning and memory 
(Adams and Dudek 2005).  In contrast, hyperexcitation of neuronal circuitry by a xenobiotic 
can lead to persistent detrimental effects on cell function as a result of de novo gene 
expression, such as during addiction to and withdrawal from drugs of abuse (Mohn et al. 
2004; Nestler 2005).  The acute behavioral effects of pyrethroids are driven by 
hyperexcitation of neuronal networks in the CNS.  However, very few studies have examined 
the response of neurons to acute or repeated low-level pyrethroid exposure in terms of altered 
gene expression and changes in downstream cellular functions.  The present experiments are 
designed to provide information on transcriptional events that occur in the brain in response 
to the acute pharmacological actions of pyrethroids at neuronal membranes in vivo.  An 
additional benefit of this work is insight into pyrethroid-induced gene expression changes 
that may, in turn, lead to changes in neuronal function.  An overview of the molecular 
mechanisms that control membrane excitability and gene expression in the adult nervous 
system is given below.  In addition, a detailed description of the molecular and cellular 
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effects of pyrethroids and hypotheses on how the pharmacological actions of pyrethroids may 
affect adaptive gene expression in neurons is provided. 
IV. Ion channel functions in the nervous system. 
IVa. Molecular mechanisms of neuronal firing and synaptic communication. 
 
In neurons, the rapid movements of Na+, K+ and Ca+2 ions across the plasma 
membrane are used to detect, integrate and transduce excitatory and inhibitory stimuli from 
post-synaptic regions of the dendritic arbor and cell soma to presynaptic axon terminals 
(McCormick 2003; Sheperd 2003a).  Differential concentrations of ions on opposite sides of 
the plasma membrane establish a membrane potential, which is the molecular basis of 
electrical excitability in neurons (McCormick 2003).  The propagation of changes in 
membrane potential (i.e. electrical activity) from the area of incoming dendritic synapses to 
outgoing axonal terminals is known as the action potential and is a key mechanism for 
intercellular communication in the nervous system (Sheperd 2003b).  Initiation of the action 
potential is controlled by the selective conductance of ions through post-synaptic ionotropic 
neurotransmitter receptors in the dendrite or cell soma.  Ion permeability through ionotropic 
receptors is increased by binding of their cognate neurotransmitters that are released from the 
pre-synaptic terminal of a neighboring neuron in response to an excitatory stimulus.  The 
result is either an excitatory (EPSP) or inhibitory (IPSP) post-synaptic membrane potential 
intracellularly localized to the activated receptor complex (Byrne 2003).  Two of the 
predominant ionotropic receptors present in neuronal networks of the cortex are excitatory 
glutamate receptors (both NMDA- and AMPA- subtypes) and inhibitory γ-amino butyric acid 
(GABAA) receptor, which produce EPSPs and IPSPs, respectively (Waxham 2003).  In the 
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dendritic tree of a single neuron, EPSPs and IPSPs are both temporally and spatially 
integrated to produce a change in the neuronal membrane potential (Sheperd 2003b).   
Changes in membrane potential in the positive direction that reach the threshold for 
action potential firing result in the opening of axonal voltage-sensitive sodium channels 
(VSSCs), thereby allowing Na+ to rapidly flow through the neuronal membrane and 
depolarize the cell.  As the cell becomes more depolarized, VSSCs deactivate (terminating 
Na+ conductance into the cell) and voltage-sensitive K+ channels (“delayed rectifier 
channels”) open.  K+ flows out of the cell to offset the net effect of Na+ ion movement on the 
membrane potential.  The action potential is propagated down the axon by clusters of 
voltage-sensitive Na+ and K+ channels sub-cellularly localized to patches of unmyelinated 
neuronal membrane (McCormick 2003).  Voltage-sensitive Ca+2 channels (VSSCs) found in 
the dendrites, soma and axon terminals of neurons also contribute to changes in membrane 
potential with different sub-types (L-, N- and P/Q) mediating divergent intracellular events 
secondary to the action potential (see next section).  When the action potential reaches the 
axon terminals, neurotransmitter filled intracellular vesicles fuse with the plasma membrane.  
This process is dependent upon the entry of Ca+2 into the cell cytoplasm via N-Type VSCCs 
(Schwarz 2003).  Neurotransmitters then diffuse across the synaptic cleft, interact with post-
synaptic receptors in neighboring cells and elicit responses such as increases in excitatory 
(glutamate) or inhibitory (GABA) tone in post-synaptic neurons or movement in innervated 
muscle cells (Deutch and Roth 2003).   
The rapid, transient increases in ionic conductance that control the membrane 
potential and trigger neurotransmitter release are the molecular basis for intercellular 
communication in the CNS, both between neighboring neurons and between neurons and 
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innervated tissues (McCormick 2003).  There is ample experimental evidence that pyrethroid 
insecticides interfere with the function of at least one key molecular mediator of this process, 
namely VSSCs.  There is limited evidence that Ca+2 and Cl- channels that contribute to the 
maintenance of the membrane potential are sensitive to pyrethroids (Narahashi et al. 1996; 
Soderlund et al. 2002; Ray et al. 2006). There is also evidence that pyrethroids may interfere 
with the mechanisms of neurotransmitter release independent of their actions on action 
potential firing.  All these effects likely contribute to the neurotoxic actions of pyrethroids.  
IVb.  Influence of neuronal activity on gene expression. 
 
 Electrical activity at the neuronal plasma membrane is not only a mechanism of rapid 
intercellular communication in the nervous system but also serves as the initiating event in a 
number of intracellular signaling cascades that control both transient and persistent responses 
of the neuron to excitatory and inhibitory stimuli (Finkbeiner and Greenberg 1998; Zhang 
and Poo 2001; Wong and Ghosh 2002).  A critical event mediating these adaptive responses 
is de novo gene expression.  Gene expression leads to increased translation of effector 
proteins which can then modulate cell function (Clayton 2000).  Gene transcription in the cell 
nucleus is coupled to changes in the function of membrane bound ion channels and 
neurotransmitter receptors through increases in the intracellular concentrations of second 
messenger molecules.  These second messengers activate or inhibit signaling transduction 
pathways that terminate in the cell nucleus and affect the activity of constitutively-expressed 
transcription factors (Schulman and Roberts 2003; Fields et al 2005).  A critical second 
messenger that activates such signal transduction pathways is Ca+2 (Schulman and Roberts 
2003).  Increases in intracellular Ca+2 concentrations ([Ca+2]i )can occur through a variety of 
mechanisms in response to changes in neuronal excitation.  These include opening of 
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voltage-sensitive Ca+2 channels (VSCC) during depolarization, activation of NMDA and 
AMPA-type glutamate receptors in response to pre-synaptic neurotransmitter release and 
activation of metabotropic glutamate receptors that increase intracellular inositol-1,4,5-
triphosphate (IP3) and trigger Ca+2 release from intracellular stores (Larea et al. 1997; 
Finkbeiner and Greenberg 1998; Verkratsky 2002; Wang et al. 2004).  Movement of Na+, K+ 
and Cl- ions across the plasma membrane regulate changes in the membrane potential which 
controls activation of VSCCs, the release of neurotransmitters and subsequent activation of 
second messenger systems.  Thus, even though these ions do not act directly to activate 
signaling cascades in the neuronal cytoplasm, they do influence the concentration of 
intracellular second messengers through electrical coupling of ion channels and 
neurotransmitter release systems. 
 Activity-dependent neuronal gene expression occurs regularly under normal 
physiological conditions in response to stimuli from the surrounding environment (Cancedda 
et al. 2003; Majdan and Shatz 2006; Tropea et al. 2006).  However, changes in the frequency, 
amplitude and type of neuronal stimulation differentially affect the activation pattern of 
intracellular second messenger systems and may result in unique patterns of gene expression.  
For example, the frequency and not the duration, of increases in [Ca+2]i controls the 
expression of the immediate-early transcription factor c-fos (Fields et al. 1997), some neural 
cell adhesion molecules (Itoh et al. 1997) and a variety of genes related to synaptic 
transmission, cell growth and motility (Xiang et al. 2007).   
 Given that alterations in neuronal firing patterns mediate the transcriptional 
expression of a variety of downstream effectors, it is reasonable to assume that 
pharmacological agents or toxicants that alter neuronal firing patterns and the excitability of 
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neuronal networks may, in turn, trigger alterations in gene expression.  This abnormal wave 
of gene expression could then result in a detrimental alteration in cellular microstructure or 
function.  As detailed below, pyrethroids interact with one (and perhaps more than one) type 
of membrane-bound ion channel that regulates neuronal firing patterns and excitability.  
Therefore, the pharmacological actions of pyrethroids may be capable of inducing alterations 
in cell function via the abnormal induction of activity-dependent genes.  The transcriptional 
response of nervous system tissue, downstream of the pharmacological interactions of 
pyrethroids at their molecular target sites, to date, has not been thoroughly explored. 
V.  Molecular targets of pyrethroids. 
Va.  Voltage-sensitive Na+ channels and pyrethroid effects on neuronal firing rates. 
 
 Voltage sensitive Na+ channels (VSSCs) are considered to be the principal molecular 
target of pyrethroids in both target and non-target species and are the most extensively 
characterized sites of pyrethroid action (Narahashi 2000; Soderlund and Knipple 2003).  As 
noted above, VSSCs open in response to changes in the neuronal membrane potential toward 
more positive values and deactivate as the neuron becomes depolarized.  Pyrethroids affect 
VSSC gating kinetics by slowing inactivation.  The result is increased conductance of Na+ 
through VSSCs during membrane depolarization, a time when unmodified VSSCs are 
normally impermeable to Na+ (Narahashi 2000).  This period of abnormal Na+ conductance 
is known as a Na+ tail current.  The effect of pyrethroids on Na+ currents was first examined 
in invertebrate and amphibian nerve preparations (Lund and Narahashi 1981; Vijverberg et 
al. 1982).  Further studies using heterologous expression systems (Choi and Soderlund 2006), 
NE-115 neuroblastoma cells (Chinn and Narahashi 1986) and primary cultures of rat dorsal 
root ganglia (Tatebayashi and Narahashi 1994), cerebellar Purkinje cells (Song and 
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Narahashi 1996) and hippocampal neurons (Motomura and Narahashi 2001) confirmed that 
pyrethroids induce prolonged Na+ tail currents in mammalian VSSCs.  In the mammalian 
CNS, seven VSSC isoforms (α-subunits) are expressed in complex overlapping patterns both 
with each other and with a variety of accessory proteins (β-subunits, Ogata and Ohishi 2002; 
Catterall 2003).  The sensitivity of different VSSC α-subunits to different pyrethroids may 
vary and the presence of β-subunits has been demonstrated to modify pyrethroid effects on 
Na+ conductance through the α-subunit channel protein (Smith & Soderlund 1998; Soderlund 
et al. 2002; Choi & Soderlund 2006).  A comprehensive characterization of the effects of 
different pyrethroids on VSSCs in the brain is not available.  However, the available data 
from different labs using a variety of cellular preparations indicate that the qualitative 
characteristics of VSSC modification are similar for all pyrethroids: i.e. persistent inward 
Na+ tail currents occur during the period of normal channel deactivation.  The duration of 
Na+ tail currents (defined as a time constant of decay, τ) are variable for different compounds 
within the pyrethroid class, sometimes dramatically so.  Typically, VSSC modification by 
Type I pyrethroids results in a Na+ tail current that lasts on the order of milliseconds while 
Type II pyrethroids produce Na+ tail currents that last on the order hundreds of milliseconds 
(Vijverberg and Van den Bercken 1990; Choi and Soderlund 2006).   
 The persistent Na+ tail currents produced by pyrethroids cause the membrane 
potential to be slightly more positive (i.e. closer to the threshold potential for neuronal firing) 
than what would be observed under normal physiological conditions.  A consequence of this 
perturbation is an increase in the frequency of neuronal depolarization in the form of 
repetitive firing of action potentials following an excitatory stimulus.  Multiple Type I and 
Type II pyrethroids have been shown to induce repetitive action potentials following a single 
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stimulus in the X. laevis peripheral nervous system (Vijverberg 1982) and invertebrate giant 
axons (Lund and Narahashi 1981, Lund and Narahashi 1982).  In mammals, repetitive firing 
of spinal and trigeminal reflex arcs as well as caudate nuclei of the brain has been observed 
in response to an excitatory stimulus (Ray 1980; Forshaw and Ray 1986).  In addition, 
neurons from a variety of brain regions have been shown to be sensitive to pyrethroids 
(Tatebayashi and Narahashi 1994; Song and Narahashi 1996a; 1996b; Motomura and 
Narahashi 2001; Ginsburg and Narahashi 2005; Meyer et al. 2007; Shafer et al. 2008).  It is 
likely that the acute manifestations of pyrethroid toxicity are the result of the summated 
effect of disrupted firing patterns at multiple neural substrates throughout the CNS.  
Hyperexcitation of these brain regions could also conceivably result in the induction of 
activity-regulated genes that affect downstream neuronal functions.  
 There is also evidence that the rate of spontaneous neuronal firing (action potentials 
that occur in the absence of stimulus) is also affected by pyrethroids.  Increased rates of 
spontaneous action potential firing have been observed in X. laevis lateral-line sense organs 
(Vijverberg and Van den Bercken 1990).  An increase in spontaneous firing is also observed 
in unstimulated hippocampal and cortical networks, in vitro (Meyer et al. 2007, Shafer – 
personal communication).  In contrast, in vitro studies by Meyer et al. (2007) and Shafer et 
al. (2008) observe decreases in the spontaneous firing rate of glutaminergic neuronal 
networks derived from the rat hippocampus, cerebrocortex and spinal cord when the 
influence of inhibitory GABAergic inputs is removed.   
The development of persistent Na+ tail currents and subsequent changes in neuronal 
firing patterns is the hypothesized molecular mechanism-of-action for acute pyrethroid 
toxicity (Figure 1.1).  As detailed above, neurons respond to increases in neuronal excitation 
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through the induction of de novo gene expression.  These gene expression changes in the 
adult brain are meant to augment the function of specifically activated neuronal circuits in 
response to a sensory stimulus (Watanabe et al. 1995; Singh et al. 1997; Hendry et al. 2003; 
Harwell et al. 2005).  Acute exposure to pyrethroids could result in non-specific, global 
hyperexcitability of neuronal circuits within the brain and result in the abnormal over-
expression of activity-dependent adaptive gene transcripts. 
While the role of changes in spontaneous firing patterns in the development of acute 
pyrethroid poisoning symptoms in adult animals is unknown, it is highly likely that changes 
in the spontaneous activity of neurons in the developing nervous system would lead to 
detrimental alterations in interneuronal connectivity and cell function.  Early in development, 
neurons rely on spontaneous electrical activity to mediate the outgrowth of neuronal 
processes and the formation of functional synapses (Wong and Ghosh 2002).  Pyrethroid-
induced disruption of spontaneous activity would likely have a detrimental effect on these 
developmental events.  It is difficult to predict the nature of these effects given the 
contradictory reports on spontaneous activity in developed neurons and an incomplete 
knowledge of how pyrethroids interact with developing neurons. 
Vb. Pyrethroid effects on voltage-sensitive Ca+2 channels.  
 
Pyrethroids have also been shown to interact with a number of voltage-sensitive Ca+2 
channel (VSCC) isoforms expressed in the nervous system, however pyrethroid mediated 
effects on these channels are not as well characterized as effects on VSSCs and remain 
controversial  (Shafer and Meyer 2004).  VSCC effects are observed in vitro at pyrethroid 
concentrations similar to those that produce effects on Na+ channel function (Symington et 
al. 2007a; 2007b).  Much like VSSCs, multiple isoforms of VSCCs are expressed in the 
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mammalian nervous system.  Different VSCC isoforms mediate different neuronal functions.  
Cav1.3 (L-Type) channels present on neuronal cell bodies and in dendrites mediate the 
neuronal membrane potential and are linked to downstream intracellular signaling cascades 
that mediate activity-regulated gene transcription.  Cav2.1 (P/Q-Type) and Cav2.2 (N-type) 
mediate neurotransmitter release of axon terminals and may also influence gene transcription.  
The function of Cav3.1-Cav3.3 (T-Type) channels is less well known but is thought to 
mediate oscillatory bursts in pace-maker cells of the thalamus (Catterall et al. 2005).  The 
pharmacological effects of only a small number of pyrethroids on VSCCs have been 
reported.  Hildebrand et al. (2004) demonstrated that allethrin (a Type I pyrethroid) inhibited 
Ca+2 currents through rat Cav1.3 (L-Type), Cav2.1 (P/Q-Type) and Cav3.1 (T-Type) VSCCs 
expressed in human embryonic kidney cells.  Hagiwara et al. (1988) also noted an inhibition 
of L- and T-Type VSCCs in cardiac node cells.  More recent studies (Symington and Clark 
2005; Symington and Clark 2007) have demonstrated that deltamethrin either inhibits or 
enhances Ca+2 influx through N-Type VSCCs depending on the phosphorylation state of the 
neuron.  Shafer and Meyer (2004) have criticized this body of research and suggest a number 
of serious limitations, including: only in vitro observations, lack of concentration-response 
relationships, the use of indirect measures of VSCC function, and contradictory results from 
different laboratories/preparations.  The role of VSCCs in pyrethroid toxicity is clearly 
controversial at this time. 
As neurotransmitter release is dependent upon entry of Ca+2 into the neuron, indirect 
evaluations of VSCC function can be made based on studies of pyrethroid-induced 
neurotransmitter release.  Previous reports using a variety of experimental models 
consistently demonstrate that neurotransmitter release is increased in the presence of 
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pyrethroids.  Studies using synaptosomal preparations demonstrated increased 
neurotransmitter release in the presence of pyrethroids following a depolarizing stimulus (for 
review, see Shafer & Meyer 2004).  These studies, however, did not examine the 
mechanisms of increased neurotransmitter release.  More recent work (Symington and Clark 
2005; Symington et al. 2007) also report increased Ca+2 entry into, and NT-release from, 
synaptosomes treated with deltamethrin.  These effects on neurotransmitter release were 
abolished in the presence of ω-conotoxin MVIIC, a Cav2.2 (N-type VSCC) channel blocker, 
indicating that this channel mediated the effect.  However, in these same studies the Type I 
pyrethroid cismethrin also caused increased internal Ca+2 concentrations, with no effects on 
neurotransmitter release.  The authors attribute this observation to differences in the route of 
Ca+2 entry into the synaptosomes enhanced by the two compounds   These observations 
suggest that the effects of different pyrethroids on Ca+2 entry may not be equivalent.   
Pyrethroids have also been shown to have heterogeneous effects on neurotransmitter 
release in vivo.  A series of microdialysis studies sampled the extracellular milieu of various 
brain regions of conscious rats treated with a variety of pyrethroids and demonstrates that: 1) 
different pyrethroids produce non-homologous increases or decreases in neurotransmitter-
release, 2) pyrethroid-mediated effects on neurotransmitter release differ depending on brain 
region and type of neurotransmitter, 3) dose-dependent, biphasic effects on  neurotransmitter 
release may occur and 4) some high dose effects on neurotransmitter release are eliminated 
by treatment with VSCC antagonists independent of pyrethroid actions at sodium channels 
(Hossain et al. 2004; Hossain et al. 2006; Hossain et al. 2008).  Finally, Meyer and Shafer 
(2006) have reported that permethrin (a Type I pyrethroid) and not deltamethrin (a Type II 
pyrethroid) caused increases in neurotransmitter release independent of pyrethroid actions at 
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VSSCs in cultured hippocampal neurons.  In total, these observations indicate that 
neurotransmitter release is sensitive to pyrethroids.  However, the specific effects of different 
pyrethroids on VSCCs and neurotransmitter release are difficult to predict, may differ 
between compounds, and may result in divergent patterns of activity-dependent gene 
expression between pyrethroids following an acute exposure in vivo. 
Vc. Pyrethroid effects on voltage-sensitive Cl- channels. 
 
 The role of voltage-sensitive Cl- channels in the toxicity of pyrethroids is not well 
understood.  A decrease in the probability of opening of a Cl- permeable, Ca+2-independent 
voltage-sensitive anion channel has been reported for several Type II pyrethroids in NE-115 
neuroblastoma cells (Burrr and Ray 2004).  Entry of Cl- into neurons through a voltage-
sensitive anion channel could antagonize the effect of prolonged Na+ entry (through VSSCs) 
on the membrane potential.  Therefore, inhibition of Cl- conductance by pyrethroids would 
enhance VSSC-mediated pyrethroid effects on membrane excitability.  Type II pyrethroid 
actions at this channel occur in vitro at concentrations comparable to those that produce 
effects on VSSC function (Ray and Fry 2006)  However, the molecular composition, 
physiological properties and in vivo expression patterns of the pyrethroid sensitive anion 
channel identified in NE-115 cells has not been fully characterized.  Therefore, the relevance 
of pyrethroid effects at this molecular target in vivo is yet to be established.  There are no 
known instances where Cl- acts directly as a second messenger in the neuronal cytoplasm.  It 
is unlikely that Cl- entry into neurons directly activates signaling networks that control gene 
expression.  However, Cl- entry may antagonize activity-dependent gene expression by 
maintaining the membrane potential at values lower than those needed to induce entry of 
Ca+2 into the cell through voltage-sensitive Ca+2 channels.  Antagonizing Cl- entry, in turn, 
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could lead to increased activation Ca+2-dependent signaling networks that control activity-
dependent gene expression. 
Vd. Pyrethroid effects on GABAergic receptors. 
 
 A possible role for a direct effect of pyrethroids on GABAA receptors has been 
vigorously investigated over the past 30 years.  Inhibitory GABAergic interneurons are 
expressed throughout the mammalian cerebrocortex (Hof et al. 2003).  These interneurons 
have synaptic contacts on the dendrites and cell soma of excitatory glutaminergic pyramidal 
neurons in the cortex.  The neurotransmitter γ-amino butyric acid (GABA) is released from 
presynaptic terminals of interneurons, diffuses across the synaptic cleft, binds to postsynaptic 
GABAA receptors and triggers Cl- entry into the postsynaptic neuron.  This leads to 
hyperpolarization of the postsynaptic neuron and an overall decrease in neuronal excitability.   
 Radioligand binding experiments have demonstrated that Type II pyrethroids displace 
[35S]TBPS from the picrotoxin binding site of GABAA receptors in vitro (Lawrence and 
Casida, 1983; Lawrence et al. 1985; Crofton et al. 1987; Lummis et al. 1987; Olsen et al. 
1989).  Type I pyrethroids do not display this activity (Crofton et al. 1987).  Displacement of 
GABAA receptor ligands by Type II pyrethroids occurs at concentrations much higher (> 3 
orders of magnitude) than those required to produce effects on VSSC-mediated Na+ currents 
and actual blockade of Cl- influx was observed at even higher concentrations (Lawrence et al. 
1985; Abalis 1986; Ray and Fry 2006).  In contrast, some studies did not detect any 
modification of GABAA-mediated chloride conductance in the presence of Type II 
pyrethroids (Ogata et al. 1988).  An argument against GABAA receptor antagonism as a 
mechanism of pyrethroid toxicity in vivo is demonstrated by the studies of Gilbert et al. 
(1989), Joy et al. (1990) and Joy and Albertson (1991).  These studies did not detect any 
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pyrethroid-mediated modulation of GABAA function in a pair-pulsed stimulus paradigm at 
high doses, but in fact observed the opposite of the predicted effect (i.e., reduced inhibition 
of neuronal activity) for only some high doses of the pyrethroids tested.  All of these data 
indicate that an alteration in GABAA receptor function by pyrethroids does not occur at tissue 
concentrations comparable to those that produce effects on VSSC function.  However, they 
do not exclude the possibility that antagonism (or agonism) of GABAA receptor function 
occurs at high administered doses of pyrethroids and contributes the divergent poisoning 
symptoms produced by the two different pyrethroid classes (Crofton and Reiter 1987).  
Given these findings, it is equally unlikely that a direct pharmacological action of pyrethroids 
at the GABAA receptor complex would contribute to alterations in activity-dependent gene 
expression patterns in vivo at administered doses that do not cause profound signs of 
pyrethroid poisoning. 
VI. Pyrethroid effects on gene expression. 
 
As noted above, modulation of VSSC or VSCC function and neurotransmitter release 
by pyrethroids provides several mechanisms whereby these compounds may influence 
activity-regulated gene expression in a neuron.  Based on the pharmacological actions of 
pyrethroids, it can be hypothesized that these compounds cause changes in activity-regulated 
gene expression by altering the intracellular concentration of second messengers (i.e. Ca+2) 
that initiate and mediate activity-regulated transcription in the nucleus.  This may occur via 
three distinct mechanisms.  First, pyrethroids may interact with a molecular target site, such 
as VSCCs, that directly controls the pattern and duration of transient intracellular Ca+2 
concentrations.  Second, pyrethroids may indirectly increase the intracellular levels of Ca+2 
by enhancing Na+ influx (or blocking Cl- influx), which depolarizes the membrane potential 
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and triggers activation of Ca+2 channels and Ca+2 entry.  Lastly, pyrethroids may increase 
neurotransmitter release by producing repetitive firing patterns in presynaptic neurons, 
thereby simulating or inhibiting the excitatory state of post-synaptic neurons and activating 
multiple intracellular second messenger systems via neurotransmitter receptor stimulation.  
Based on the available data, the concentrations required to pharmacologically alter the 
function of the VSSC, VSCC and Cl- channel types are very similar (Ray and Fry 2006).  
This means that all of the pharmacological actions may be occurring simultaneously in an 
integrated neuronal circuit affected by pyrethroids.   
This multitude of pharmacological actions, combined with the inherent complexity of 
intracellular signaling pathways known to control activity-regulated gene expression and an 
incomplete knowledge of the genes that may be affected by alterations in neuronal activity, 
make predictions regarding the effects of pyrethroids on gene expression and intracellular 
signaling extremely difficult.  An experimental approach that empirically identifies and 
characterizes the transcriptional response of the nervous system to pyrethroids in vivo serves 
as a starting point for the systematic examination the complex intracellular events affected by 
the integrated pharmacological actions of pyrethroids at the neuronal membrane.  The overall 
framework for this molecular approach is to define gene expression changes that occur in 
response to pyrethroids in vivo, validate these changes in an in vitro model of functioning 
neuronal networks, and use pharmacological tools and biochemical manipulations to 
determine which molecular actions of the pyrethroids are mediating the response.  The 
experiments conducted in the present study are designed to address the first component 
of this frame-work: i.e. the identification of activity-regulated gene expression changes 
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in vivo.  An additional benefit of this work is insight into potential changes in neuronal form 
or function that may occur downstream of pyrethroid effects on neuronal activity. 
 Previous research provides limited evidence that acute pyrethroid exposure alters the 
expression of some genes in the central nervous system. Hassouna et al. (1996) observed 
increases in c-fos and JunB immunoreactivity in multiple brain regions of Sprague-Dawley 
rats several hours after a single i.p. treatment with either permethrin or cypermethrin.  In 
addition, Imamura et al. (2006) reported increased expression of brain-derived neurotrophic 
factor (Bdnf) in the cortex of rats acutely exposed to deltamethrin.  Bdnf, c-fos and JunB are 
all immediate early genes (IEGs) whose expression is known to correlate with excitatory 
activation of neuronal circuits (Herdegen and Leah 1998; Fukuchi et al. 2005).  Together, 
these data provide evidence that one of the responses of nervous system tissue in vivo to 
pyrethroid exposure is an upregulation in the expression of genes controled by neuronal 
activity.   
 In addition, changes in the expression of neurotransmitter synthesis and transport 
machinery have been observed following pyrethroid exposure.  Studies by Gillette et al. 
(2003) and Elwan et al. (2006) report an upregulation of the striatal dopamine transporter 
following repeated i.p. exposure to permethrin and deltamethrin.  In the Elwan et al. (2006) 
study increased expression was coupled with increased transporter activity.  Furthermore, Liu 
et al. (2006) report decreases in tyrosine hydroxylase, the penultimate enzyme in 
monoaminergic NT synthesis, following ten days of deltamethrin exposure.  This change in 
expression was coupled with a decrease in dopamine content.  The relationship of these gene 
expression changes to pyrethroid-induced effects on neuronal firing is unknown.  However, 
these data demonstrate that gene expression changes in response to pyrethroids can lead to 
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persistent alterations in neuronal function.  Given these data, gene expression changes 
induced by pyrethroids should be included in a comprehensive mode-of-action model 
describing the toxicity of these compounds.  However, there is currently a lack of data 
concerning this aspect of pyrethroid neurotoxicity. 
VII. Hypothesis and goals. 
 
 The present research was designed to test the hypothesis that in vivo pyrethroid 
exposures result in changes in activity-regulated gene expression in neurons of the 
central nervous system.  There were two specific aims in this research project.   Specific 
Aim 1 determined whether gene transcription in the rat cortex is affected by 
pyrethroids in vivo, at doses that do not produce profound symptoms of pyrethroid 
poisoning. The goals of this specific aim included: 1) identifying genes that are 
transcriptionally induced or repressed by acute pyrethroid exposure, 2) characterization of the 
time course of gene expression following acute exposures, and 3) comparison of the 
similarities and differences in dose-dependent gene expression patterns between a 
representative Type I and Type II pyrethroid.   
A corollary hypothesis that pyrethroid exposures result in alterations in neuronal 
morphogenesis was also tested in light of the findings from the first phase of 
experimentation.  Furthermore, a gene candidate believed to be driven by the 
pharmacological actions of pyrethroids at the neuronal membrane and linked to pyrethroid 
effects on neurite branching morphogenesis was further examined in the second chapter of 
this work.   
Specific Aim 2 tested whether acute exposure to equipotent doses of multiple 
Type I and Type II pyrethroids in vivo resulted in similar alterations in gene expression 
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patterns: i.e., is there a structure-activity relationship for the transcriptional effects of 
pyrethroids? The goals under this specific aim included:  1) identification of suites of up- 
and down-regulated genes for each of six pyrethroids tested in an acute time course model, 2) 
cross compound enrichment analysis and qRT-PCR analysis of genes altered by the 
individual pyrethroids, and 3) exploration of gene networks commonly affected by the 
pyrethroid test panel.   
The present data contribute to the development of a comprehensive mode-of-action 
model for the pyrethroids and provide insight into an aspect of pyrethroid neurotoxicology 
that to date remain poorly characterized. 
VIII. Experimental design.  
 
 Throughout the duration of this work an acute in vivo dosing paradigm was used to 
examine pyrethroid effects on gene expression.  The acute exposure model was selected for a 
variety of reasons.  First, the most extensively characterized, quantitative measures of 
pyrethroid toxicity are behaviors that have been examined using an acute dosing paradigm 
(see section 1 above and Wolansky et al. 2006).  The present studies use exactly the same 
dosing conditions (species, strain, sex, age, route, vehicle and delivery volume) as used in 
these evaluations of acute toxicity in order to provide a reliable dose-metric with which to 
compare equipotent doses of pyrethroids and neurotoxic effect thresholds.  In addition, 
extensive pharmacokinetic models for the test compounds used in the first chapter of this 
work (i.e. deltamethrin and permethrin) have been developed based in acute oral dosing 
studies (Mirfazaelian et al. 2006; Tornero-Velez et al. 2007).  Estimates of the time-to-peak 
tissue concentrations and elimination half-lives in the brain helped guide the selection of time 
points used in the in vivo portion of these studies.  Estimates of brain concentrations from 
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these models were also used to compare in vivo results to in vitro functional assays.  
Toxicological and pharmacokinetic profiles for sub-chronic or repeated dosing schedules 
with pyrethroids are not as extensively characterized as the acute dosing paradigms.  
Therefore, comparisons of relative potency or estimations of tissue dosimetry could not be 
made with a great deal of confidence if a repeated dosing schedule was used. 
 In the second chapter of this work high-throughput oligonucleotide microarrays are 
used for the identification of pyrethroid-sensitive genes and comparison of the global 
transcriptional responses of the rat frontal cortex between two “model” pyrethroids, 
deltamethrin (Type II) and permethrin (Type I).  The frontal cortex was selected as the tissue 
of interest as previous studies have demonstrated increases in activity-regulated gene 
transcripts and disruption of neuronal firing patterns in vivo in this region of the brain 
following acute pyrethroid exposure (Ray 1980; Hassouna et al. 1996; Wu and Liu 2003).  
Linear and isotonic regression models (Tusher et al. 2002; Hu et al. 2005) were used to 
identify dose-dependent gene expression changes and thresholds for effects.  For a select 
number of transcripts, gene expression changes are confirmed by qRT-PCR.  In addition, an 
in vitro growth assay is used to examine a potentially neurotoxic effect of pyrethroids on 
neuronal morphology that was identified during functional category level analysis of 
microarray data.  These in vitro data demonstrate that exposure to pyrethroids can stimulate 
abnormal changes in neuronal morphology, and also indicates that pyrethroids may act as 
developmental neurotoxicants.   
 Chapter Three focused on characterizing transcriptional and translational upregulation 
of Ca+2/calmodulin-dependent protein kinase 1-gamma (Camk1g) by pyrethroids. Camk1g 
was identified in Chapter Two as a reliable indicator of pyrethroid exposure.  Previous 
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studies in the literature indicated that this protein can mediate neuronal branching and growth 
and is transcriptionally regulated by changes in neuronal excitability.  Increased expression 
of Camk1g was identified and confirmed in the initial dose-response microarray study.  
Subsequent qRT-PCR analysis demonstrates that the Ca+2-sensitive splice variant of Camk1g 
(i.e. Camk1g1) is upregulated by pyrethroids whereas the Ca+2-insensitive splice variant of 
Camk1g (Camk1g2) is not.  These results support a role for Ca+2 in the acute toxicity of 
pyrethroids.    
Chapter Four expands upon the results of Chapter Two by comparing global gene 
expression profiles from the cortex of rats exposed to equipotent doses of either permethrin, 
bifenthrin or tefluthrin (Type I pyrethroids) or deltamethrin, cypermethrin or cyfluthrin (Type 
II compounds).  Equipotent doses were once again based on the results of Wolansky et al. 
(2006).  The LIMMA (Linear Models for Microarray Data) analysis method was used to 
detect treatment related changes in gene expression for each of the individual compounds 
(Smyth 2005).  Suites of altered transcripts for each individual compound were then tested 
for enrichment in the expression profiles of other pyrethroids in the test panel using the 
SAFE algorithm (Barry et al. 2005).  SAFE was also used to examine enrichment of GO 
categories and KEGG pathways in each compound in the test panel.  Finally Igenuity® 
pathway analysis was used to construct a gene regulatory network commonly affected by the 
Type II pyrethroids in the test panel.  Chapter Five summarizes the major findings, 
implications, and future directions of this work.  
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Figure 1.1.  Mode-of-action for the acute effects of pyrethroids.  The sequence outlined on 
the left of the figure corresponds to the sequential events leading from pyrethroid exposure to 
acute toxicity.  Following an administered dose of pyrethroids accumulation of a target tissue 
(i.e. brain) dose occurs and is controlled by absorption, distribution, metabolism and 
elimination rates intrinsic to the system.  In the target tissue, pyrethroids interact with a 
variety of voltage-sensitive ion channels, primarily voltage-sensitive sodium channels, which 
impact the membrane potential.  Under normal physiological conditions an excitatory 
stimulus results in the firing of a single action potential as a means of intracellular 
communication in the nervous system.  In presence of pyrethroids, a repetitive firing of the 
action potential is produced which leads to acute adverse effects at the behavioral level.  
These adverse effects range from mild effects on neurobehavioral endpoints such as 
ambulatory motor activity at low doses to profound signs of poisoning at high doses.  The 
right side of the figure lists data gaps in the comprehensive mode-of-action of pyrethroids.  
Changes in voltage-sensitive ion channel function and membrane excitability can lead to 
subsequent changes in gene expression and adaptive or adverse changes in cellular form or 
function.  To date, these types of effects have not been extensively characterized for 
pyrethroids. 
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Figure 1.2.  Examples of pyrethroid chemical structures. Chemical structures of the Type I 
pyrethroid permethrin (top) and the Type II pyrethroid deltamethrin (bottom).  A primary 
structural difference between the two types is the presence or absence of an α-cyano group 
on the alcohol moiety of the compound (arrow).  The two compounds are used in Chapters 2 
and 3 of the present work. 
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Abstract. 
 
 Pyrethroids are neurotoxic pesticides that interact with membrane bound ion channels 
in neurons and disrupt nerve function.  The purpose of this study was to characterize and 
explore changes in gene expression that occur in the nervous system subsequent to the 
pharmacological actions of pyrethroids at the neuronal membrane.  Rats were acutely 
exposed to either deltamethrin (0.3 – 3 mg/kg) or permethrin (1 – 100 mg/kg) followed by 
collection of cortical tissue at 6 hours.  The doses used range from those that cause minimal 
signs of intoxication in a behavioral test to doses well below apparent no effect levels.  
Affymetrix GeneChips® were used to obtain global gene expression profiles and detect 
changes in gene expression.  A group of dose-responsive transcripts were identified using 
penalized linear (SAM) and isotonic (PIR) regression methods.  A sub-set of these genes 
were confirmed by qRT-PCR.  A separate set of rats were used to characterize the time 
course of transcript expression. Both differences and similarities in the transcriptional 
response were observed when comparing permethrin and deltamethrin.  Changes in Camk1g, 
Ddc, Gpd3, c-fos and Egr1 mRNA levels were consistently observed across multiple test 
cohorts for both compounds.  In addition, Significance Analysis of Function and Expression 
(SAFE) identified significantly enriched gene categories common for both pyrethroids 
including some related to branching morphogenesis and intracellular Ca+2 signaling.  In vitro 
exposure of primary cortical cell cultures to both deltamethrin and permethrin resulted in an 
increase in the number of neurite branch points without effects on total neurite length.  The 
effects on neuronal branching and gene expression identified here may represent novel 
aspects of pyrethroid neurotoxicity. 
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Introduction. 
 
 Pyrethroid insecticides are structural analogs of pyrethrum, a natural constituent of 
extracts from flowers of Chrysanthemum cinerariaefolium.  Pyrethroids now represent a 
significant percentage of the world insecticide market (Amweg et al. 2005).  This usage 
results in an increased potential for human exposure.  Pyrethroid residues have been detected 
in sediments from agricultural run-off (Qin et al. 2006), residential dust samples (Colt et al. 
2004), child-care centers (Tulve et al. 2006) and pyrethroid metabolites have been detected in 
human urine (Leng et al. 1997).  A current focus in the field of pyrethroid research is 
examining the diverse neurotoxic mechanisms-of-action proposed for these compounds and 
determining if compounds belonging to this chemical class act through the same or similar 
mechanisms-of-action to produce similar adverse health outcomes (Soderlund et al. 2002). 
 Pyrethroids are neurotoxicants that disrupt nervous system function by interacting 
with membrane bound ion channels and altering their normal gating kinetics (Narahashi 
1996).  The primary molecular targets of pyrethroids are neuronal voltage-sensitive sodium 
channels (VSSCs, Catterall 1992; Ogata and Ohishi 2002).  Prolongation of whole-cell Na+ 
currents has been observed in a variety of cultured nervous system tissues exposed to 
pyrethroids (Song et al. 1996; Motomura and Narahashi 2001; Spencer et al. 2001; Ginsburg 
and Narahashi 2005).  Furthermore, in vitro studies utilizing heterologous expression systems 
have demonstrated that pyrethroids increase sodium current through some mammalian VSSC 
isoforms (Nav1.2, Nav1.4 & Nav1.8) although the complete complement of mammalian 
VSSCs have not been examined for pyrethroid sensitivity (Smith and Soderlund 1998; Choi 
and Soderlund 2005; Shafer et al. 2005).  Pyrethroids may also alter the gating kinetics of 
both neuronal voltage-sensitive Ca+2 (VGCCs, Shafer et al. 2005; Syminton and Clark 2005) 
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and voltage-sensitive Cl- channels (Burr and Ray 2004) at nominal concentrations similar to 
those that cause effects on VSSCs (Ray and Fry 2006).  Isoforms of all of the aforementioned 
molecular targets are expressed in the plasma membrane of mammalian neuronal cells.   
 Pyrethroids affect mammalian nervous system function by producing 
hyperexcitability in neurons and increasing neuronal firing rates (Ray 1980; Wright et al. 
1988; Vijverberg and van den Bercken 1990; Ray 2001).  The acute manifestations of 
neurotoxicity observed in mammals following pyrethroid exposure are driven by this 
increased neuronal hyperexcitability which is in turn a result of the pharmacological actions 
of pyrethroids at their molecular target sties, primarily VSSCs (Ray 2001).  Under normal 
conditions, neuronal membrane depolarization results in the activation of intracellular Ca+2-
dependent signaling pathways that control the induction of gene expression (Fields et al. 
2005).  In some cases, these transcriptional responses lead to persistent adaptive changes in 
cellular functions (i.e. neuronal plasticity; Bading 2000; McClung and Nestler 2008).  Some 
neuroactive chemicals that are known to alter neuronal firing patterns or disrupt 
neurotransmission can trigger the induction of unique groups of gene transcripts which may 
in turn impact neuronal function (Bahi and Dreyer 2005; Cai et al. 2006; Xiang et al. 2007).  
While alterations in neuronal excitability is considered a critical event in the toxiciological 
mechanism(s)-of-action for pyrethroids, to date, the impact of pyrethroid-induced neuronal 
hyperexcitability on intracellular signaling pathways and inducible gene-regulatory networks 
have not been extensively examined.   
 In the present study Affymetrix GeneChip® microarrays were used to characterize 
the global transcriptional response of mammalian nervous system tissue following an acute 
oral exposure to two model pyrethroids: permethrin and deltamethrin.  The dose ranges used 
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in this study include doses that cause minimal neurotoxic signs to doses well below apparent 
‘no effect’ levels in in vivo behavioral tests (Wolansky et al. 2006).  Low doses were used to 
minimize any potential transcriptional changes which may be due solely to excessive 
systemic toxicity at high pyrethroid doses.  The goals of this study were to: 1) identify 
significant dose-dependent alterations in gene transcription, 2) determine at what point 
significant alterations in gene transcription occur along the dose-effect curve for pyrethroids 
and 3) determine if any of the dose-responsive genes are components of biological processes 
that may be sensitive to pyrethroids based on the hypothesized neurotoxic mechanisms-of-
action for these compounds.  Penalized linear (Significant Analysis of Microarrays, SAM) 
and isotonic (PIR) regression models (Tusher et al. 2001; Hu et al. 2005) as well as 
Significant Analysis of Function and Expression (SAFE, Barry et al. 2005) were used, 
respectively, to: 1) identify dose-responsive alterations in gene transcription and 2) identify 
Gene Ontology categories (Harris et al. 2004) and canonical cellular signaling networks 
(Kanehisha et al. 2004) that may be altered by pyrethroids.  Alterations in transcript 
expression detected using microarrays were confirmed by qRT-PCR for a subset of 
pyrethroid-responsive genes.  In addition, the time course of expression was characterized for 
a limited number of dose-responsive transcripts by qRT-PCR.  Data from the in vivo gene 
expression studies lead to an investigation of pyrethroid effects on neuronal morphogenesis.  
Both permethrin and deltamethrin increased the number of branch points in a primary 
cortical cell culture with no effects on total neurite length or cell viability. 
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Methods. 
 
Chemicals.  Permethrin (3-phenoxybenzyl (1R,S)-cis-trans-3-(2,2-dichlorovinyl)-2,2-
dimethyl-cyclopropanecarboxylate, 92.0% purity, isomer composition: 40 % cis, 60 % trans, 
1:1 ratio of 1R & 1S) and deltamethrin ((S)-cyano-(3-phenoxyphenyl)methyl (1R)-cis-3-(2,2-
dibromovinyl)-2,2-dimethylcyclopropane carboxylate, 98.9 % purity, isomer composition: 
100% 1R, 3R, αS ) were generously donated by FMC Corporation (Philadelphia, PA) and 
Bayer Cropscience (Research Triangle Park, NC), respectively.  Pyrethroids were dissolved 
in corn oil (Sigma-Aldrich, St. Louis, MO) at 1, 10, 40 & 100 mg/mL permethrin and 0.3, 1 
& 3 mg/mL deltamethrin.  Dosing volume was 1mL/kg. 
 
Animal Care and Treatment.  Male Long-Evans rats (49-62 days of age) were obtained from 
Charles River Laboratories (Wilmington, MA) and housed two per cage in standard 
polycarbonate hanging cages (45 cm X 24 cm X 20 cm) with heat sterilized pine shavings for 
bedding (Beta Chips, Northeastern Products, Inc., Warrensburg, NY).  Animals were 
maintained on 12h:12h photoperiod (lighted hours: 06:00-18:00) and allowed a 5-7 day 
period of acclimation to the colony prior to dosing.  Colony rooms were maintained at 22.0 ± 
2.0°C with a relative humidity of 55 ± 20%.  Food (Purina 5001 Rat Chow) and tap water 
were provided ad libitum.  The facility was approved by the American Association for 
Accreditation of Laboratory Animal Care (AAALAC) and all experimental procedures were 
approved in advance by the by the US EPA, National Health and Environmental Effects 
Research Laboratory Animal Care and Use Committee.   
 Four cohorts of animals were used in this study (Table 2.1).  Cohort 1 was used for 
preliminary data collection to demonstrate that the selected doses of the two compounds 
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would alter gene transcription.  Cohort 2 replicated these findings and expanded group sizes.  
Cohorts 1 & 2 were combined for microarray data analyses.  Dose-response Cohort 3 was 
examined exclusively by quantitative real-time RT-PCR (qRT-PCR).  Individual dose-
response cohorts were exposed on separate days.  All dosing occurred between 06:30 and 
07:00 hours and the last test subject was euthanized before 18:00 hours.  Dosing and 
euthanasia times for individuals were counterbalanced across time of day.  Cohort 4 was used 
in qRT-PCR time course studies.  In the time course studies rats were treated via oral gavage 
with 3 mg/kg deltamethrin, 100 mg/kg permethrin or vehicle.  Each time point contained 
pyrethroid-treated and time-matched vehicle controls.  All test subjects were dosed and 
euthanized between 07:30 & 17:30 hours.  In every experimental cohort, test subjects were 
removed from the colony suite one hour prior to dosing and allowed to acclimate in a quiet 
holding room maintained under similar environmental conditions.  Subjects were 
administered a single oral dose of test compound by gavage (1 mL/kg delivery volume), and 
allowed to recover in their home cage prior to euthanasia at 6 hours (dose-response studies) 
or 1, 3, 6 or 9 hours (time course studies).  Subjects were then individually removed to an 
adjoining suite with a separate HVAC system for euthanasia by decapitation.  
 Whole brains were rapidly removed and placed on a cold plate (4°C).  The cerebral 
cortex was removed by making a vertical incision at the anterior edge of the optic tract with a 
stainless steel razor, and rapidly frozen on a bed of dry ice.  Cortical samples, without striatal 
tissue, were then bisected into contralateral hemispheres, weighed, frozen in liquid nitrogen 
and stored at -80°C. 
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RNA Extraction.  Cortical samples were homogenized in 1 mL of TRI Reagent (Molecular 
Research Center, Inc., Cincinnati, OH) per 50-100 mg of tissue using a Polytron® PT-K 
homogenizer (Kinematica, Lucerne, Switzerland) and total RNA was isolated per 
manufacturer’s instructions.  Total RNA pellets suspended in DEPC-treated H2O were then 
subject to DNase I treatment and re-extracted with acid:phenol chloroform, pH = 4.7 
(Ambion Inc., Austin, TX) and chloroform according to manufacturer’s protocol and re-
suspended in DEPC-treated H2O until use.  The total RNA concentration of each sample was 
determined (absorbance @ 260 nm) on a Beckman-Coulter DU® 800 spectrophotometer 
(Fullerton, CA) and adjusted to 1.0 µg/µL prior to sample storage at -80ºC.  The ratio of 
absorbance values at 260 nm and 280 nm (Ab 260/280) was used to assess purity of total 
RNA samples.  All samples used in these studies had Ab 260/280 ratios > 1.6 (data not 
shown).  Preliminary PCR experiments using primers for rat β-actin genomic DNA (outlined 
in Tully et al. 2006) demonstrated that the above protocol adequately prevents genomic DNA 
contamination of total RNA samples (data not shown).  In addition, the RNA integrity of 
each sample was determined using an Agilent 2100 Bioanalyzer and RNA 6000 Nano 
LabChip Kit (Waldbron, Germany) according to manufacturer’s instructions.  All samples 
used in microarray and qRT-PCR experiments had 18S:28S rRNA ratios > 1.6 (data not 
shown).  Following the RNA purity and integrity screens, aliquots of each total RNA sample 
(1 µg/µL for microarray hybridization or 25 ng/µL for qRT-PCR assays) were stored at -
80°C until use. 
 
Microarray design, sample preparation and data collection.  All protocols for microarray 
sample preparation (except total RNA extraction, as above), GeneChip® hybridization, array 
 47 
scanning and data collection were performed by Expression Analysis, Inc., (Durham, NC).  
Affymetrix Rat Genome 230 2.0 GeneChip® oligonucleotide microarrays (Santa Clara, CA) 
were used in this experiment.  These microarrays contain 31,042 probe sets that represent 
~28,000 unique Rattus norvegicus genes and expressed sequence tags (ESTs).  First and 
second strand cDNA synthesis, RNase H digestion and (ds)cDNA isolation for each sample 
were performed according to manufacturer’s protocol (Affymetrix 2004).   Synthesis and 
clean-up of biotin-labeled cRNA was performed using a BioArrayTM High YieldTM RNA 
transcript labeling kit (Enzo Life Sciences, Farmingdale, NY) and Qiagen RNeasy spin 
columns (Spoorstraat, Netherlands), respectively, according to manufacturer’s instructions.  
Biotin-labeled cRNA was fragmented using Affymetrix 5X fragmentation buffer (200mM 
Tris acetate pH=8.1, 100 mM KOAc, 150 mM MgOAc). 
 Fragmentation of biotin-labeled cRNA, GeneChip® hybridizations, washes and 
staining were performed according to standard Affymetrix protocols (Affymetrix 2004).  
Hybridizations were performed in an Affymetrix Hybridization Oven 640.  Washes were 
performed on an Affymetrix Fluidics Station 450 using the EukGE-WS2v4-450 fluidics 
script.  GeneChips® were scanned using an Affymetrix GeneChip® 3000 Scanner with the 
GCOS v1.2 software package.  Target intensity was set to a value of 500 with all other 
scanning parameters set at the factory defaults.  The 3`/5` ratios for GAPDH and β-actin 
internal controls genes ranged between 0.93 – 1.11 and 1.2 – 2.01, respectively, indicating 
that degradation of RNA did not occur during sample preparation for hybridization.   The 
intensity of hybridization controls (BioB, BioC, BioD and Cre) increased linearly on all 
arrays.  Gene expression profiles for this experiment have been archived in the NCBI Gene 
Expression Omnibus (GEO) repository with the series accession number GSE7955. 
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Microarray Data Analysis.  Two methods for the calculation of probe set expression 
summaries were compared: GeneChip® Operating Software v1.2 signal algorithm (GCOS, 
Affymetrix 2002) and Robust Multiarray Average (RMA, Irizarry et al. 2003).  RMA 
expression summaries were calculated using RMAExpress© v.4.7 (University of California 
at Berkeley).  RMA provided less within group variation in expression summary values as 
compared to GCOS v1.2, especially with probe sets with low fluorescent intensities (see 
Appendix A, Table 1).  This is consistent with previous comparisons of the two methods 
(Millenaar et al. 2006) RMA expression summaries were used for the remainder of 
microarray data analysis.  Microarray data from Cohorts 1 & 2 were combined for statistical 
analysis providing sample sizes of twelve for the control group and eight for each dose 
condition. 
 Analysis of dose-response relationships were performed using Significance Analysis 
of Microarrays (SAM, Tusher et al. 2001, version 2.21), with the quantitative/linear 
regression modeling component (SAM User’s Manual, Chu et al. 2005).  In addition to 
identifying dose-responsive genes, SAM provides permutation-based estimates of the false-
discovery rate (FDR) associated with lists of genes for which the null hypothesis is rejected.  
The SAM statistic (di) penalizes lowly expressed genes, and is most powerful when the dose-
response function is nearly linear in the range examined.  To potentially increase power and 
account for non-linearity in dose-response relationships, the SAM analyses were 
supplemented by penalized isotonic regression (PIR) according to the method of (Hu et al. 
2005) which was specifically designed for microarray analysis.  Similar to SAM, PIR 
penalizes lowly expressed genes and provides a permutation-based estimate of the false 
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discovery rate.  In contrast to SAM, PIR allows for the dose-response relationship to be 
nonlinear, but assumes the relationship is increasing or decreasing as a function of increasing 
dose, and not the reverse direction.  This method results in a score (the M-statistic) for each 
probe set that quantifies the evidence for an increasing or decreasing dose-response 
relationship.  
 To ensure that the rigorously conservative, permutation-based approaches for 
controlling Type I error did not exclude probe sets with dose-dependent increases or 
decreases in expression, an additional analysis was conducted with each regression model.  
Empirical p-values from the PIR analysis or SAM analysis were used to filter out probe sets 
with no apparent dose-related changes in expression (threshold p-value < 0.01).  The reduced 
group of probe sets were then analyzed using a one-way analysis of variance (ANOVA) 
followed by a Benjamini-Hochberg correction for control of multiple comparisons.  Dose 
was used as the independent factor.  Probe sets meeting the Benjamini-Hochberg correction 
at an FDR < 0.05 were included in the gene lists of interest for each compound (Tables 2.2 & 
2.3), analysis of dose thresholds for transcriptional changes (Figure 2.2) and the comparison 
of effects between compounds (Figure 2.3).  Genes of interest for qRT-PCR confirmation 
were ranked based on the results of the SAM and PIR analyses in conjunction with the results 
of the one-way ANOVA.  For probe sets that passed the one-way ANOVA significance 
threshold, a Dunnett’s multiple-comparison mean contrast test (Dunnett, 1955) was 
performed comparing the means of the respectively dose groups to the mean of the control 
group.  Regression analysis were performed using R© version 2.3.0 statistical computing 
analysis software.  Dunnett’s tests were performed using SAS v8.1 (SAS Institute, Inc., Cary, 
NC).   
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Quantitative real-time RT-PCR.  qRT-PCR for each transcript of interest was performed 
using TaqMan® One-Step RT-PCR Master Mix Reagent Kits and TaqMan® Gene 
Expression Assays on a ABI 7900HT Sequence Detection System (Applied Biosystems, 
Foster City, CA).  AmpliTaq Gold® DNA Polymerase / dNTP mix, MultiscribeTM reverse 
transcriptase / RNA inhibitor mix and TaqMan® Gene expression primer-probe mix specific 
for the transcript of interest were combined according to manufacturer’s specifications 
(Applied Biosystems 2005).  The reaction mixture was then dispensed into the reaction plate 
(15 µL / well) and 125 ng of total RNA (5 µL) was added.  Each sample was measured in 
triplicate for each transcript of interest and an internal reference gene.  Reaction plates were 
maintained at 5°C during loading procedure.    During data collection, reactions were 
incubated at 48°C for 45 min followed by incubation at 95°C for 10 min and 40 cycles of 
94°C for 25 sec and 60°C for 1 min.   
 qRT-PCR assays were designed via the Applied Biosystems (ABI) primer / probe 
selection algorithm and bioinformatics pipeline (Applied Biosystems 2006).  The 
amplification efficiency of each assay utilized in this experiment was examined using a serial 
dilution of pooled total RNA from rat frontal cortex.  Efficiencies were calculated as: Ex = 
10(-1/m) – 1, where E is the amplification efficiency of target transcript x and m is the slope of 
threshold cycles vs log [total RNA concentration] across the range of dilutions (Applied 
Biosystems 2004).  Assay identification numbers, context sequences, amplicon lengths and 
calculated amplification efficiencies are listed in Appendix A, Table 2. 
 Nine transcripts identified as being up- or down-regulated were examined by qRT-
PCR to confirm the dose-responsive trends observed during microarray analysis (see arrows, 
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Tables 2.2 & 2.3).   The time course of expression for a number of transcripts identified as 
dose-responsive was also examined in Cohort 4.  qRT-PCR data from deltamethrin and 
permethrin dose-response and time course studies were analyzed according to the 2-∆∆CT 
method as described by (Livak and Schmittgen 2001).  β-actin expression did not change as a 
function of time or dose for either compound (data not shown) and was used at the internal 
reference for all 2-∆∆CT calculations.  For dose-response studies, the mean ∆∆CT of vehicle 
treated controls were used as the 2-∆∆CT calibrator (Livak and Schmittgen 2001) to obtain 
approximations of fold-change from control.  For time course studies, the mean ∆∆CT of 
vehicle treated controls were used as the 2-∆∆CT calibrator for each time-matched treatment 
group. 
 Data from Wolansky et al. (2006) were used to assign equipotent dose-levels (EDL) 
to the administered doses used in the present study to provide a comparative dose-metric 
between the two test compounds (see Table 2.1).  Statistical analysis of qRT-PCR dose 
response data was performed using a two-way ANOVA with compound and equipotent dose 
level (EDL) as independent variables and 2-∆∆CT as the dependent variable followed by 
Dunnett’s mean contrast test.  Transcripts with a significant compound by EDL interaction 
were further analyzed using a one-way ANOVA with dose as the independent variable 
followed by Dunnett’s mean contrast test.  Statistical analysis of time course data was 
performed using a two-way ANOVA with time and treatment as independent variables and 2-
∆∆C
T as the dependent variable.  Transcripts with a significant time*treatment interaction (p < 
0.05) were additionally analyzed with a one-way ANOVA at each time point with treatment 
as the independent variable (p < 0.05) 
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Significance Analysis of Function and Expression (SAFE).  The SAFE method (Barry et 
al. 2005) was used to identify pathways/functional categories whose genes are coordinately 
regulated in a dose-dependent manner. SAFE is similar to other pathway enrichment 
procedures (e.g. DAVID, Dennis et al. 2003), but accounts for correlation in gene expression 
within pathways using array permutation to rigorously control error rates.  SAFE and 
accompanying array annotation were loaded from Bioconductor (v.1.8, Gentleman et al. 
2004), which includes 126 KEGG pathways, 700 GO-BP (Gene Ontology biological 
processes) pathways, 142 GO-CC (Gene Ontology cellular component) pathways and 307 
GO-MF (Gene Ontology molecular functions) pathways.  SAFE tests for enrichment of 
significant dose-response relationships for genes within each pathway, and accordingly we 
first calculated the linear regression dose-response p-value for each gene.  Genes with a 
nominal p-value < 0.05 formed the gene list to which the enrichment analysis was performed.  
SAFE (SAFE manual, Barry 2006) enables the user to define a pathway enrichment statistic 
and a Pearson test of binomial proportions (Pearson 1911) was then implemented.  The 
Pearson statistics is similar to Fisher’s exact test commonly employed in pathway enrichment 
testing (GSEA, Mootha et al. 2003), but does not consider the number of significant genes to 
have been fixed a priori (Barry et al. submitted).  10,000 permutations of dose levels were 
used by SAFE to assess the significance of the entire procedure, using the (Yekutieli and 
Benjamini 1999) procedure to control the FDR while accounting for the multiple 
pathways/categories.  All categories with an estimated FDR < 0.1 are reported in Table 2.4, 
Part I.   
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Combining pathway evidence for the two pyrethroids.  One aim of using these statistical 
methods in this study was to identify gene categories showing enrichment for dose-
responsiveness for both permethrin and deltamethrin. The Fisher combined p-value method 
(Fisher 1930) allows accrual of evidence across multiple hypotheses, and thus is ideal for 
testing combined evidence for enrichment of each pathway for both chemicals.  Under the 
null hypothesis that neither chemical shows enrichment for the pathway, each of the two p-
values is uniform [0,1], and the Fisher statistic 
S = -2(ln(pdelta)+ln(pnorm)) 
 is distributed as 22χ .  The Fisher approach has favorable optimality properties (Littell and 
Folks 1973) and results in a new (combined) p-value for each pathway.  For the multiple 
pathways tested, the Benjamini-Hochberg (1995) method was applied to control the false 
discovery rate (FDR < 0.1). 
      Fisher’s statistic can be asymmetrically sensitive to very small p-values for a single 
chemical, even if the results for the other chemical are not significant.  Thus, among 
pathways with a significant Fisher statistic, the focus was placed on those which showed 
SAFE p-values < 0.05 for both chemicals.  
 
Cell culture and treatment.  Cortical cultures containing neurons and glia were prepared 
from neocortices of newborn rat pups according to the protocol used by Chandler et al. 
(1993) with modifications.  Neocortices were harvested under sterile conditions in a buffer 
solution containing 137 mM NaCl, 5 mM KCl, 170 µM Na2HPO4, 205 µM KH2PO4, 5 mM 
glucose, 59 mM sucrose, 100 U/ml penicillin and 0.1 mg/ml streptomycin, pH 7.4.  The 
cortices were minced with scissors and digested using 0.25% trypsin for 5 minutes, then with 
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addition of 0.016% DNase for a further 5 minutes at 37°C and mixed at 30 rpm.  The cortices 
were centrifuged (400xg, 1600 rpm) for 5 minutes at room temperature, the supernatant was 
aspirated and the tissue pellet was re-suspended in Gibco® DMEM/GlutaMAX-1 (Invitrogen 
Corp, Carlsbad, CA) containing 10 mM HEPES, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin and 10% horse serum, pH = 7.4.  The tissue was dissociated by trituration and 
filtered through a 100-µm Nitex screen.  Cells were plated at a density of 50,000 cells/well in 
96-well polystyrene plates (Corning, Inc., Corning, NY) that had been pre-coated with poly-
L-lysine.  Cells were incubated at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
Multi-compartment pharmacokinetic models for the disposition of deltamethrin and 
permethrin (Tornero-Velez et al. 2007, Mirfazaelian et al. 2006) were used to predict tissue 
concentrations of deltamethrin and permethrin in the brain at 6 h following the acute 
administered doses used in this study.  Predictions are listed in Table 2.7.  These estimated 
brain concentrations were then used to select nominal media concentrations of pyrethroids 
for use in the functional neurite morphogenesis cell model.   
For in vitro exposure of cells, pyrethroids were prepared in DMSO using semi-
logarithmic serial dilutions of concentrated stock solutions to yield working solutions ranging 
from 0.001 – 0.03 mM and 0.01 – 3 mM for deltamethrin and permethrin, respectively.  On 
the day of use, working solutions were diluted 1/1000 into the cortical media to produce a 
final chemical concentration range of 0.001 – 0.03 µM and 0.01 – 3 µM for deltamethrin and 
permethrin respectively.  The final DMSO concentration in the cortical media was 0.1%.  
Chemicals were added to the cells 2 hours after plating to ensure the cells adhered to the 
poly-L-lysine and incubated for a 96-hour exposure period.     
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Evaluation of neurite outgrowth.  A Neurite Outgrowth Hitkit (Thermo-Fisher Scientific, 
Waltham, MA) was used to evaluate cortical cell neurite outgrowth and branching.  Cortical 
cells were fixed for 20 min using a 4% paraformaldyde solution dissolved in PBS at 37o C.  
Hoechst 33258 dye was included in the fixative to label cell nuclei.  Cell bodies and 
processes were labeled using an anti-βIII tubulin primary antibody, followed by an Alexa 
Fluor 488-conjugated secondary antibody.  Plates were evaluated using a Cellomics 
ArrayScan VTI high content imaging platform for automated image capture and analysis.  A 
multiple bandpass emission filter and matched excitation filters were used to acquire 
fluorescence images of the nuclei (blue) and cell body/processes (green) using a high-
resolution charge-coupled device (CCD) camera.  The acquired images were analyzed using 
the Neuronal Profiling bioapplication (Thermo Fisher Scientific) to measure cell-based 
changes in neuronal morphology (i.e., total neurite length, neurite count, branch points, and 
cell body area).  Using a 10X objective, a sufficient number of fields were acquired for the 
analysis of at least 200 cells per well.    
 
Cell viability.  Cellular viability was determined in cortical cell cultures grown as described 
above in opaque 96 well plates using the CellTiter-Glo Viability Assay (Promega Corp., 
Madison, WI).  The number of viable cells in each well was determined through 
quantification of ATP, an indication of metabolically active cells.  Addition of the CellTiter-
Glo reagent (100 µl/well) caused cells to lyse and induced a luciferase-catalyzed reaction of 
ATP with luciferin that produced a luminescent signal proportional to the amount of ATP 
present.  Luminescence in each well was measured thirty minutes after adding the reagent 
using a FLUOstar Optima plate reader (BMG LABTECH, Durham, NC).  Preliminary 
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experiments verified that ATP content was proportional to the number of live cells in a well 
(data not shown).           
Results. 
 
Microarray dose-response analyses.  Both the PIR (isotonic) and SAM (linear) penalized 
regression methods identified dose dependent increases and decreases in mRNA expression 
in the cerebrocortex 6 h after an acute, oral exposure to both deltamethrin and permethrin.  A 
comparison the PIR and SAM regression models demonstrate that the two methods yield 
similar results in terms of identifying dose-responsive probe sets in both the deltamethrin and 
permethrin treated dose-response cohorts (Figure 2.1A & 2.1B).  The rank order of statistical 
significance was similar between the two methods in that probe sets with test-statistics in the 
higher end of the observed PIR M-statistic range also had test-statistics in the higher end of 
the observed SAM di-statistic range.  The same trend was observed in the lower end of the 
test-statistic ranges. 
 The SAM analyses identified a small number of probe sets with dose-dependent 
increases in expression following either deltamethrin (n = 7) or permethrin (n = 10) exposure 
using the permutation-based false discovery rate values as the significance criteria (FDR: q < 
0.10, see Figure 2.1A & 2.1B).  The PIR analyses did not identify any probe sets for either 
pyrethroid with dose-dependent changes in expression at this q < 0.10 FDR significance 
threshold.  However, the probe sets with q < 0.10 in the deltamethrin and permethrin SAM 
analyses also had M-statistics in the extreme upper portion of the observed PIR test-statistic 
range.  Therefore, these methods yield comparable results in that a rank-ordered list of dose-
dependent changes in expression constructed using either the PIR or SAM test-statistics 
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identifies the same groups of probe sets as being the most significantly changed in the 
deltamethrin and permethrin test cohorts. 
 A less statistically conservative method of identifying dose-related changes in probe 
set expression identified a larger number significantly altered probe sets than that observed 
using the FDR criteria.  Both PIR and SAM also calculate an empirical p-value associated 
with the regression model for each probe set on the microarray.  Using a threshold of p < 
0.01 the SAM analysis identified 70 and 61 probe sets with dose-dependent changes in 
expression for deltamethrin and permethrin, respectively, while the PIR analysis identified 93 
and 85, respectively (Figure 2.1A-B).  In the deltamethrin analyses, 49.5 % of all the probe 
sets identified had p < 0.01 for both the SAM and PIR methods (Figure 2.1A, green points).  
Likewise, in the permethrin analyses, 53.7 % of all the probe sets identified had p < 0.01 for 
both the SAM and PIR methods (Figure 2.1B, green points).  Therefore, the overlap between 
probe sets identified as dose-responsive using the empirical p-value thresholds is incomplete.  
Similar to what is observed using the FDR q-value significance criteria, use of the empirical 
p-value significance criteria also demonstrates that probe sets commonly identified using 
either the PIR or SAM method tend to appear at the top of a rank ordered list of significance, 
as indicated by the convergence of green points in the upper-right and lower-left hand 
corners of Figures 2.1A and 2.1B.   
 To provide a measure of multiple-comparison Type I error control, all the probe sets 
for each compound that had empirical p-values < 0.01 in either the SAM or PIR regression 
methods were additionally analyzed with a one-way ANOVA with dose as the independent 
factor, followed by a Benjamini-Hochberg multiple testing correction (significance threshold, 
p < 0.05).  For deltamethrin and permethrin, 95 of 109 (87.1 %) and 53 of 89 (59.5 %) probe 
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sets passed the ANOVA significance threshold.  A larger percentage of probe sets 
(deltamethrin: 12.9 %, permethrin: 44.3 %) identified in the SAM analyses did not pass the 
ANOVA significance threshold as compared to those identified in the PIR analyses 
(deltamethrin: 8.7 %, permethrin: 23.8 %).  The full list of probe sets considered significantly 
dose-responsive for deltamethrin (n = 95) and permethrin (n = 53) are given in Tables 2.2 
and 2.3.  Probe sets listed on these tables that correspond to known protein-coding RefSeq 
database entries were considered candidates for qRT-PCR confirmation in dose-response 
Cohorts 3 and 4. 
 The dose-dependent changes in mRNA expression identified with the above analyses 
are relatively small in magnitude, < 2-fold change from control.  Figure 2.2 illustrates the 
dose-response patterns detected by the SAM and PIR analyses in terms of fold-change from 
control.  For deltamethrin, the magnitude of fold-changes in expression ranged from 0.51 to 
1.96 (Figure 2.2A-C).  Similarly for permethrin, fold-change values ranged from 0.54 to 
1.56-fold (Figure 2.2D-F).  No fold-change exclusion criteria were used to filter gene 
expression changes in the present study.   
 Further analysis of the dose-response functions illustrated in Figure 2.2 indicate that 
significant alterations in mRNA expression occur at doses below those needed to produce 
acute behavioral effects.  For each probe set included in the gene-of-interest lists for 
deltamethrin (Table 2.2) and permethrin (Table 2.3) a Dunnett’s mean contrast test was 
performed comparing the mean of each dose condition with the mean of the vehicle treated 
control group.  The cumulative results of these tests are illustrated in the inset panels of 
Figure 2.2.  A majority of the probe sets identified as dose-responsive had mean expression 
values in the 3 mg/kg deltamethrin and 100 mg/kg permethrin dose groups different from 
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those in the vehicle treated control group (78.9 % and 77.3 %, respectively).  Of those probe 
sets, 25.3 % and 19.5 % also had mean expression values in the 1 mg/kg deltamethrin and 10 
mg/kg permethrin dose groups different from controls.  These doses are below those needed 
to produce acute neurotoxic effects on behavior.  In addition, these data demonstrate that the 
PIR analyses detected a greater number of probe sets with mean expression values in the 
behavioral “NOAEL level” dose groups (see Table 2.1) as being different from control as 
compared to the SAM analyses (Figure 2.2B & E, insets).    
 
Comparison of transcriptional effects across compounds.  A comparison of the probe sets 
identified as dose-responsive in the PIR and SAM regression analyses demonstrates that the 
transcriptional response elicited by the two pyrethroids has some common characteristics.  
The panels in Figures 2.3 plot the –log10 of the empirical p-values associated with the PIR 
regression (2.3A) or SAM regression (2.3B) for each probe set identified as dose-responsive 
for either deltamethrin or permethrin.  Data from the PIR regression analyses demonstrate 
that expression of 27.2 % of all probe sets identified as dose-responsive for either pyrethroid 
are significantly altered by both compounds at an empirical p-value threshold of p < 0.05 
(Figure 2.3A).  Likewise, SAM analyses demonstrated that 27.8 % of all dose-responsive 
transcripts are altered by both pyrethroids (Figure 2.3B).  Differences in the transcriptional 
response profiles between pyrethroids are also apparent and may represent divergent 
biological actions elicited by the different pyrethroids.   
 
Quantitative real-time RT-PCR.  Measurement of transcript expression by qRT-PCR 
confirmed the dose-related trends in expression observed during microarray analysis in a 
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group of nine transcripts taken from Tables 2.2 and 2.3.  Table 2.4 summarized the results of 
these assays and compares them to the fold-change expression values derived from the 
microarray study.  To confirm dose-related changes in transcript expression from the 
microarray study, a separate cohort of test subjects was dosed under the same conditions as 
those used previously.  This provides both a technical and biological replication of the results 
observed in the microarray analyses.  Given the similarities observed in the transcriptional 
responses elicited by deltamethrin and permethrin, qRT-PCR data were analyzed with a two-
way ANOVA with compound and equipotent dose-level (EDL) as the independent factors (p 
< 0.05 significance threshold).  Where a significant interaction of compound and EDL or a 
significant main effect of compound was observed, data were subsequently analyzed by a 
one-way ANOVA within compound with dose as the independent factor.  
 Of the nine transcripts examined by qRT-PCR, Ca+2/calmodulin dependent protein 
kinase 1γ (Camk1g) and dopa decarboxylase (Ddc), were commonly affected by both 
compounds, indicating that for these genes there was no differences in the changes in 
expression elicited by equipotent doses of either pyrethroid.  Camk1g mRNA expression was 
significantly increased with both compounds with expression levels different from control at 
the three highest equipotent dose levels examined (Dunnett’s test, p <0.05).  Camk1g qRT-
PCR expression values closely resembled those observed in the microarray study.  Ddc 
mRNA expression was significantly decreased with both compounds in the qRT-PCR assays 
with significant decreases in expression at the ED30 and ED50 dose levels (Dunnett’s test, p 
<0.05).    In contrast to Camk1g, the microarray dose-response cohort demonstrated a dose-
related change in Ddc expression for deltamethrin only even though a clear dose-dependent 
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decrease in Ddc mRNA expression was observed in both the deltamethrin and permethrin 
qRT-PCR cohorts.   
 A significant interaction between compound and EDL was observed for glycerol-3-
phosphate dehydrogenase 1 (Gpd1) and FK506-binding protein 5 (Fkbp51), indicating that 
equipotent doses of the two pyrethroids did not elicit similar changes in expression at 6 hours 
post-exposure.  A main effect of dose was observed for Gpd1 and Fkbp51 mRNA only for 
deltamethrin (Table 2.4).  For both Gpd1 and Fkbp51 the mean expression level in the 3 
mg/kg deltamethrin dose groups was different from control (Dunnett’s test, p <0.05).  In 
addition, the qRT-PCR expression values for Gpd1 and Fkbp51 closely match those observed 
in the microarray study.  
 The immediate early genes, FBJ murine osteosarcoma viral oncogene homolog (c-
fos) and early growth response 1 (Egr1) were differentially affected by the two pyrethroids at 
6 h post-exposure, however, no significant main effect of dose (EDL) was observed for either 
compound.  For deltamethrin, the direction of fold-change for c-fos and Egr1 is down in most 
dose groups measured by qRT-PCR.  The expression of c-fos was significantly decreased 
from control values for 3 mg/kg deltamethrin only.  In contrast, for permethrin no change in 
the expression of c-fos and Egr1 mRNA across dose groups in the qRT-PCR cohort.  While 
c-fos and Egr1 expression at 3 mg/kg deltamethrin and 100 mg/kg permethrin reflect the 
direction of fold-change observed in the microarray study, very little similarity is apparent 
between qRT-PCR and microarray expression values at the lower dose levels (Table 2.4). 
 There were no effects of pyrethroid exposure on mRNA expression for heat shock 
27kDa protein (Hsp27), brain derived neurotrophic factor (BDNF) or Ras association 
(RalGAS/AF-6) domain family 6 (Rassf5).  In the case of BDNF, qRT-PCR expression 
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values closely approximate the expression values observed in a second probe set not 
identified as dose-responsive in the microarray analyses.  
 Characterization of the time course of mRNA expression for Camk1g, Gpd1, c-fos 
and Egr1 demonstrates that altered expression of these transcripts also occurs at times earlier 
than 6 h following acute, oral pyrethroid exposure.  Figure 2.4 illustrates the time course of 
gene expression changes following exposure to either 3 mg/kg deltamethrin or 100 mg/kg 
permethrin.  A summary of the statistical analyses performed on these data is provided in 
Table 2.5.  Treatment-related increases in Camk1g and Gpd1 mRNA expression were 
observed for both deltamethrin and permethrin.  For deltamethrin, both Camk1g and Gpd1 
mRNA had maximally induced expression at 3 h followed by persistent elevations at 6 h 
(Figure 2.4).  Both of these changes reached statistical significance in the time course cohorts 
(Table 2.5).  For permethrin, both Camk1g and Gpd1 had maximal induction at 6 h preceded 
by slight elevations at 3 h.  Permethrin-mediated Gpd1 induction was statistically significant 
while Camk1g induction reflected the trends observed in the dose-response cohorts but did 
not reach statistical significance.  Ddc mRNA expression was decreased following both 
deltamethrin and permethrin exposure.  For deltamethrin decreased expression began at 6 h 
and persisted through 9 h while for permethrin, expression decreased at 6 h only.   
 In the qRT-PCR time course cohorts both deltamethrin and permethrin exposure 
results in the induction of the immediate early genes c-fos and Egr1, albeit with different 
temporal characteristics.  This is contrary to the trends in c-fos and Egr1 expression observed 
in the deltamethrin and permethrin dose-response cohorts, where the former pyrethroid 
produced a trend toward decreased expression while the latter produced a trend toward 
increased expression.  Expression of c-fos and Egr1 increases at 3 h for both deltamethrin 
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and returns to control levels at 6 h.  For permethrin, expression of c-fos and Egr1 increases at 
3 h, remains persistently elevated at 6 h and returns to control levels by 9 h.  Even though the 
microarray data at 6 h demonstrates opposite trends in c-fos and Egr1 expression for 
deltamethrin and permethrin, the data in Figure 2.4 demonstrate that the two pyrethroids, in 
fact, elicit similar responses in the expression of some immediate early genes.  The 
expression of other immediate early genes, such as BDNF, is apparently not affected by 
pyrethroids under the dosing paradigm used in this study. 
 In summary, the mRNA expression levels measured using microarray compared 
favorably with those observed using qRT-PCR in most cases.  In addition, the dose-
dependent trends and time course profiles examined in these qRT-PCR studies for Camk1g, 
Gpd1, Ddc, c-fos and Egr1 are qualitatively similar for both deltamethrin and permethrin.   
 
Significant Analysis of Function and Expression (SAFE).  Seven GO categories were 
identified as commonly enriched for both pyrethroids using SAFE analysis and Fisher’s χ2 
method (Table 2.6, part I).  The composition of the commonly enriched categories for both 
chemicals included genes involved in neuronal morphogenesis, intracellular Ca+2 signaling 
and small molecule transport.  In addition, five GO-BP categories and two canonical KEGG 
pathways were identified as enriched in the individual SAFE analyses of permethrin and 
deltamethrin, respectively (Table 2.6, part II).  For permethrin, the SAFE findings include 
enriched gene categories related to neuronal morphogenesis and developmental patterning.  
For deltamethrin the SAFE findings include two KEGG metabolic pathways, one of which 
involves synthesis of the precursor molecules for monoamine neurotransmitters. 
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 SAFE plots of the GO categories ‘morphogenesis of a branching structure’ and 
‘Ca+2/calmodulin dependent protein kinase complex’ demonstrated significant category 
enrichment for both permethrin and deltamethrin (Figure 2.5).  This is evidenced by the 
divergence of the stair step line from the unity line near the far left of Figure 2.5, panels A-D.  
A SAFE plot of a GO category not significantly enriched for either compound is given in 
Figure 2.5, panels E-F for comparison purposes.  The most significantly dose-responsive 
transcripts for each of the enriched GO categories are illustrated in the heatmaps to the right 
of Figure 2.5, panels A-D.  These heatmaps demonstrate that appreciable dose-dependent 
increases in the expression of probe sets contained within the enriched GO categories occurs 
following pyrethroid exposure.  The functional category level analysis of the microarray data 
provided the basis for testing the hypothesis that pyrethroids affect neuronal branching 
morphogenesis. 
 
Pyrethroid effects on neurite length and branching in primary mixed cortical cell cultures.  
Both deltamethrin and permethrin produce an increase in the number of neurite branch points 
following a 96 h exposure (Figure 2.6A & D).  The range of predicted tissue concentrations 
(in µM) from the PK predictions (Table 2.7) are marked near the x-axes and correspond well 
to areas along the in vitro dose-response curve where changes in branching were observed.  
An average increase of ~25% above control in the number of neurite branch points was 
observed at nominal media concentrations ranging from 0.01 - 0.03µM deltamethrin and 0.01 
– 3µM permethrin.  No significant increase in total neurite length was observed for either 
compound save at the 0.01µM exposure level for permethrin.  Changes in cell viability were 
not apparent in the concentration ranges tested. 
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Discussion. 
 
 A principal finding of the present study was that acute, oral pyrethroid exposure 
caused dose-dependent alterations in gene transcription in the cortex at doses of deltamethrin 
and permethrin that were below those required to elicit acute neurotoxic effects in the whole 
animal (Wolansky et al. 2006).  Both similarities and differences in the overall transcriptional 
response were observed when comparing the two pyrethroids.  Quantitative real-time RT-
PCR analysis in additional cohorts of animals provided an independent biological and 
technical replicate of the findings from the microarray data set.  In addition, transcripts for 
which the time course of gene expression was characterized demonstrated qualitative 
similarities in the response for both pyrethroids.  Finally, SAFE analysis of the microarray 
data identified several GO categories jointly enriched by both deltamethrin and permethrin 
including some related to branching morphogenesis.  Subsequently, a significant increase in 
the number of neurite branch points was observed in a primary cortical cell culture model.  
The transcriptional and functional changes observed in this study are consistent with the 
downstream responses expected to occur following perturbation of normal neuronal firing 
patterns (Majdan and Shatz 2006; Xiang et al. 2007) such as those that may be produced by 
pyrethroid-mediated effects on ion channel function. 
 The following sections include interpretations of the microarray analysis findings, the 
data analysis framework, a discussion of how some of the individual transcripts identified in 
this study may be regulated by the pharmacological actions of pyrethroids, some hypothesis 
of how changes in the expression of these genes may contribute to pyrethroid neurotoxicity 
and finally a discussion of the pyrethroid effects on neuronal morphology. 
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Microarray dose response analyses.  Dose-dependent alterations in transcript expression 
were observed in the frontal cortex at 6 h following acute exposure to pyrethroids.  In the 
present study Affymetrix GeneChips® were used as a discovery tool for identifying dose-
dependent changes in gene transcription.  The PIR and SAM penalized regression models 
used in this study provided qualitatively similar outcomes in terms of identifying dose-related 
alterations in gene expression.  The two penalized regression analyses demonstrated that both 
methods ranked a similar sub-set of transcripts as being the most dose-responsive for each 
compound (Figure 2.1A & 2.1B).  Prior to experimentation, the shape of the dose-response 
curve for any potential alterations in gene transcription was unknown.  The SAM regression 
model, which was designed to test if dose-response curves are fitted by a linear function, 
detected a number of dose-dependent changes in gene transcription.  However, Figure 2.2 
clearly illustrates the heterogeneity of the transcriptional dose-response functions observed in 
the present study.  Not all of these functions are adequately fitted by a linear model.  A 
penalized isotonic regression (PIR) analysis developed from Hu et al. (2005) that searches for 
monotonic increases or decreases in expression without testing the fit to a particular dose-
response function, identified dose-related changes in expression that were not detected by 
SAM.  A majority of these had significant increases in expression from control at the 
“NOAEL” dose of the test compounds.  While both SAM and PIR identified the same subset 
of transcripts as being the most-significantly dose-responsive within each compound (Figure 
2.1A & B), the PIR method provided superior detection of probe sets with treatment related 
changes in expression that did not fit a linear model. 
 Collectively, these data indicate that the pyrethroid dose thresholds required to elicit 
changes in gene expression vary from gene to gene and that the regulation of some genes 
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occur at lower pyrethroid doses than others.  For some transcripts, appreciable alterations in 
mRNA expression occurred exclusively at the highest administered dose of either pyrethroid 
compound.  For other transcripts, changes were observed at doses not associated with any 
observable neurotoxic effects (Figure 1.2 insets and Table 2.4).  The biological factors 
mediating the heterogeneity in dose-response functions for different pyrethroid-sensitive 
transcripts are unclear but could be due to several factors.  In neurons, induction or 
repression of gene expression is controlled by a large and diverse network of intracellular 
signaling cascades that control the activity of numerous transcription factors in the cell 
nucleus.  These neuronal signaling pathways are activated by either: 1) changes in 
cytoplasmic second messenger levels in response to activation of voltage-sensitive ion 
channels, ionotropic or metabotropic neurotransmitter receptors or membrane bound receptor 
complexes or 2) exogenous ligands that are transported into the cell (such as glucocorticoids) 
to directly enhance transcription factor activity (de Kloet 1998; West et al. 2002; Schulman 
and Roberts 2003; Schoneveld 2004).  Some of these signal transduction pathways may 
become activated at lower administered doses of pyrethroids than others, thereby causing the 
transcripts they control to become induced or repressed at different points along the 
administered dose range.  Alternatively, the use of only one time point in the dose-response 
study may have contributed to the differences in dose-responsive expression patterns 
between genes.  Differences in the duration of signaling pathway stimulation or transcription 
factor activation and the rate of mRNA synthesis and degradation may result in variable 
temporal expression patterns between pyrethroid-sensitive genes.    
 Time course data demonstrate that pyrethroid-sensitive genes have varying temporal 
profiles of expression (Figure 2.4).  The sampling time of 6 h in the initial phase of this study 
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was selected to capture both ‘early’ and ‘late’ transcriptional changes in response to 
pyrethroid exposure.  The time course data at 6 hr are consistent with the data from the dose-
response study which was collected 6 h after exposure.  In addition, the available time course 
data implies that additional alterations in gene expression not detected in the dose-response 
study may occur at time points other than the one sampled.  The qRT-PCR data shown here 
support this conclusion (Figure 2.4). 
 In the present experiment, the cortex was selected as the tissue-of-interest based on 
previous studies demonstrating rapid accumulation of both deltamethrin and permethrin 
following an acute oral dose, disruption of cortical neuronal firing patterns, and induction of 
gene products known to be upregulated following neuronal excitation (Ray 1980; Anadon 
1991; Hassouna et al. 1996; Anadon 1996; Condes-Lara 1999).  However, the use of a brain 
tissue that is a heterogenous mixture of neuronal sub-types (e.g. glutaminergic, GABAergic), 
glial cells and vascular endothelia (Hof et al. 2003) presented a particular challenge in 
analysis of the microarray data: namely, analysis of transcripts with low relative abundance 
in the total RNA sample.  One result of this cellular heterogeneity is lower relative 
fluorescent signal intensities (and therefore lower expression summaries) of neuron-specific 
transcripts in the microarray data set than what would be observed using a total RNA sample 
from an exclusively neuronal cell population (c.f. Ginsberg and Che 2005).  Effectively, the 
neuronal mRNA is diluted by mRNA from other cell types.  Arbitrary exclusion of lowly 
expressed mRNAs from the analysis based on a fluorescence threshold may unduly discard 
probe sets that have biologically relevant changes in expression.  To control for lowly 
expressed genes without excluding potentially meaningful data from the analysis, both the 
SAM and PIR penalized regression methods use an adjustment factor in the calculation of the 
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test-statistics to force probe sets with very low signal intensities to change more dramatically 
to be considered significant (Tusher et al. 2001; Hu et al. 2005).  In the present study the 
penalized regression analyses reduced the number of lowly-expressed, and potentially 
unreliable, probe sets included in the dose-responsive gene-of-interest list (Appendix A, 
Figure 1) while also provided a means of surveying the entire data set for pyrethroid-
responsive genes.  
 The magnitude of the transcriptional alterations (expressed as fold-change from 
control) observed in the present study are comparable to those observed in other microarray 
studies that examine the acute effects of pharmacological agents on gene transcription in the 
brain (Li et al 2004; Xie et al. 2004; Dow et al. 2005; Bowyer et al 2007).  The relatively 
small number of significant changes in expression was not unexpected given the nature of the 
pyrethroid exposures used: i.e. even the highest doses used in this study were only slightly 
above the threshold needed to elicit acute behavioral effects (Bloom et al. 1983; Peele and 
Crofton 1987; McDaniel and Moser 1993; Wolansky et al. 2006).  The low doses and 
resulting small magnitude transcriptional changes observed in this study are likely the 
reasons why only a very small number of transcripts were identified as dose-responsive using 
the permutation based FDR estimates as the significance criteria (q < 0.01).  In analyses of 
training data sets, it has been demonstrated that the SAM analyses can efficiently detect 
treatment related effects in transcripts with changes in expression (> ~1.5-fold) by using the 
permutation-based FDRs as a significance threshold (Tusher et al. 2001; Larsson et al. 2005).  
However a systematic analysis of how well these permutation methods perform in picking up 
small magnitude gene expression changes has not been performed.   
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Comparison across compounds.  The present data demonstrate both similarities and 
differences in the global transcriptional response in rat cortex to acute, low-dose deltamethrin 
and permethrin exposure (Figure 2.3).  Of the transcripts examined by qRT-PCR (Table 2.4 
and Figure 2.4), Camk1g, Ddc, Gpd1, c-fos and Egr1 all had similar expression profiles for 
both deltamethrin and permethrin.  These similarities were not readily apparent upon 
examination of the microarray probe set data (Cohorts 1 & 2) or 6 h qRT-PCR data (Cohorts 
3 & 4).  For instance, the immediate early genes c-fos and Egr1 were identified as dose-
responsive for permethrin during microarray analysis and had opposite trends in expression 
at 6 h for the two pyrethroids.  Similarly, Camk1g and Gpd1 were identified during 
microarray analysis for deltamethrin, but not permethrin, even though a similar trend in the 
direction of change is observed across compounds.  Characterization of the time course of 
mRNA expression for these genes clearly demonstrates a commonality in the transcription 
responses elicited by the two compounds.  The results of the SAFE functional category level 
analysis support the conclusion that the biological activities of the two pyrethroids overlap.  
Several categories were found to be commonly upregulated between the two compounds.  
How many of these individual gene changes or impacted functional categories are relevant to 
the neurotoxicology of pyrethroids remains yet to be determined.  These data provide 
guidance on some novel cellular functions affected by pyrethroids. 
 
Biological significance of experimental findings.  Interestingly, probe sets corresponding to 
the primary molecular targets for pyrethroids were not altered for either pyrethroid tested in 
the microarray study.  Specifically, there were no treatment related changes in any of the 
VSSC or VSCC isoforms / subunits or any subunits that comprise neurotransmitter receptors 
 71 
complexes (Cull-Candy et al. 2001; Ogata and Ohishi 2002; Catteral et al. 2003; Farrant and 
Kalia 2007).  This finding is supported by an in vitro study by Xiang et al. (2007) that used a 
variety of pharmacological manipulations to increase the firing rates of cultured neuronal 
networks from rat cortex and examined the global transcriptional response of those neurons 
following stimuli.  No changes in the expression of VSSC or VSCC isoforms / sub-units or 
neurotransmitter receptors were identified in that study in response to increases in neuronal 
firing rates.   The Xiang et al. (2007) study did detect increases in the expression some 
voltage-sensitive K+ channels: Kcna1 and Kcnk12.  These particular K+ channel sub-types 
were not altered in the present study, however Kcnf1 was upregulated following pyrethroid 
exposures.  The present data do not rule out the possibility that pyrethroids cause 
transcription-independent changes in the expression or functional state of ion channels or 
neurotransmitter receptor complexes.  Such responses are known to occur in neurons in 
response to excitatory or depolarizing stimuli (Paillant et al. 1996; Giraud et al. 1998; 
Shiraishi et al. 2001; Kim et al. 2007).  The present data do not support transcriptional 
induction or repression of VSSCs, VSCCs or neurotransmitter receptor subunits as a 
neuronal response to pyrethroids. 
 The immediate early transcription factors c-fos and Egr1 were upregulated following 
both deltamethrin and permethrin exposure and are in agreement with previous studies of 
IEG expression in the cortex following acute pyrethroid exposure (Hassouna et al. 1996; Liu 
and Wu 2001).  Increased Egr1 and c-fos expression supports the conclusion that neurons in 
the cortex were activated by deltamethrin and permethrin in the present study.  Egr1 and c-
fos are among the genes induced by increased neuronal firing in the Xiang et al. (2007) study 
as well as in other paradigms for studying neuronal activity (Zangenehpour et al. 2002; Patra 
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et al. 2004).  Immediate early gene (IEG) induction is known to be the most rapid 
transcriptional response of neurons following increased activity (Steward et al. 1998; 
Dassesse et al. 1999; Guzowski et al. 1999; Clayton 2000).  The time course for the 
expression of the IEGs c-fos and Egr1 does not support de novo gene transcription as being 
responsible for mediating the acute behavioral effects of pyrethroids.  The earliest time that 
increased IEG expression is observed in the present study is at 3 h.  IEG expression is at 
control levels at 1 h.  Onset of behavioral effects occurs prior to the onset of increased IEG 
expression (i.e. 30 min – 1 h, Crofton and Reiter 1984).  Therefore, the novel gene 
expression changes described herein can not mediate the acute neurotoxic signs of pyrethroid 
intoxication. 
 An increase in the expression Ca+2/calmodulin dependent protein kinase 1g (Camk1g) 
mRNA was also observed following deltamethrin and permethrin exposure in vivo.  There is 
evidence in the literature that Camk1g mRNA expression is regulated by changes in neuronal 
firing patterns similar to IEGs.  In the Xiang et al. (2007) study increases and decreases in the 
expression of Camk1g mRNA matches nearly perfectly with increases and decreases in 
neuronal burst firing rates.  Increases in Camk1g mRNA expression have been reported in 
response to acute or chronic exposure to the opiod analgesic morphine in mouse striatum and 
chronic exposure to the atypical antipsychotic olanzipine in the rat frontal cortex (Fatemi et 
al. 2006; Korostynski et al. 2007).  Both of these agents are known to increase spontaneous 
and / or stimulus evoked bursting activity in some brain regions in vivo (Stanzione et al.1988; 
Gronier and Rasmussen 2005) further supporting that Camk1g mRNA expression is 
correlated with changes in neuronal activity.  Therefore, increased Camk1g mRNA 
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expression observed in the present study is most likely due to pyrethroid-induced alterations 
in neuronal firing rates within the frontal cortex. 
 Increased expression of Camk1g may impact on the structure and function of 
pyrethroid affected neurons.  This is consistent with recent data from in vitro models of 
developmental neurite and dendrite morphogenesis.  Wayman et al. (2006) demonstrated that 
Camk1g plays a specific role in the activity-dependent growth of hippocampal neurons 
between 7-9DIV by mediating activation of a Ras/MEK/ERK signaling cascade in response 
to excitatory stimuli and triggering CREB-mediated transcription of Wnt-2, a soluble 
autocrine factor that promotes dendritic growth.  Takemoto-Kimura et al. (2007) 
demonstrated that Camk1g is covalently modified, inserted into lipid rafts and targeted to 
neuronal dendrites where it activates a Rac signaling pathway that mediates the 
morphogenesis of cortical neurons.  In both the Wayman et al. (2006) and Takemoto-Kimura 
et al. (2007) studies, knockdown or overexpression of Camk1g altered depolarization and 
neurotrophin-stimulated outgrowth of neuronal processes, respectively.  Takemoto-Kimura et 
al. (2007) also demonstrated that Camk1g-mediated effects are restricted to dendrites (axons 
were not affected).  The role of Camk1g in maintenance and activity-regulated plasticity of 
dendritic arbors in adults (Sin et al. 2002) is currently unknown.  Given this knowledge of 
Camk1g activity in vivo, it is plausible that pyrethroid-mediated increases in Camk1g 
expression (especially in a developmental context) could result in changes in neuronal 
morphology.  In the present study, in vitro exposure of developing cortical neurons to both 
deltamethrin and permethrin resulted in an increase in the number of neurite branch points. 
The role of Camk1g induction in mediating these effects remains unknown.   
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 The transcriptional upregulation of glycerol-3-phosphate dehydrogenase 1 (Gpd1) 
and FK506-binding protein (Fkbp51) mRNA in the present study has two major implications: 
1) that in vivo pyrethroid exposure results in the activation of hypothalamic-pituitary-adrenal 
(HPA) axis and 2) that the non-neuronal cell populations in the brain are sensitive to 
pyrethroids, most likely through an indirect activation of the HPA axis.  The expression of 
Gpd1 mRNA was transiently increased following deltamethrin and permethrin exposure 
(Table 2.4 and Figure 2.4).  Similarly, expression of Fkbp51 mRNA dose-dependently 
increased at 6 h following deltamethrin exposure only (Table 2.4), although this transcript 
was not examined in the time course cohort.  These changes in Gpd1 and Fkbp51 mRNA 
expression suggest that pyrethroids can have effects on glial cell populations as the proteins 
encoded by these transcripts are expressed in the brain exclusively in oligodendrocytes 
(Leveille et al. 1980) and T-cell lymphocytes (Baughman et al. 1995).  However, the 
induction of these mRNAs is likely an indirect action of pyrethroids via activation of the 
HPA axis (de Kloet et al. 1998).  Both the Gpd1 and Fkbp51 genes contain glucocorticoid 
receptor binding motifs either in the upstream promoter region (Gpd1, Cheng and de Vellis 
2000) or in an intronic region (Fkbp5,; Hubler and Scammell 2004) and increased expression 
of both is dependent upon glucocorticoid hormone stimulation (Nicols et al. 1996; Baughman 
et al. 1997).  Glucocorticoids are release in the circulation from the adrenals in response to a 
variety of stressors.  Interestingly, increased circulating corticosterone levels were reported in 
the rat following deltamethrin exposures; albeit at very high, intravenous doses (de Boer et 
al. 1998).  Increases in Gpd1 and Fkbp51 expression may be considered to be components of 
a generalized, non-specific stress response brought about by overstimulation of the HPA axis 
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by pyrethroids.  The potential impact of increased Gpd1 and Fkbp51 expression the health 
and function of affected glia, to date, is unclear. 
 Data from the present study suggest that the pathways controlling monoaminergic 
neurotransmitter synthesis may be affected by pyrethroids.  Both deltamethrin and 
permethrin caused decreases in the expression aromatic L-amino acid decarboxylase (Ddc) 
mRNA in the frontal cortex at 6 h (Table 2.4).  Small differences in the time course of Ddc 
mRNA expression between the compouds were observed with deltamethrin causing a more 
persistent decrease than permethrin.  Ddc is the final enzyme in the synthesis pathways of 
dopamine and serotonin, neurotransmitters derived from the amino acids tyrosine and 
tryptophan, respectively (Deutch and Roth 2003). This is consistent with previous reports 
noting a depletion of dopamine and serotonin in a variety of brain regions following repeated 
exposure to deltamethrin (Martinez-Larranaga et al. 2003; Liu et al. 2006; Liu and Shi 2006).  
In the case of dopamine depletion, two of these studies demonstrate concurrent decreases in 
the expression of tyrosine hydroxylase, the penultimate enzyme in dopamine synthesis (Liu 
et al. 2006; Liu and Shi 2006).  Expression of Ddc was not examined in these studies.   
 The increased expression of c-fos, Egr1 and Camk1g in the present study are most 
likely regulated by pyrethroid-induced changes in the neuronal firing patterns of cortical 
neurons.  In contrast, the increased expression of Gpd1 and Fkbp51 mRNA indicates that the 
HPA-axis was activated by pyrethroid exposure indicating an excitatory effect of these 
compounds on the sympathetic nervous system.  Previous studies have utilized transient 
activity-dependent alterations in gene expression to map out activated neuronal circuits in 
response to excitatory or neurotoxic stimuli (Carvajal et al. 2005; Guzowski et al. 2005; 
Guzowski 2006) essentially using the expression of these mRNA species as biomarkers of 
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pharmacological or excitatory actions at the neuronal membrane.  The data from this study 
indicate that c-fos, Egr1 and Camk1g may be appropriate for use in this type of functional 
mapping in examination of the pharmacological actions of pyrethroids. 
 
Pyrethroid effects on branching morphogenesis.  Both deltamethrin and permethrin 
increased the number of neurite branch points in an in vitro model of cortical neuronal 
development with no effects on total neurite length.  The pharmacokinetic modeling data 
show these effects occurred at media concentration ranges comparable to tissue 
concentrations predicted to be present in the brain following an acute exposure in vivo (Table 
2.7, Figure 2.6).  This confirms the results from the functional category (SAFE) analysis 
which predicted that branching morphogenesis would be affected by pyrethroids.  This was 
based on dose-dependent patterns of gene expression for mRNA transcripts that code 
proteins which have been shown to control neurite branching and morphogenesis in the 
nervous system.  These genes include Cxcl12, Notch1, β-catenin and Camk1g (Redmond et 
al. 2000; Yu and Malenka 2003; Pujol et al. 2005; Wayman et al. 2006; Takemoto-Kimura et 
al. 2007).  A majority of the studies concerning the function of this group of genes focused 
on their role in developmental neuronal morphogenesis.  Therefore, a development model of 
neurite growth was used to assess pyrethroid effects on neuronal branching.  The gene 
expression data from the present study support that pyrethroid effects on neurite branching 
and not length may be due to increased expression of a suite of genes that shifts the growth 
pattern of neurons away from extension of neuronal processes and more towards neurite 
branching.  Overexpression of Notch1 in rat cortical neurons results in an increase in 
neuronal branching and an antagonism of neurite extension (Redmond et al. 2000).  
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Likewise, overexpression of β-catenin and Cxcl12 results in increased dendritic and axonal 
branch tip number, respectively and has no or opposite effects on measures of length (Yu and 
Malenka 2003; Pujol et al. 2005).  All of these transcripts are upregulated following 
pyrethroid exposure in vivo (see Figure 2.5 heatmaps).  The exact cellular mechanisms that 
mediate pyrethroid-induced increases in branching are currently unknown. 
 The present data support that pyrethroids affect the developmental morphogenesis of 
neurons.  However, these data are not consistent with the results of previous studies of 
pyrethroid effects on developmental neuronal outgrowth.  Treatment of developing X. laevis 
neurons with 10 nM deltamethrin resulted in an increase in total neurite length in the 
presence of extracellular Ca+2 (Lautermilch and Spitzer 2000).  In contrast, exposure of N2A 
neuroblastoma or C6 glioma cells the pyrethroid cypermethrin resulted in no effect on 
morphology (Flaskos et. al 2007).  The disparity between the results from these studies and 
the present study could be due to differences in the compounds tested, exposure conditions 
and cell types.  Preliminary experiments in PC-12 neuroblastoma cells (data not shown) did 
not demonstrate any effects on neurite branching or length.  This supports the observations of 
Flaskos et al. (2007) and indicates a disparity between different cell culture models for 
detecting pyrethroid effects on neuronal morphology.  The present data is the first to 
demonstrate an effect of pyrethroids on the branching morphology of primary cultured 
neurons.   
 Disruption of neuronal morphogenesis in the developing nervous system by 
pyrethroids could result in detrimental effects on neurological function later in life.  
Intermittent exposure to stimulant drugs such as amphetamine can produce an increase in 
dendritic branching in vivo in both juvenile and adult rats (Robinson and Kolb 2004; Diaz 
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Heijtz et al. 2003; Robinson and Kolb 1999).  These morphological changes are thought to 
underlie some of the adverse neurological effects associated with abuse of stimulant drugs 
(e.g., learning deficits) (see Robinson and Kolb 2004; Gonzalez et al. 2005).  In addition, 
lead exposure during development results in neurological deficits that have been associated 
with changes in neuronal morphology (Petit and LeBoutillier 1979; McConnell and Berry 
1979; Costa et al. 2004).  Both lead and stimulant drugs facilitate neurite outgrowth in in 
vitro cell culture models that is similar, but not identical, to the increased branching observed 
with pyrethroids in the present study (Kern et al. 1993; Audesirk and Cabell 1999; Crumpton 
et al. 2001; Park et al. 2002; Park et al. 2003).  Collectively, these works demonstrate that in 
vitro models of neuronal outgrowth are sensitive to neurotoxic agents that produce 
neurological deficits and consequent changes in neuronal morphology in vivo.   Several 
questions remain to be addressed before definitive conclusions regarding pyrethroid effects 
on neuronal morphogenesis can be made, including: 1) whether or not pyrethroid-induced 
changes in morphology occur in vivo, 2) are effects on morphogenesis specific to cortical 
neurons, and 3) do all compounds in the pyrethroid class produce the same types of effects 
on neuronal branching morphogenesis?   
 In conclusion, the present study has identified a group of genes whose transcription is 
altered in a dose-dependent manner in the rat cortex following in vivo pyrethroid exposure.  
A majority of the gene expression changes observed in this study are consistent with the 
induction of neuronal hyperexcitability by pyrethroids.  The gene expression changes 
observed are transient, comparable between the two pyrethroids tested and provide insight 
into the cellular response of the neurons downstream of the pharmacological effects of these 
compounds at the neuronal membrane.  Most importantly, this study provides evidence that 
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branching of cortical neurons is increased by pyrethroids, suggesting that neurotoxic action 
of these compounds includes effects on neuronal morphology. 
Supplementary Data. 
 
Appendix A, Table 1 compares coefficients of variation for probe set expression summaries 
using either GCOSv1.2 or RMA.  Appendix A, Table 2 provides assay identification 
numbers, context sequences, amplicon lengths and calculated amplification efficiencies for 
Applied Biosystems TaqMan® qRT-PCR assays used in this study.  Appendix A, Figure 1 is 
a comparison of rank order of significance between SAM-based linear regression and 
Benjamini-Hochberg adjusted ANOVA analysis methods. 
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Table 2.1.  Group sizes of cohorts used in this study. 
 
 
 Permethrin Deltamethrin  
Dose (mg/kg) : Vehicle 1.0 10.0 40.0 100.0 0.3 1.0 3.0 
EDL : Control <NOAEL NOAEL ED30 ED50 <NOAEL NOAEL ED30 
 
Microarray Dose Response a 
Cohort 1 6 3 3  3 3 3 3 
Cohort 2 6 5 5  5 5 5 5 
         
qRT-PCR Dose-Response b 
Cohort 3 7 7 7 7 7    
 
7     7 7 7 
qRT-PCR Time Course c 
Cohort 4 84    84    
 
84       84 
 
a Microarray data from Cohorts 1 & 2 were combined (n=8 / treatment group) with control 
values from cohorts 1 & 2 (n=12) for dose-response analysis of permethrin and deltamethrin 
mediated effects, respectively.  b  Test animals in Cohort 3 were split into two dose-response 
studies for permethrin and deltamethrin, respectively, for qRT-PCR confirmation of gene 
expression changes observed during the microarray study.  C  Test animals in Cohort 4 were 
used for qRT-PCR time course studies. Four time points (1,3,6,9 hours: n = 8 / treatment 
group) per compound with time matched controls (n = 8 / control group).  
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Table 2.2.  List of probe sets with dose-dependent changes in expression for deltamethrin.  Affymetrix probe set IDs without a gene 
symbol are expressed sequence tags (ESTs).   Probe sets with arrows correspond to genes examined by qRT-PCR.  Positive SAM di or 
PIR M scores denote upregulated probe sets.  Negative SAM di or PIR M scores denote downregulated probe sets. 
 
Affymetrix 
  
Linear Regression (SAM) Isotonic Regression (PIR) ANOVA 
 Gene ID GenBank Gene Symbol Score(di) p-value q-value M p-value q-value p-value 
  1371363_at BI277042 Gpd1 5.63 0.0000 0.00 2.34 0.0000 0.24 0.0032 
  1388901_at AW534837 Fkpb51 5.46 0.0000 0.00 2.21 0.0000 0.42 0.0051 
  1367577_at NM_031970 Hsp27 4.60 0.0001 0.00 1.90 0.0002 0.97 0.0195 
  1369560_at NM_022215 Gpd1 4.53 0.0001 0.00 1.91 0.0002 1.00 0.0134 
 1373415_at AI407050    4.37 0.0001 0.00 1.80 0.0004 1.00 0.0195 
  1368064_a_at U31884 Ddc -4.35 0.0001 0.14 -1.95 0.0002 1.00 0.0195 
  1391229_at BG381458 Camk1g 4.22 0.0002 0.00 2.11 0.0000 0.51 0.0063 
  1393128_at BI288424 RGD1311086 4.13 0.0002 0.00 1.76 0.0005 1.00 0.0205 
  1380611_at BI284255 Fkpb51 3.90 0.0004 0.11 1.62 0.0012 1.00 0.0276 
 1390659_at BI302830    3.82 0.0005 0.11 1.49 0.0028 1.00 0.0276 
 1392492_at AA956982    3.70 0.0007 0.11 1.66 0.0009 1.00 0.0276 
 1369303_at NM_031019 Crh 3.62 0.0009 0.11 1.73 0.0006 1.00 0.0276 
 1389159_at BM385437    3.56 0.0011 0.18 1.47 0.0031 1.00 0.0319 
 1375199_at BG378641    3.54 0.0011 0.18 1.41 0.0045 1.00 0.0295 
 1390449_at BI289132    3.48 0.0013 0.19 1.64 0.0011 1.00 0.0295 
 1388271_at BM383531 LOC689415 3.48 0.0013 0.19 1.44 0.0037 1.00 0.0300 
 1384396_at AI144852    3.45 0.0014 0.19 1.62 0.0012 1.00 0.0276 
 1390606_at BI289052 RGD1564108_predi
cted 
-3.42 0.0015 0.14 -1.82 0.0004 1.00 0.0276 
 1382619_at AI072460    3.39 0.0017 0.19 1.60 0.0013 1.00 0.0276 
 1370989_at AI639318 Ret 3.38 0.0017 0.19 1.49 0.0028 1.00 0.0300 
 1391805_at BE096676 RGD1310364_predi
cted 
3.29 0.0022 0.29 1.50 0.0027 1.00 0.0300 
 1370026_at NM_012935 Cryab 3.28 0.0022 0.29 1.46 0.0032 1.00 0.0364 
 1381693_at AW526413    -3.24 0.0024 0.14 -1.39 0.0046 1.00 0.0364 
 1374626_at BG371585 Lrg1 3.23 0.0025 0.33 1.45 0.0036 1.00 0.0323 
 1378261_at BE102806    3.15 0.0030 0.41 1.29 0.0089 1.00 0.0429 
 1373354_at BF418347    3.14 0.0031 0.41 1.51 0.0025 1.00 0.0299 
 1372761_at AI228076    3.09 0.0035 0.41 1.29 0.0088 1.00 0.0467 
 1378008_at BF417386    3.08 0.0037 0.51 1.60 0.0014 1.00 0.0276 
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 1376709_at BM388442 Slc39a8 -3.07 0.0038 0.14 -1.49 0.0026 1.00 0.0364 
 1368650_at NM_031135 Klf10 -3.07 0.0038 0.14 -1.30 0.0077 1.00 0.0356 
 1368891_at AI014001    3.03 0.0041 0.51 1.34 0.0066 1.00 0.0460 
 1380329_at AI717253 Tmem10 -3.03 0.0041 0.14 -1.28 0.0086 1.00 0.0496 
 1373298_at BI288011    3.03 0.0042 0.51 1.49 0.0027 1.00 0.0351 
 1376928_at BE106737    3.03 0.0042 0.51 1.41 0.0045 1.00 0.0295 
 1372564_at AI411375 Ets2 3.03 0.0042 0.51 1.41 0.0045 1.00 0.0396 
 1382188_at BF397703 RGD1311086 3.02 0.0042 0.51 1.40 0.0048 1.00 0.0345 
 1380682_at BF396302 Rkhd3_predicted 2.99 0.0045 0.51 1.45 0.0035 1.00 0.0329 
 1370454_at AB003726    2.99 0.0046 0.51 1.32 0.0075 1.00 0.0369 
 1388522_at AI170820 RGD1310383_predi
cted 
2.97 0.0048 0.51 1.40 0.0047 1.00 0.0356 
 1389507_at AI072446 Nedd4l 2.97 0.0048 0.51 1.42 0.0043 1.00 0.0306 
 1372491_at AI229647 RGD1565591_predi
cted 
2.92 0.0054 0.56 1.19 0.0159 1.00 0.0442 
 1375138_at AA893169 Timp3 2.92 0.0054 0.56 1.22 0.0134 1.00 0.0319 
 1371922_at AI169140    2.91 0.0056 0.56 1.28 0.0098 1.00 0.0402 
 1374419_at AI044435    2.90 0.0057 0.56 1.53 0.0021 1.00 0.0306 
 1372966_at AI178784 RGD1310174_predi
cted 
2.89 0.0059 0.56 1.23 0.0128 1.00 0.0476 
 1383665_at BE096055 Lpin2_predicted 2.86 0.0063 0.59 1.21 0.0142 1.00 0.0496 
 1384841_at AA858815    -2.86 0.0064 0.14 -1.46 0.0031 1.00 0.0421 
 1385892_at AA900322    2.84 0.0067 1.15 1.40 0.0046 1.00 0.0276 
 1390163_at BF282174    2.83 0.0068 1.15 1.38 0.0052 1.00 0.0440 
 1370530_a_at AB000779 Pld1 -2.81 0.0071 0.14 -1.34 0.0062 1.00 0.0493 
 1385778_at BF409913 Siat7E 2.79 0.0075 1.15 1.38 0.0055 1.00 0.0276 
 1388401_at BI296155 Finb_predicted 2.79 0.0076 1.15 1.17 0.0180 1.00 0.0429 
 1395986_at BF391439 Slit2 -2.78 0.0077 0.14 -1.27 0.0094 1.00 0.0419 
 1382186_a_at AI136314 RGD1311086 2.77 0.0078 1.15 1.15 0.0204 1.00 0.0442 
 1369973_at NM_017154 Xdh 2.76 0.0080 1.15 1.18 0.0167 1.00 0.0472 
 1393337_at AW524476 Tcfcp2l1_predicted 2.73 0.0088 1.16 1.37 0.0056 1.00 0.0276 
 1382225_at BF284510    2.72 0.0090 1.16 1.28 0.0095 1.00 0.0427 
 1368438_at NM_022236 Pde10a 2.70 0.0094 1.16 1.11 0.0255 1.00 0.0496 
 1387260_at NM_053713 Klf4 -2.69 0.0096 0.14 -1.49 0.0026 1.00 0.0429 
 1372356_at BI285307 Usp54 2.69 0.0097 1.16 1.12 0.0240 1.00 0.0442 
 1371442_at BI282904 Hyou1 2.68 0.0099 1.16 1.03 0.0384 1.00 0.0467 
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 1375296_at AI407178 LOC684097 2.66 0.0105 1.16 1.40 0.0047 1.00 0.0427 
 1398899_at AI170414 Polr2c 2.64 0.0110 1.16 1.67 0.0009 1.00 0.0195 
 1380835_at BF389476 RGD1565346_predi
cted 
2.62 0.0115 1.16 1.38 0.0053 1.00 0.0467 
 1377518_at AW251224 Camk1g 2.59 0.0123 1.16 1.29 0.0090 1.00 0.0315 
 1375761_at AW532391    2.57 0.0128 1.16 1.36 0.0061 1.00 0.0356 
 1383861_at BF394135    2.57 0.0129 1.16 1.35 0.0065 1.00 0.0306 
 1392321_at BE120641    2.57 0.0130 1.16 1.29 0.0092 1.00 0.0467 
 1372090_at AI231566 Max 2.53 0.0143 1.16 1.31 0.0080 1.00 0.0306 
 1397261_at AI547508 Max   -2.50 0.0152 0.14 -1.42 0.0040 1.00 0.0295 
 1376768_at BM386807    2.40 0.0191 1.16 1.52 0.0023 1.00 0.0276 
 1381557_at BI289045 Gna14 2.35 0.0216 1.16 1.29 0.0087 1.00 0.0442 
 1397677_at AI501069    -2.30 0.0243 0.14 -1.42 0.0039 1.00 0.0467 
 1398373_at AA799400 B3galt3 2.29 0.0248 1.16 1.29 0.0091 1.00 0.0396 
 1395253_at BE107893    -2.25 0.0273 0.14 -1.39 0.0046 1.00 0.0388 
 1372037_at AI104117 Pdlm7 2.18 0.0319 1.16 1.28 0.0098 1.00 0.0351 
 1382112_at BM385698 LOC682926 -2.16 0.0333 1.15 -1.26 0.0096 1.00 0.0344 
 1397229_at BF565781    -2.15 0.0342 1.15 -1.26 0.0095 1.00 0.0295 
 1391147_at BF404398    -2.13 0.0354 1.15 -1.36 0.0056 1.00 0.0427 
 1397198_at BE111113    -2.13 0.0361 1.15 -1.26 0.0096 1.00 0.0427 
 1396401_at AW433899    2.11 0.0377 1.16 1.47 0.0031 1.00 0.0319 
 1385821_at BF392004    -2.09 0.0390 1.15 -1.55 0.0019 1.00 0.0300 
 1384959_at BI295935    2.03 0.0449 1.16 1.41 0.0045 1.00 0.0295 
 1372448_at D86711 Medl19_predicted 2.01 0.0467 1.16 1.36 0.0060 1.00 0.0276 
 1376463_at AA955579    -1.97 0.0510 1.15 -1.33 0.0067 1.00 0.0402 
 1386344_at BG662519    1.97 0.0511 1.16 1.29 0.0089 1.00 0.0295 
 1395169_at BF388779 Zcch8_predicted 1.96 0.0516 1.16 1.29 0.0092 1.00 0.0442 
 1375752_at AI577874 Bves -1.96 0.0519 1.15 -1.41 0.0042 1.00 0.0376 
 1370869_at AI102790 Bcat1 1.92 0.0561 1.16 1.28 0.0096 1.00 0.0345 
 1367706_at NM_031353 Vdac1 1.74 0.0820 1.16 1.29 0.0090 1.00 0.0295 
 1385645_at AA875088    -1.73 0.0827 1.15 -1.32 0.0069 1.00 0.0295 
 1377514_at BF413478    -1.59 0.1087 1.15 -1.30 0.0079 1.00 0.0295 
 1380905_at AA893260    -1.56 0.1162 1.15 -1.72 0.0007 1.00 0.0276 
 1393978_at BF415134 Stfa2_predicted 1.40 0.1564 1.16 1.32 0.0077 1.00 0.0223 
 1396505_at BE113909    -0.64 0.5102 1.15 -1.27 0.0090 1.00 0.0254 
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Table 2.3.  List of probe sets with dose-dependent changes in expression for permethrin.  Affymetrix probe set IDs without a gene 
symbol are expressed sequence tags (ESTs).   Probe sets with arrows correspond to genes examined by qRT-PCR.  Positive SAM di or 
PIR M scores denote upregulated probe sets.  Negative SAM di or PIR M scores denote downregulated probe sets. 
 
 
Affymetrix 
  
Linear Regression (SAM) Isotonic Regression (PIR) ANOVA 
 
Gene ID GenBank Gene Symbol Score(di) p-value q-value M p-value q-value p-value 
 1393119_at BM388725   5.20 0.0000 0.00 2.22 0.0000 0.96 0.0050 
 1373415_at AI407050   4.89 0.0001 0.00 2.06 0.0001 1.00 0.0050 
 1390412_at AI229664 Slc40a1 -3.50 0.0006 0.18 -1.70 0.0016 1.00 0.0050 
 1373035_at AI031032   4.76 0.0001 0.00 1.96 0.0002 1.00 0.0078 
 1373298_at BI288011   4.22 0.0001 0.00 2.08 0.0001 1.00 0.0078 
 1369303_at NM_031019 Crh 4.26 0.0001 0.00 1.92 0.0003 1.00 0.0113 
 1391901_at AA956085   4.19 0.0002 0.00 1.84 0.0005 1.00 0.0139 
 1374610_at AI599365   4.06 0.0002 0.00 1.91 0.0003 1.00 0.0139 
 1395303_at BF397734   -0.80 0.3465 0.69 -1.48 0.0041 1.00 0.0139 
 1396401_at AW433899   0.71 0.4017 1.32 1.44 0.0038 1.00 0.0139 
 1392791_at AA964492   3.88 0.0003 0.00 1.65 0.0012 1.00 0.0170 
 1368677_at NM_012513 Bdnf 3.85 0.0003 0.00 1.52 0.0025 1.00 0.0170 
 1370415_at AF002251 Rassf5 3.37 0.0008 0.12 1.85 0.0004 1.00 0.0170 
 1393389_at BF396237   3.25 0.0011 0.18 1.39 0.0049 1.00 0.0170 
 1375043_at BF415939 c-fos 3.23 0.0012 0.18 1.41 0.0045 1.00 0.0170 
 1379910_at AI136097 RGD1561967_predicted 2.79 0.0037 0.55 1.42 0.0043 1.00 0.0170 
 1398464_at AI575255   -2.58 0.0066 0.69 -1.38 0.0067 1.00 0.0170 
 1389090_at BI284350 Wrnip1 1.32 0.1319 0.79 1.30 0.0079 1.00 0.0170 
 1381557_at BI289045 Gna14 2.67 0.0052 0.61 1.87 0.0004 1.00 0.0176 
 1376602_a_at AI030899 Fbxo22 0.89 0.2974 1.32 1.27 0.0096 1.00 0.0186 
 1387025_at NM_019234 Dync1i1 2.76 0.0041 0.55 1.29 0.0085 1.00 0.0208 
 1370454_at AB003726   3.85 0.0003 0.00 1.15 0.0185 1.00 0.0215 
 1395197_at BI293027   -3.61 0.0005 0.18 -1.75 0.0013 1.00 0.0230 
 1368321_at NM_012551 Egr1 2.87 0.0030 0.50 1.21 0.0132 1.00 0.0230 
 1375986_at AI103155   2.83 0.0034 0.50 1.59 0.0017 1.00 0.0230 
 1372019_at AI231789 RGD1310128_predicted 2.62 0.0059 0.69 1.35 0.0061 1.00 0.0230 
 1390716_at BE098148   -1.87 0.0401 0.69 -1.55 0.0031 1.00 0.0230 
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 1397745_at BF414336   -0.91 0.2860 0.69 -1.43 0.0051 1.00 0.0230 
 1387024_at NM_053883 Dusp6 2.59 0.0064 0.75 1.01 0.0398 1.00 0.0230 
 1372363_at BF404414 RGD1561203_predicted 2.54 0.0073 0.79 1.33 0.0067 1.00 0.0230 
 1374787_at BI282169   2.50 0.0081 0.79 1.34 0.0064 1.00 0.0230 
 1382275_at AI236989 MGC125015 2.24 0.0158 0.79 1.46 0.0034 1.00 0.0230 
 1383685_at BI276972 Heatr1_predicted 1.54 0.0836 0.79 1.32 0.0072 1.00 0.0230 
 1381400_at AI137973   1.42 0.1080 0.79 1.33 0.0068 1.00 0.0230 
 1380509_at AW253985   1.37 0.1193 0.79 1.40 0.0047 1.00 0.0230 
 1369067_at NM_031628 Nr4a3 2.77 0.0040 0.55 1.15 0.0187 1.00 0.0270 
 1395272_at BF394456 LOC682937 -1.88 0.0394 0.69 -1.33 0.0084 1.00 0.0305 
 1385778_at BF409913 Siat7E 2.36 0.0116 0.79 1.43 0.0041 1.00 0.0305 
 1391301_at AA997499 LOC682355 0.51 0.5404 1.32 1.35 0.0062 1.00 0.0305 
 1371731_at AI408151 RGD1566215_predicted 3.13 0.0015 0.28 1.44 0.0038 1.00 0.0315 
 1378407_at BF401415   2.28 0.0145 0.79 1.29 0.0083 1.00 0.0315 
 1392108_at BF390648   2.85 0.0032 0.50 1.34 0.0064 1.00 0.0347 
 1382225_at BF284510   3.29 0.0010 0.12 1.50 0.0028 1.00 0.0349 
 1381070_at AI233106   2.01 0.0286 0.79 1.51 0.0026 1.00 0.0351 
 1367652_at AI713966 Igfpb3 1.38 0.1190 0.79 1.35 0.0063 1.00 0.0358 
 1395991_at BE107556 Rimbp2 3.11 0.0016 0.28 1.39 0.0050 1.00 0.0400 
 1372998_at BG381555   2.45 0.0094 0.79 1.20 0.0144 1.00 0.0405 
 1384884_at AW528484 RGD1307595_predicted 1.18 0.1755 1.32 1.35 0.0060 1.00 0.0405 
 1382613_at AW144049   -2.68 0.0051 0.69 -1.50 0.0039 1.00 0.0408 
 1388911_at AI177134 Prim2 2.50 0.0082 0.79 1.45 0.0036 1.00 0.0408 
 1396747_at BE121159   2.33 0.0128 0.79 1.32 0.0071 1.00 0.0428 
 1376616_at BF551036   -2.40 0.0107 0.69 -1.36 0.0071 1.00 0.0429 
 1388583_at BF283398 Cxcl12 2.92 0.0027 0.42 1.36 0.0057 1.00 0.0477 
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Table 2.4.  qRT-PCR confirmation of transcripts identified as dose-responsive. 
                Deltamethrin                                   Permethrin  
Dose (mg/kg) :  Va 0.3  1  3 Va  1 10 40   100 
bEDL: Control sub-NOAEL NOAEL   ED30 Control sub-NOAEL NOAEL   ED30    ED50      . 
 Camk1g 1.03 ± 0.10 1.23 ± 0.18 1.40 ± 0.18* 1.57 ± 0.14* 1.04 ± 0.13 1.05 ± 0.14 1.97 ± 0.28* 1.76 ± 0.32* 1.72 ± 0.30*          
  1391229_at 1.00 ± 0.04 1.10 ± 0.03 1.26 ± 0.07 1.31 ± 0.06 1.00 ± 0.04 1.16 ± 0.10 1.09 ± 0.05  1.25 ± 0.09 
  1377518_at 1.00 ± 0.05 1.07 ± 0.08 1.40 ± 0.12 1.36 ± 0.16 1.00 ± 0.05 1.20 ± 0.13 1.09 ± 0.09  1.45 ± 0.17 
 
 Ddc 1.01 ± 0.06 0.79 ± 0.06 0.89 ± 0.07 0.70 ± 0.05* 1.04 ± 0.12 0.97 ± 0.10 0.91 ± 0.10 0.81 ± 0.11* 0.71 ± 0.09*    
  1368064_a_at 1.00 ± 0.03 0.96 ± 0.04 0.90 ± 0.05 0.80 ± 0.03 1.00 ± 0.03 1.04 ± 0.04 1.01 ± 0.04  1.00 ± 0.05 
 
 Gpd1 1.06 ± 0.13 1.16 ± 0.13 1.04 ± 0.12 2.04 ± 0.28* 1.04 ± 0.14 0.94 ± 0.07 0.97 ± 0.06 1.24 ± 0.15 1.23 ± 0.13  
  1371363_at 1.00 ± 0.11 0.88 ± 0.07 1.42 ± 0.17 1.94 ± 0.19 1.00 ± 0.11 1.03 ± 0.10 1.03 ± 0.09  1.19 ± 0.18  
  1369560_at 1.00 ± 0.08 0.88 ± 0.05 1.25 ± 0.13 1.55 ± 0.14 1.00 ± 0.08 0.98 ± 0.09 0.95 ± 0.10  1.12 ± 0.16 
 
 Fkbp51 1.01 ± 0.06 0.92 ± 0.06 1.02 ± 0.07 1.52 ± 0.14* 1.02 ± 0.09 1.03 ± 0.09 1.00 ± 0.06 0.95 ± 0.07 1.03 ± 0.12 
  1388901_at 1.00 ± 0.05 1.00 ± 0.03 1.17 ± 0.05 1.41 ± 0.09 1.00 ± 0.05 0.92 ± 0.05 1.06 ± 0.03  1.07 ± 0.05 
  1380611_at 1.00 ± 0.04 1.04 ± 0.07 1.16 ± 0.08 1.35 ± 0.10 1.00 ± 0.04 0.96 ± 0.07 0.99 ± 0.06  1.07 ± 0.09 
  
 c-fos 1.19 ± 0.27 0.63 ± 0.14 1.09 ± 0.43 0.54 ± 0.08* 1.09 ± 0.21 1.49 ± 0.25 1.30 ± 0.22 0.91 ± 0.11 1.25 ± 0.27 
  1375043_at 1.00 ± 0.16 1.01 ± 0.31 0.72 ± 0.12 0.69 ± 0.06 1.00 ± 0.16 0.54 ± 0.07 0.57 ± 0.08  1.56 ± 0.34 
 
 Egr1 1.04 ± 0.12 0.81 ± 0.05 0.90 ± 0.16 0.87 ± 0.07 1.01 ± 0.07 1.10 ± 0.10 1.10 ± 0.11 1.09 ± 0.08 1.12 ± 0.10 
  1368321_at 1.00 ± 0.08 0.93 ± 0.09 0.95 ± 0.08 0.98 ± 0.06 1.00 ± 0.08 0.77 ± 0.02 0.89 ± 0.09  1.19 ± 0.08 
 
 BDNF 1.07 ± 0.18 0.78 ± 0.12 0.91 ± 0.11 1.02 ± 0.10 1.08 ± 0.17 1.06 ± 0.14 1.27 ± 0.22 0.83 ± 0.12 1.09 ± 0.11  
  1368678_at 1.00 ± 0.02 1.00 ± 0.02 0.98 ± 0.01 0.99 ± 0.02 1.00 ± 0.02 0.99 ± 0.01 0.96 ± 0.02  1.04 ± 0.03 
  1368677_at 1.00 ± 0.06 1.16 ± 0.10 1.09 ± 0.07 1.16 ± 0.06 1.00 ± 0.06 0.91 ± 0.08 0.91 ± 0.06  1.39 ± 0.14 
 
 Hsp27 1.06 ± 0.17 0.77 ± 0.06 0.96 ± 0.12 1.12 ± 0.12 1.01 ± 0.05 0.95 ± 0.13 0.96 ± 0.10 1.14 ± 0.13 1.19 ± 0.24  
  1367577_at 1.00 ± 0.09 1.00 ± 0.07 1.15 ± 0.05 1.41 ± 0.05 1.00 ± 0.09 1.14 ± 0.12 1.10 ± 0.06  1.31 ± 0.19 
 
 Rassf5 1.00 ± 0.02 0.90 ± 0.06 0.98 ± 0.05 1.08 ± 0.07 1.02 ± 0.08 1.00 ± 0.06 0.95 ± 0.04 0.92 ± 0.06 1.08 ± 0.05  
  1370415_at 1.00 ± 0.02 1.11 ± 0.06 1.11 ± 0.06 1.15 ± 0.05 1.00 ± 0.02 1.11 ± 0.06 1.11 ± 0.04  1.23 ± 0.05  
Bold values are 2-∆∆CT values (± SE) from qRT-PCR Cohorts 3 (DLT) & 4 (PERM).  Values in italics are fold-change from control (± SE) for microarray probe 
sets (Cohorts 1 & 2) corresponding to the transcript of interest.  All gene expression measurements were at 6 h following pyrethroid exposure.  aV = Vehicle 
control.  bEDL = Equipotent Dose Level, defined from Wolansky et al (2006) – see methods section.  Main effects in two-way ANOVA: RED = EDL (p <0.05) 
and COMPOUND*EDL (p > 0.05), GREEN = COMPOUND (p < 0.05) and COMPOUND*EDL (p > 0.05), BLUE = COMPOUND*EDL (p <0.05) and main 
effect of DOSE in a one-way ANOVA for deltamethrin.  *= Significant difference from vehicle control in a Dunnett’s mean contrast test (p <0.05). 
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 Table 2.5.  Two-way analysis of variance (ANOVA) for qRT-PCR time course data. 
 
 
        3 mg/kg Deltamethrin 100 mg/kg Permethrin     
Gene                                  Pair                          Pair 
Name Factor  F p-value Wise F p-value Wise 
___________________________________________________________________ 
 
Camk1g TRT 4.56 0.0371** 3 h 2.16 0.1472 n.e. 
 TIME 1.75 0.1665  1.14 0.3391  
 TRT*TIME 2.07 0.1140  0.54 0.6586 
 
Gpd1 TRT 17.56       n/a 3,6 h 12.76 0.0007** 6 h 
 TIME 4.05       n/a  1.55 0.2126 
 TRT*TIME 4.44 0.0072**  1.42 0.2465     
 
Ddc TRT 4.48 0.0387 6,9 h 0.01 0.9419 n.e. 
 TIME 1.78 0.1620  1.01 0.3970 
 TRT*TIME 2.17 0.1025  0.91 0.4438 
 
c-fos TRT 5.78      n/a 3 h 10.66 0.0019** 3 h 
 TIME 6.35      n/a  2.99 0.0386** 
 TRT*TIME 6.26 0.0010**  1.56 0.2014 
 
Egr1 TRT 7.63      n/a 3 h 26.12      n/a 3,6 h 
 TIME 10.43      n/a  8.26      n/a 
 TRT*TIME 7.62 0.0002**  8.40 0.0001** 
 
BDNF TRT 0.14 0.7110 n.e. 2.04 0.1587 n.e. 
 TIME 0.29 0.8358  1.24 0.3052 
 TRT*TIME 0.22 0.8814  0.69 0.5633 
 
_____________________________________________________________________ 
 
Two-way ANOVA factors are: TIME, TRT, TIME*TRT.  Analysis of 2-∆∆CT values is presented.  
n.e. = no effect.  n/a = not applicable.  ** = significant effect at p < 0.05.  Pair-wise comparisons 
are within time for a main effect of treatment (p < 0.05). 
 
 88 
Table 2.6.  Significant Analysis of Function and Expression (SAFE).    
                DLT     PERM 
 Category I.D. and name   size* p-value p-value 
 
Part I. Commonly enriched gene categories for both permethrin and deltamethrin‡ 
 
GO Biological Process 
 GO:0048754, ‘branching morophogenesis of a tube’ 66 0.0171 2.00E-04 
 GO:0001763, ‘morphogenesis of a branching structure’ 67 0.0172 2.00E-04 
 GO:0007162, ‘negative regulation of cell adhesion’ 27 0.0175 0.0025 
 GO:0015718, ‘monocarboxylic acid transport’ 30 0.0051 0.0125 
 GO:0007498, ‘mesoderm development’ 57 0.0105 0.0067 
 
GO Cellular Component 
 GO:0005954, ‘calcium- and calmodulin-dependent protein kinase complex’ 25 0.0053 0.0146 
 
GO Molecular Function 
 GO:0046915, ‘transition metal ion transporter activity’ 44 0.0026 0.0348 
 
 
 Category I.D. and name   size*        p-value** 
 
Part II. Enriched gene categories identified by SAFE. 
Deltamethrin 
 
KEGG Pathway 
 KEGG:00564, ‘Glycerophospholipid metabolism’ 73 0.0404 
 KEGG:00400, ‘Phenylalanine, tyrosine and tryptophan biosynthesis 12 0.0928 
 
Permethrin 
GO Biological Process 
 GO:0048754, ‘branching morphogenesis of a tube’ 66 0.0349 
 GO:0001763, ‘morphogenesis of a branching structure’ 67 0.0349 
 GO:0001569, ‘patterning of blood vessels’ 31 0.0406 
 GO:0009880, ‘embryonic pattern specification’ 49 0.0554 
 GO:0045655, ‘regulation of monocyte differentiation’ 32 0.0932 
  
 
‡ = GO catergories or KEGG pathways with p < 0.1 for both test compounds using SAFE & Fisher’s χ2 method.   * 
= number of Affymetrix probe sets included in GO category or KEGG pathway groupings. 
** = GO categories or KEGG pathways with an adjusted p < 0.1 for SAFE method. 
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Table 2.7.  Pharmacokinetic estimates of pyrethroid brain concentrations. 
 
 Administered  Brain 
 Dose (mg/kg) Time (h) Concentration (µM)___ 
 
Deltamethrina 0.3 6 0.005 
 1 6 0.0169 
 3 6 0.050 
 
Permethrinb 1 6 0.060 
 10 6 0.582 
 100 6 5.940 
________________________________________________________________ 
a Estimates based on Mirfazaelian et al. (2006). 
b Estimates based on Tornero-Velez et al. (2007). 
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Figure 2.1.  Comparison of PIR and SAM regression methods.  Panels A & B plot the 
penalized isotonic regression (PIR) test statistic (M, x-axis) against the penalized linear 
regression (SAM) test statistic (di, y-axis) for deltamethrin and permethrin, respectively.  All 
31,042 probe sets present on the Affymetrix Rat 230 2.0 array are shown.  Data points in 
green have an empirical p-value < 0.01 for both the PIR and SAM methods.  Data points in 
blue have an empirical p-value < 0.01 for the PIR regression only.  Data points in orange 
have an empirical p-value < 0.01 for the SAM regression only.  Data points circled in red 
have a q-value < 0.10 in permutation-based FDR calculations employed in the SAM 
algorithm.
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Figure 2.2.   Dose-response functions identified by PIR and SAM regression methods.  Panels A-F plot dose-response functions for 
probe sets identified by PIR (B & E), SAM (C & F) or both regression methods (A & D) for deltamethrin (A-C) and permethrin (D-F).  
Only probe sets that had a Benjamini-Hochberg adjusted p-value < 0.05 for a main effect of dose in a one-way ANOVA are shown.  
For each probe set expression summaries for each treatment group were normalized to vehicle control and plotted as fold-change from 
control.  The color scheme corresponds to that used in Figure 1, with green curves being detected by both PIR and SAM regression 
methods, blue curves being detected exclusively with the PIR method and orange curves being detected exclusively with the SAM 
method.  Insets on each panel are the summated results of a Dunnett’s many-to-one mean contrast test performed within each probe set 
comparing the means of the lowest (C-L), middle (C-M) and highest (C-H) doses to the mean of vehicle treated control.  y-axis is 
number of probe sets identified under each comparison at a significance level of p <0.05.  Note the green portion of the stacked bars in 
the insets are the same values for panels A-C and D-E, respectively. 
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Figure 2.3.  Comparison of probe sets identified by PIR or SAM between pyrethroids.  Panels A and B plot the –log10 (empirical p-
value) for deltamethrin (x-axis) against the –log10 (empirical p-value) for permethrin (y-axis) for probe sets identified during PIR or 
SAM regression analyses, respectively.  All probe sets that had a Benjamini-Hochberg adjusted p-value <0.05 for a one-way ANOVA 
for either permethrin or deltamethrin are included in the plot.  Dashed boxes represent p < 0.05, p < 0.005, and p < 0.0005 empirical p-
value thresholds.  All points in the upper right of the figures, within the dashed boxes, meet the respective p-value criteria for both 
pyrethroids.  27.2% and 27.8% of all probe sets identified during PIR or SAM analysis, respectively, had empirical p-values of p 
<0.05 for both compounds.
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Figure 2.4.  qRT-PCR time course results.  Transcript expression over time following a 
single acute dose of 3 mg/kg deltamethrin (top) or 100 mg/kg permethrin (bottom).  Gene 
symbols are listed on the y-axis.  Data were analyzed using two-way ANOVA followed by 
one-way ANOVA within time points were interaction was observed.  (**) denotes no 
interaction of time and treatment and a main effect of treatment (p < 0.05).  (‡) denotes no 
interaction of time and treatment and a main effect of both time and treatment (p < 0.05).  (*) 
denotes a significant effect of treatment for that time point (p < 0.05).  (†) denotes a 
significant main effect of dose from qRT-PCR dose-response analysis (Table 2.4).  Values 
for time-matched vehicle controls are not shown. 
 94 
Figure 2.5.  Composition and expression patterns of significantly enriched GO categories 
from SAFE analysis.  Panels A-D are SAFE plots for two commonly enriched categories for 
both deltamethrin (A & C) and permethrin (B & D).  Panels E & F are SAFE plots for a 
category not enriched for either deltamethrin (E) or permethrin (F).  The x-axis of each plot 
denotes the position of all probe set in a rank ordered list of significance (from left to right) 
according to the empirical p-value from a linear regression across dose. The y-axis is a 
cumulative percentage calculated by taking the rank position of a given probe set either 
within the entire data set (solid unity line) or the interrogated Gene Ontology sub-category 
(solid stair-step line) and dividing them by the total number of probe sets contained within 
the entire data set or interrogated category, respectively.  The degree of deviation of the stair-
step line from the unity line indicates enrichment.  The probe sets (excluding ESTs) that are 
ranked highest in significance for each GO category for both compounds in panels A-B and 
C-D are denoted at the top of each panel and included in a heatmap to the side of the 
respective panels.  In the heatmaps, each row of tiles is a probe set and each column of tiles 
represents the mean fold-change from control with increasing doses of each compound 
running from right to left.  Colorbar for heatmaps is given in panel G. 
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Figure 2.6.  Pyrethroid effects on branching and neurite length in primary cortical cell 
cultures.  Changes in the total number neurite of branch points (A & D), total neurite length 
(B & E) and cell viability using an ATP-luciferase assay (C & F) in primary cortical cell 
cultures exposed to deltamethrin (A-C) or permethrin (D-F).  n = 3 different cultures.  Values 
for each end point are normalized to untreated controls (± standard error).  Untreated control 
values are shown in white. The bold lines underneath each curve represent the range of 
estimated brain concentrations expected to occur during the in vivo exposures used in the 
present study (Mirfazaelian et al. 2006 and Tornero-Velez et al. 2007).  Significance was 
determined using a One-way ANOVA, * = p < 0.10, ** = p < 0.05. 
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Abstract. 
 
 Pyrethroid insecticides induce neurotoxicity in mammals by interfering with ion 
channel function in excitable neuronal membranes.  Previous work demonstrated dose-
dependent increases in the expression of Ca+2/calmodulin dependent protein kinase (Camk1g) 
mRNA following acute deltamethrin (DLT) and permethrin (PERM) exposure.  The present 
study tests the hypothesis that changes in Camk1g expression in the rat following acute 
pyrethroid exposure are due to a specific increase in the Camk1g1 (Ca+2-sensitive) splice 
variant and not the Ca+2-insensitive splice variant Camk1g2.  Long-Evans rats (n = 8 / group) 
were acutely exposed (p.o.) to PERM (1, 10, 40, 100 mg/kg), DLT (0.3, 1, 3 mg/kg) or corn 
oil vehicle.  Frontal cortex was collected at 6 h post-dosing.  In addition, rats were exposed to 
PERM (100 mg/kg) or DLT (3 mg/kg) and frontal cortex was collected at 1, 3, 6 or 9 hours 
along with time matched vehicle controls.  Expression of Camk1g1 and Camk1g2 mRNA 
was measured by quantitative real-time RT-PCR and quantified with the 2-∆∆CT method.  
Dose-dependent increases in Camk1g1 mRNA expression were observed for DLT and 
PERM at 6 h.  In addition, a dose-dependent increase in Camk1g2 was also observed at 6 h 
with DLT only, although it was very small in magnitude (<1.2-fold).  The increases in 
Camk1g1 expression for DLT and PERM peak between 3 & 6 h post-exposure and return to 
control levels by 9 h.  There was no detectable increase in Camk1g1 protein as assessed with 
Western blots.  This study demonstrates that following an acute in vivo exposure, 
deltamethrin and permethrin increase expression of Camk1g1 mRNA in rat cortex.  These 
changes in Camk1g1 mRNA expression may be caused by the actions of pyrethroids at the 
neuronal membrane. 
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Introduction. 
 
 Pyrethroids are insecticides commonly used in a variety of agricultural, veterinary, 
domestic and human healthcare related applications (Heudorf and Angerer 2003).  As the use 
of other insecticide classes such as organophosphates and organochlorines has declined, 
pyrethroid usage has risen.  It is estimated that pyrethroids comprise ~25% of the world 
insecticide market (Amweg et al. 2003).  Exposure assessments have detected pyrethroids 
and pyrethroid residues in the urine of pesticide applicators, blood samples of pregnant urban 
mothers, residential carpet dust, and in surface wipe samples from U.S. child-care centers 
(Leng et al. 1997; Whyatt et al. 2003; Colt et al. 2004; Weston et al. 2004; Tulve et al. 2006).  
These data indicate that the potential for human pyrethroid exposure is present in a variety of 
settings. 
   Pyrethroids are neurotoxicants that interact with voltage-sensitive ion channels 
expressed in nerve membranes (Narahashi 1996).  The primary molecular targets of 
pyrethroids are voltage-sensitive Na+ channels (VSSCs) expressed in neuronal axons.  
Pyrethroids slow the deactivation of these channels and induce persistent Na+ currents that 
occur at membrane potentials when VSSCs are normally impermeable to Na+ (Na+ tail 
currents, see Narahashi 2001).  Voltage sensitive Ca+2 channels and voltage-sensitive Cl- 
channels have also been shown to be affected by pyrethroids (Burr and Ray 2004; Shafer and 
Meyer 2004; Symington and Clark 2005).  The net effect of the pharmacological actions of 
pyrethroids at these channels is an alteration in neuronal firing patterns that is thought to 
underlie the poisoning symptoms and transient effects on behavior observed following acute 
in vivo pyrethroid exposures (for review see Ray 2001; Soderlund et al. 2002; Wolansky and 
Harrill 2008).  Alterations in neuronal firing patterns from pharmacological or sensory 
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stimuli have also been shown to trigger de novo gene expression that contributes to long-
lasting adaptive changes in neuronal form and function, such as late-phase long term 
potentiation and synaptic terminal remodeling (Bading 2000; West et al. 2002; Fields et al. 
2005).  To date, alterations in the expression of activity-regulated genes downstream of the 
pharmacological interactions of pyrethroids with molecular targets at the neuronal membrane 
remain poorly characterized.   
 Previous work in this laboratory on the acute in vivo actions of pyrethroids revealed a 
dose-dependent increase in the expression of Ca+2/calmodulin dependent protein kinase 1g 
(Camk1g) mRNA in the frontal cortex of the rat following exposure to two pyrethroids: 
deltamethrin and permethrin (Harrill et al, submitted).  Treatment of in vitro cultures of 
interconnected cortical neurons to pharmacological agents that increase spontaneous firing 
rates also results in an increase in Camk1g mRNA expression (Xiang et. al 2007).  Likewise, 
sub-chronic in vivo exposure of laboratory animals to pharmacological agents known to 
increase spontaneous and sensory evoked neuronal firing patterns also results in an increase 
in Camk1g mRNA expression (Lampl et al. 1998; Gronier and Rasmussen 1998; Dingledine 
2005; Fatemi et al. 2006).  Thus, the increase in Camk1g mRNA expression following in vivo 
pyrethroid exposure is consistent with increases in neuronal excitability elicited by these 
compounds 
 In the rat brain, Camk1g is expressed in two alternative mRNA splice variants that are 
transcribed from the same chromosomal locus (13q27).  These splice variants are termed 
Camk1g1 and Camk1g2 and contain 13 and 12 exons, respectively (Nishimura et al. 2003).  
The domain structure of the protein encoded by the rat Camk1g1 splice variant includes a 
kinase catalytic domain, overlapping Ca+2/calmodulin-binding and autoinhibitory domains, 
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C-terminal prenylation and palmitoylation motifs, and has 99% amino acid homology with 
the Camk1g1 protein expressed in mice (Nishimura et al. 2003; Takemoto-Kimura et al. 
2003; Takemoto-Kimura et al. 2007).  The activity of the Camk1g1 protein is dependent 
upon both the presence of Ca+2-bound calmodulin and activation by an upstream CaM kinase 
kinase (Nishimura et al. 2003).  In contrast, the rat Camk1g2 mRNA splice variant lacks exon 
11 (see Figure 3.1).  The transcribed Camk1g2 protein does not contain a Ca+2/calmodulin-
dependent binding domain and the kinase activity of this protein is not enhanced in the 
presence of Ca+2-bound calmodulin (Nishimura et al. 2003).  In addition, a frame shift in the 
amino-acid coding sequence of Camk1g2 occurs upon excision of exon 11, resulting in a C-
terminal tail that lacks the lipidification sites present in Camk1g1 and essential to Camk1g1 
function (Nishimura et al. 2003; Takemoto-Kimura et al. 2007).  In previous studies that 
detected pyrethroid-induced increases in the expression of Camk1g mRNA in rat cortex, 
neither the Affymetrix microarray probe sets nor the qRT-PCR assays used distinguished 
between the expression of the Camk1g1 and Camk1g2 splice variants (Harrill et al. 
submitted).   
 Proteins in the Ca+2/calmodulin dependent protein kinase family act as intracellular 
signaling molecules that detect transient increases in Ca+2 concentrations in the neuronal 
cytoplasm (such as those that occur in response to an incoming excitatory stimulus) and 
transduce those signals to downstream effector proteins by means of phosphorylation (Agell 
et al. 2002).  In this manner activation of CaM-kinase cascades can bring about alterations in 
neuronal function in response to neuronal activity.  A specific role of Camk1g in regulating 
activity-dependent outgrowth and branching in developing neurons has recently been 
described by Wayman et al. (2006) and Takemoto-Kimura et al. (2007).  Both of these works 
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use constitutive overexpression or knock-down of Camk1g to demonstrate a role for Camk1g 
in controlling neuronal outgrowth in cultures derived from mouse hippocampus and rat 
cortex, respectively.  In addition, these dendritogenesis studies used constructs based on the 
mouse and rat Camk1g1 protein.  Wayman et al. (2006) demonstrate a Camk1g specific 
activation of the Ras/MEK/ERK signaling pathway in response to depolarization, a 
subsequent activation of the transcription factor CREB and transcription of Wnt-2, a soluble 
extracellular autocrine factor that promotes dendritic growth.  Takemoto-Kimura et al. (2007) 
demonstrate that Camk1g is lipidified, inserted into membrane rafts that deliver the activated 
protein to dendritic arbors and controls neurotrophin stimulated dendrite growth and 
branching through the activation of a STEF/Rac signaling pathway.  However, neither of 
these studies addressed the transcriptional regulation of Camk1g expression in response to 
changes in neuronal membrane excitability. 
 The highly divergent structure and functions of the proteins encoded by the two 
Camk1g splice variants, makes it important to determine whether pyrethroids alter expression 
of one or the other splice variants.  Differential up-regulation of Camk1g1 or Camk1g2 
mRNA by pyrethroids would have a different impacts on intraneuronal downstream signaling 
pathways because of the dissimilar structure and upstream regulatory mechanisms that 
control the kinase activity of these two proteins (Takemoto-Kimura et al. 2007).  The goals 
of the present study included characterizing the effects of acute pyrethroid exposure on the 
expression of Camk1g1 and Camk1g2 mRNA splice variants in the rat frontal cortex, and 
determining if acute pyrethroid exposures in vivo result in a change in the expression of 
Camk1g1 protein.  A low dose exposure paradigm was used (i.e. doses that ranged from 
below to slightly above the threshold for detecting changes in neurobehavioral function, 
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Wolansky et al. 2006) to prevent possible confounding effects of more highly toxic 
exposures.    
Methods. 
 
Chemicals and dose solutions.  Permethrin (3-phenoxybenzyl (1R,S)-cis-trans-3-(2,2-
dichlorovinyl)-2,2-dimethyl-cyclopropanecarboxylate, 92.0% purity, isomer composition: 40 
% cis, 60 % trans, 1:1 ratio of 1R & 1S) and deltamethrin ((S)-cyano-(3-
phenoxyphenyl)methyl (1R)-cis-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane 
carboxylate, 98.9 % purity, isomer composition: 100% 1R, 3R, αS ) were generously donated 
by FMC Corporation (Philadelphia, PA) and Bayer Cropscience (Research Triangle Park, 
NC), respectively.  Chemical structures are shown in Figure 3.2.  Pyrethroids were dissolved 
in corn oil (Sigma-Aldrich, St. Louis, MO) at 1, 10, 40 & 100 mg/mL permethrin and 0.3, 1 
& 3 mg/mL deltamethrin.  Dosing volume was 1mL/kg.  qRT-PCR primers, probes and 
reagents were obtained from Applied Biosystems (Foster City, CA).  AP7253b rabbit 
polyclonal antibody for Camk1g1 was obtained from Abgent, Inc. (San Deigo, CA).  Mouse 
monoclonal antibody (sc-47751) for βII tubulin was obtained from Santa Cruz 
Biotechnologies, Inc. (Santa Cruz, CA).  HRP-conjugated rabbit and mouse secondary 
antibodies were obtained from KPL, Inc. (Gaithersburg, MD).  
 
Animal care and treatment.  Male Long-Evans rats (49-62 days of age) were obtained from 
Charles River Laboratories (Wilmington, MA) and housed two per cage in standard 
polycarbonate hanging cages (45 cm X 24 cm X 20 cm) with heat sterilized pine shavings for 
bedding (Beta Chips, Northeastern Products, Inc., Warrensburg, NY).  Animals were 
maintained on 12h:12h photoperiod (lighted hours: 06:00-18:00) and allowed a 5-7 day 
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period of acclimation to the colony prior to dosing.  Colony rooms were maintained at 22.0 ± 
2.0°C with a relative humidity of 55 ± 20%.  Food (Purina 5001 Rat Chow) and tap water 
were provided ad libitum.   
 For the dose-response studies, rats were treated by oral gavage with 0.3, 1 or 3 mg/kg 
deltamethrin, 1, 10, 40 or 100 mg/kg permethrin or corn oil vehicle.  Dose-effect data from 
Wolansky et al. (2006) were used to: 1) pick doses that were slightly below, at, and slightly 
above the threshold for detecting neurotoxic effects, and 2) assign equipotent dose-levels 
(EDL) to the administered doses to provide a comparative dose-metric between the two test 
compounds.  Dosing for dose-response studies occurred between 06:30 and 07:00 hours and 
the last test subject was euthanized before 18:00 hours.  Dosing and euthanasia times for 
individuals were counterbalanced across time of day.  In the time course studies rats were 
treated via oral gavage with 3 mg/kg deltamethrin, 100 mg/kg permethrin or vehicle.  All test 
subjects were dosed and euthanized between 07:30 & 17:30 hours.  Rats were removed from 
the colony suite one hour prior to dosing and allowed to acclimate in a quiet holding room 
maintained under similar environmental conditions.  Subjects were administered a single oral 
dose of test compound by gavage, and allowed to recover in their home cage prior to 
euthanasia for 6 hours (dose-response studies) or 1, 3, 6, 9, 12 or 24 hours (time course 
studies).  Subjects were then individually removed to an adjoining suite with a separate 
HVAC system for euthanasia by decapitation.  The facility was approved by the American 
Association for Accreditation of Laboratory Animal Care (AAALAC) and all experimental 
procedures were approved in advance by the by the US EPA, National Health and 
Environmental Effects Research Laboratory Animal Care and Use Committee. 
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 Whole brains were rapidly removed and placed on a cold plate (4°C).  The frontal 
cortex was removed by making a vertical incision at the anterior edge of the optic tract with a 
stainless steel razor, and rapidly frozen on a bed of dry ice.  Cortical samples, without striatal 
tissue, were then bisected into contralateral hemispheres, weighed, frozen in liquid nitrogen 
and stored at -80°C.  In the time course study, one contralateral hemisphere was used for 
RNA extraction and qRT-PCR assays while the other hemisphere was used to make protein 
homogenates for Western Blot analysis. 
 
RNA extraction.  Frontal cortex samples were homogenized in 1 mL of TRI Reagent 
(Molecular Research Center, Inc., Cincinnati, OH) per 50-100 mg of tissue using a 
Polytron® PT-K homogenizer (Kinematica, Lucerne, Switzerland) and total RNA was 
isolated per manufacturer’s instructions.  Total RNA pellets suspended in DEPC-treated H2O 
were then subject to DNase I treatment and reextracted with acid:phenol chloroform, pH = 
4.7 and chloroform according to manufacturer’s protocol and resuspended in DEPC-treated 
H2O until use (Ambion Inc., Austin, TX).  The total RNA concentration of each sample was 
determined (absorbance @ 260 nm) on a Beckman-Coulter DU® 800 spectrophotometer 
(Fullerton, CA) and adjusted to 1.0 µg/µL prior to sample storage at -80ºC.  The ratio of 
absorbance values at 260 nm and 280 nm (Ab 260/280) was used to assess purity of total 
RNA samples.  All samples used in these studies had Ab 260/280 ratios > 1.6 (data not 
shown).  Preliminary PCR experiments using primers for rat β-actin genomic DNA (outlined 
in Tully et al. 2006) demonstrated that the above protocol adequately prevents genomic DNA 
contamination of total RNA samples (data not shown).  In addition, the RNA integrity of 
each sample was determined using an Agilent 2100 Bioanalyzer and RNA 6000 Nano 
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LabChip Kit (Waldbron, Germany) according to manufacturer’s instructions.  All samples 
used in qRT-PCR experiments had 18S:28S rRNA ratios > 1.6 (data not shown).  Following 
the RNA purity and integrity screens, aliquots of each total RNA sample were stored at -
80°C until use. 
 
Quantitative real-time RT-PCR.  qRT-PCR assays were performed using TaqMan® One-
Step RT-PCR Master Mix Reagent Kits and TaqMan® Gene Expression Assays on a ABI 
7900HT Sequence Detection System (Applied Biosystems, Foster City, CA).  The custom 
designed qRT-PCR assays used to distinguish between the Camk1g1 and Camk1g2 mRNA 
splice variants (Applied Biosystems, Foster City, CA) were targeted to exon junctions unique 
to the respective transcripts (see figure 3.1).  AmpliTaq Gold® DNA Polymerase / dNTP 
mix, MultiscribeTM reverse transcriptase / RNA inhibitor mix and TaqMan® Gene expression 
primer-probe mix specific for the transcript of interest were combined according to 
manufacturer’s specifications (Applied Biosystems 2005).  The reaction mixture was then 
dispensed into the reaction plate (15 µL / well) and 125 ng of total RNA (5 µL) was added.  
Each sample was measured in triplicate for each transcript of interest and internal reference 
gene.  Reaction plates were maintained at 5°C during loading procedure.  During data 
collection, reactions were incubated at 48°C for 45 min followed by incubation at 95°C for 
10 min and 40 cycles of 94°C for 25 sec and 60°C for 1 min.   
 Details of the qRT-PCR assays used in this work are listed in Table 3.1.  The 
amplification efficiency of each assay utilized in this experiment was examined using a serial 
dilution of pooled total RNA from rat cerebrocortex.  Efficiencies were calculated as: Ex = 
10(-1/m) – 1, where E is the amplification efficiency of target transcript x and m is the slope of 
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threshold cycles versus log10 [total RNA concentration] across the range of dilutions 
(Applied Biosystems 2004).  All assays used in this experiment had amplification 
efficiencies in the range of 100 +/- 10% within in the standard operating range of TaqMan 
assays suggested by the manufacturer (Applied Biosystems 2004).  qRT-PCR data from 
deltamethrin and permethrin dose-response and time course studies were analyzed according 
to the 2-∆∆CT method as described by (Livak and Schmittgen 2001).  β-actin expression did 
not change as a function of time or dose for either compound (data not shown) and was used 
at the internal reference for all 2-∆∆CT calculations.  For dose-response studies, the mean ∆∆CT 
of vehicle treated controls were used as the 2-∆∆CT calibrator (Livak and Schmittgen 2001) to 
obtain approximations of fold-change from control.  For time course studies, the mean ∆∆CT 
of vehicle treated controls were used as the 2-∆∆CT calibrator for each time-matched treatment 
group. 
 Statistical analysis of qRT-PCR dose response data was performed using a two-way 
ANOVA with compound and equipotent dose level (EDL) as independent variables and 2-
∆∆C
T as the dependent variable followed by Dunnett’s mean contrast test.  EDLs were defined 
as follows: group 1 (control) – vehicle controls for both compounds, group 2 (“sub-
NOAEL”) – 0.3 mg/kg DLT & 1 mg/kg PERM, group 3 (“threshold”) – 1 mg/kg DLT & 10 
mg/kg PERM, group 4 (“ED30”) – 3 mg/kg DLT & 40 mg/kg PERM, group 5(“ED50”) – 100 
mg/kg PERM.  Statistical analysis of time course data was performed using a two-way 
ANOVA with time and treatment as independent variables and 2-∆∆CT as the dependent 
variable.  Data were additionally analyzed with a one-way ANOVA at each time point with 
treatment as the independent variable (p < 0.05) to determine times of peak effect. 
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Western blot analysis.  Cortical tissue was homogenized in a buffer containing (in mM): 
Tris-HCl (50), NaCl (150), EDTA (1), EGTA (1), Na3VO4 (1), 1 % Trition X-100, 1% 
C24H39NaO4 , 0.1 % SDS and 5 uL of Protease Inhibitor Cocktail III (Calbiochem, Inc., ) per 
5 uL total buffer (pH = 7.4).  Protein was homogenized with thirty even up and down strokes 
with a teflon pestle in a glass tube.  Homogenates were then centrifuged at 12,000 x g at 4°C 
for 10 minutes.  Supernatant was removed and protein concentrations measured using Pierce 
BCATM Protein Assay Kit (Rockford, IL).  Proteins were then stained with a 1:1 volume of 
Laemmli buffer (Bio-Rad, Hercules, CA) and stored at -80°C until use.  On day of use, 
protein samples were boiled for 5 min and allowed to cool to room temperature.  12 µg of 
total protein for each sample was separated on 10% PreciseTM pre-cast polyacrylamide gel 
(Pierce, Inc., Rockford, IL) with running buffer containing (in mM): Tris-HCl (100), HEPES 
(3), SDS (3), pH = 8.0.  Gels were run at a constant voltage of 100 V for 15 min following by 
125 V for 80 min.  Proteins were then transferred to a nitrocellulose membrane using a 
TransBlot SD Semi-Dry Transfer cell (Bio-Rad, Inc., Hercules, CA) using a buffer 
containing (in mM): Tris-Base (48), Glycine (39), 0.000375% SDS and 20 % methanol.  
Proteins were transferred at 20 V for 30 min.  Membranes were then washed with Tris-
buffered saline (TBS, 42.1 mM Tris-HCl, 7.5 mM Tris-Base, 0.9% NaCl, pH=7.5) 
containing 0.03% Tween-20 and blocked for 1 h in 5% non-fat dry milk (Bio-Rad, Inc., 
Hercules, CA) diluted in TBS with 0.03% Tween-20.  Membranes were then incubated 
overnight in blocking solution containing 0.03% Tween-20 and a 1:1000 dilution of 
Camk1g1 primary antibody at 4°C.  Membranes were then washed with TBS contained 
0.01% Tween-20 and incubated with at 1:5000 dilution of rabbit HRP-conjugated secondary 
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antibody in blocking solution at room temperature for 1 h.  Membranes were then washed 
again with TBS, 0.01% Tween-20 and incubated for 5 min at room temperature with 
SuperSignal® West Dura Extendend Duration Substrate (Pierce, Inc., Rockford, IL) 
according to manufacturer’s instructions.  Blots were imaged (400 sec exposure) and optical 
densities of the stained bands quantified on a Bio-Rad VersaDocTM Imaging system and 
Quantity One® 1-D Analysis software (v4.6, Bio-Rad, Inc., Hercules, CA).  Membranes 
were then stripped for 10 min with RestoreTM Western Blot Stripping Buffer (Bio-Rad).  
Membranes were sequentially reprobed with β-II tubulin primary antibody (1:2500) and 
mouse secondary antibody (1:10,000) and imaged according to the above protocol save that 
the primary incubation was for 1 h at room temperature and blots were visualized for 200 
sec.  Western blot expression ratios were calculated by normalizing each Camk1g signal to 
the corresponding β-tubulin signal and divided by the mean Camk1g/β-tubulin ratio from the 
control treated samples.  Each time point was examined independently on separate gels. 
Results. 
 
 Acute oral exposure of rats to 0.3 – 3 mg/kg deltamethrin or 1 – 100 mg/kg 
permethrin resulted in a dose-dependent increase in the expression of Camk1g1 in the frontal 
cortex at 6 h post-exposure (Figure 3.2C and 3.2D).  The mRNA expression patterns 
observed using the Camk1g1 specific assay (red curve, Figure 3.2C and 3.2D) closely 
approximates, but does not exactly match, those observed using a qRT-PCR assay that 
detects both splice variants (blue curve, Figure 3.2A and 3.2B).  For deltamethrin, expression 
of Camk1g1 was increased compared to control (~1.75-fold) across all doses at 
approximately the same level of expression.  For permethrin, expression of Camk1g1 
increased at 10 mg/kg and higher by ~2-fold greater compared to controls.  This closely 
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matches the results of the Camk1g assay that detects both splice variants.  A very small yet 
statistically significant increase in the expression of the Camk1g2 splice variant was observed 
at the ED30 for motor activity (Wolansky et al. 2006) for each compound tested (Figure 3.2E 
and 3.2F).  Results of the statistical analyses of these data are given in Table 3.2.  It is 
apparent from these data that increased expression of the Camk1g1 splice variant is the main 
factor underlying the results obtained in the previous study by Harrill et al. (submitted). 
 The time course of Camk1g mRNA splice variant expression following either 3 
mg/kg deltamethrin or 100 mg/kg permethrin exposures demonstrates that the increases in 
Camk1g1 and Camk1g2 are transient after an acute in vivo exposure (Figure 3.3A and 3.3B).  
Results of the statistical analyses of these data are given in Table 3.3.  An appreciable 
increase in the expression of Camk1g1 mRNA is observed at 3 and 6 h with both compounds 
and returns to control levels by 9 h.  The changes in Camk1g1 mRNA expression are larger 
in magnitude than those for Camk1g2 mRNA with both compounds.  Similar to the dose-
response data, the increases in Camk1g1 mRNA expression closely match the increases 
observed using the qRT-PCR assay that detects both splice variants.  These data also support 
that increased expression of the Camk1g1 splice variant is the main contributor to the results 
obtained in the previous study (Harrill et al. submitted).   
 Since it was determined that Camk1g1 mRNA was changing most dramatically in 
response to pyrethroid exposure, alterations in Camk1g1 protein expression was examined in 
the in vivo time course samples used in this study.  An antibody specific for a region the C-
terminal tail of Camk1g1 (and not Camk1g2) was used to detect changes in protein levels.  
The predicted molecular weight of rat Camk1g1 protein is ~ 53 kDa.  The Camk1g1 primary 
antibody detected a protein band with a slightly larger molecular weight (~ 60 kDa, Figure 
 122 
3.4B).  Both antibodies were able to detect linear increases in expression of their respective 
proteins across a range of diluted protein standards (Figure 3.4C and D).  β-tubulin was used 
as the loading control as treatment had no effect on expression (data not shown).  No 
significant change in the expression of Camk1g1 protein was observed following treatment 
with either 3 mg/kg deltamethrin or 100 mg/kg permethrin (Figure 3.5).   
Discussion. 
 
 The data from the present study demonstrate induction of Camk1g1 mRNA following 
acute in vivo exposure to both deltamethrin and permethrin.  These exposures also resulted in 
modest and very low magnitude changes in the expression of the Camk1g2 mRNA splice 
variant.  No changes in the expression of Camk1g1 protein was observed following acute 
exposure to either 3 mg/kg deltamethrin or 100 mg/kg permethrin, the highest doses used in 
this study.  These data are consistent with increased Camk1g mRNA expression observed in 
the previous work using both Affymetrix microarray technology and a qRT-PCR assay 
capable of detecting both mRNA splice variants of this gene (Harrill et al., submitted).  The 
present data expand on the previous finding by demonstrating that pyrethroid-induced 
changes in Camk1g are driven mainly by increased expression of the Camk1g1 splice variant.  
Furthermore, these data demonstrate that under the dosing conditions used in this study, 
increased Camk1g1 mRNA expression is transient, returning to control levels within 9 h, and 
does not lead to a concurrent increase in Camk1g1 protein expression.      
 It appears, at the least in the case of pyrethroid exposure, that expression of the rat 
Camk1g1 and Camk1g2 mRNA splice variants are not similarly regulated.  Large treatment 
related effects on Camk1g2 mRNA expression are not present even when the expression of 
Camk1g1 mRNA is greatly affected.  Currently, the intracellular mechanisms that control 
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inducible Camk1g1 or Camk1g2 mRNA expression are not known.  Splice variant specific 
upregulation of activity-dependent mRNA species is not unprecedented in the central 
nervous system.  Brain derived neurotrophic factor (Bdnf) mRNA be can expressed in a 
variety of splice variants in the CNS and different splice variants are expressed in response to 
different types, or different durations, of neuronal activity (Khundakar and Zetterstrom 2006; 
Liu et al. 2006).  Differential activation of promoter elements upstream of the Bdnf 
untranslated exons controls the specific patterns of splice variant expression for this gene 
(Tabuchi et al. 2000).  The promoter elements upstream of the Camk1g coding exons have 
not been examined.  It is possible that differential activation of promoter elements in 
response to an excitatory stimulus may be the mechanism driving the differential expression 
observed here in response to pyrethroids.  Alternatively, both Camk1g1 and Camk1g2 mRNA 
may be transcribed at the same rate even in the presence of pyrethroids.  A pyrethroid-
induced increase or decrease in the rate of Camk1g1 or Camk1g2 mRNA degradation, 
respectively, would also explain the differential response.  Fukuchi et al. (2005) demonstrate 
that the half-life of mRNA expression for the pituitary adenylate cyclase-activating 
polypeptide (PACAP) increases in parallel to increases in the intensity of a depolarizing 
stimulus.  Increased depolarization of neurons affected by pyrethroids may result in a 
stabilization of the expression of Camk1g1 mRNA and not Camk1g2, therefore resulting in 
divergent, stimulus-dependent expression patterns.  The mechanism of differential Camk1g1 
and Camk1g2 mRNA expression in the rat brain requires further investigation. 
 Changes in the expression of Camk1g mRNA are consistent with changes in neuronal 
excitability, such as those produced by pyrethroids (Vijverberg and Van den Bercken 1992; 
Song and Narahashi 1996; Narahashi 2001).  Xiang et al. (2007) correlated firing rates of 
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cortical neuronal networks maintained in culture with global mRNA expression following 
stimulation.  They reported that patterns of Camk1g mRNA expression closely paralleled 
increases in neuronal firing rates.  Increased Camk1g mRNA expression (as well as the 
increased neuronal firing rates) were dependent upon activation of voltage-sensitive sodium 
channels (VSSC) and the presence of free Ca+2, as the VSSC blocker tetrodotoxin and the 
Ca+2 chelator EGTA abolished both effects (Xiang et al., 2007).  In separate studies, sub-
chronic dosing of olanzipine results in both increased burst firing in the frontal cortex in vivo, 
and increased expression of Camk1g (Fatemi et al. 2005; Gronier and Rasmussen 2006).  In 
addition, in vivo exposure of rats to the antiepileptic drug phenytoin decreased Camk1g 
mRNA expression (Dingledine et al. 2005).  Phenytoin decreases neuronal firing rates in 
several brain regions, including cortex (Matthews and Conner 1977; Lampl et al. 1998; 
Calabresi et al. 1999).  It is apparent that Camk1g mRNA expression is correlated with 
alterations in neuronal firing rates.  However, this previous research has not provided 
information on which of the Camk1g splice variants is affected by the alterations in firing 
rates.  The present data suggest that in the rat the Camk1g1 mRNA splice variant may be 
more sensitive to changes in neuronal excitability given that the pyrethroids produce a more 
robust increase in Camk1g1 mRNA as compared to Camk1g2 mRNA.   
 The finding that Camk1g1 mRNA expression and not Camk1g2 mRNA expression is 
affected by pyrethroids is significant given that the biological activities of the proteins 
encoded by these two splice variants are very distinct.  Camk1g1 kinase activity is dependent 
upon the presence of Ca+2-bound calmodulin and activation by an upstream CaM kinase 
kinase whose own activity is also regulated by intracellular Ca+2 levels.  Camk1g2 kinase 
activity is not enhanced in the presence of Ca+2-bound calmodulin or affected by the 
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Camk1g1 upstream activating kinase (Nishimura et al. 2003).  More importantly, the ability 
of Camk1g1 to regulate neuronal dendritogenesis in developing neurons is dependent upon 
sequential prenyaltion and palmitoylation of the C-terminal region of this protein (Takemoto-
Kimura et al. 2007).  Camk1g2 lacks the lipidification sites present on Camk1g1 required for 
mediating these effects.  All studies reporting biologically significant effects of Camk1g on 
neuronal morphogenesis used the Camk1g1 splice variant as the basis for their study 
(Wayman et al. 2007; Takemoto-Kimura et al. 2007).  No role for endogenous Camk1g2 
protein has been identified.  The induction of Camk1g1 mRNA in the present study indicates 
that pyrethroids may disrupt neuronal processes mediated by Camk1g1 protein such as 
dendritogenesis.  Indeed, dendritic branching has been shown to be affected by both 
deltamethrin and permethrin in in vitro developmental neurotoxicity assays (Harrill et al. 
submitted).  The induction of Camk1g1 mRNA observed here supports a putative role for the 
transcriptional induction of Camk1g1 in the pyrethroid-mediated effects on neurite 
branching.    
 The in vivo exposures utilized in the present time course study did not result in a 
significant increase in the expression of Camk1g1 protein.   This is inconsistent with the 
increased expression of Camk1g1 mRNA.  There are a number of possible explanations for 
this discrepancy.  First, the Western blot assay used may not be detecting Camk1g1 protein.  
It is possible that a post-translational modification interferes with the ability of the Camk1g1 
antibody to recognize the protein.  The primary antibody used for quantification of Camk1g1 
protein detected a strong protein band at ~ 60 kDa.  This is larger than the predicted 
molecular weight of the rat Camk1g1 protein (53 kDa).  The disparity between the predicted 
and observed Camk1g1 molecular weights is likely due to to post-translational prenylation 
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and palmitoylation of the Camk1g1 protein (Takemoto-Kimura et al. 2007).  This suggests 
that the 60 kDa band may be modified Camk1g1.  Alternatively, this band may represent a 
non-specific recognition of a different protein by the primary antibody.  Additional studies 
with purified Camk1g1 protein may help resolve this issue.   
 In contrast, the lack of measurable increases in Camk1g1 protein could be due to the 
acute dosing paradigm used in the present research.  As demonstrated in Figure 3.3, the 
pyrethroid-induced increases in Camk1g1 mRNA expression are transient and recover on a 
time scale that reflects the pharmacokinetics of these compounds. Acute oral exposure of rats 
to permethrin and deltamethrin results in a rapid accumulation of these compounds in the 
brain.  Peak concentrations occur between ~1-3 h and these compounds are cleared from the 
brain with half-lives on the order of tens of hours (Anadon et al. 1991; Anadon et al. 1996; 
Mirfazaelian et al. 2006; Tornero-Velez et al. 2007).  Triggering an appreciable increase in 
Camk1g1 protein in adult neurons may require a more sustained increase in Camk1g1 mRNA 
then what is observed in the present study.  More persistent (i.e., sub-chronic) exposures to 
pyrethroids that produce a steady-state brain burden of these compounds may be necessary to 
elevate Camk1g1 protein, but this is yet to be determined.   
 In summary, this study demonstrates that following an acute in vivo exposure to either 
deltamethrin or permethrin transiently increased expression Camk1g1 splice variant mRNA 
in the rat frontal cortex.  The transient increases in Camk1g1 mRNA did not result in 
measureable increases in Camk1g1 protein under the exposure conditions used here.  Future 
research efforts concerning Camk1g, neuronal excitability and pyrethroids should focus on 
determining how pyrethroid actions at the neuronal membrane results in the increased 
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expression of Camk1g1 mRNA and whether this response impacts neuronal structure or 
function. 
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Table 3.1.  Camk1g and Camk1g splice variant specific TaqMan assays. 
 
 GenBank   Nucleotide Exon Amplification 
Assay Ascension  Nucleotide Sequences Alignments  Junction Efficiency 
____________________________________________________________________________________________________________ 
 
Camk1g NM_182842 Referencea,b: 5’-GATGACATTTCTGAGTCAGCCAAGG-3’ 810  834 8-9 96.0 % 
 AB101231   810  834 8-9  
 AB101232   810  834 8-9  
 
Camk1g1 NM_182842 Forward: 5’-CCTCCAGATTCAGAAGAACTTTGC-3’     956  979 10-11 94.2 %  
 AB101231 Backward: 5’-CGGCGGCCGCATTG-3’ 1017  1004 10-11 
  Reporter: 5’-AAGTGGAGGCAAGCCT-3’ 987  1002  
 
Camk1g2 AB101232 Forward: 5’-CCTCCAGATTCAGAAGAACTTTGC-3’ 956  979 10-12 98.7 % 
  Backward: 5’-CCTGCTTTCACTGGTACCATGAC-3’ 1034  1012 
  Reporter: 5’-AAGTGGAGGGAACTTCAA-3’ 987  1004 
 
____________________________________________________________________________________________________________ 
aPrimer and probe sequences of Applied Biosystems pre-designed TaqMan® qRT-PCR assays are proprietary.  Reference sequence 
provided by manufacturer is listed.  bTaqMan® gene expression assay Rn00788224_m1.  
 
 
 
 
 
 
 129 
Table 3.2.  Statistical analysis of qRT-PCR dose-response data.a 
 
 
Camk1g EDL   F (4, 54)  =  4.47,  p = 0.0034** 3, 4, 5b 
 COMPOUND   F (1, 54)  =  0.96,  p = 0.3370 
 EDL*COMPOUND  F (3, 54)  =  1.16,  p = 0.3335 
 
Camk1g1 EDL   F (4, 54)  =  2.79,  p = 0.0355** 4 
 COMPOUND   F (1, 54)  =  0.04,  p = 0.8380 
 EDL*COMPOUND  F (3, 54)  =  0.78,  p = 0.5096 
 
Camk1g2 EDL   F (4, 54)  =  2.57,  p = 0.0484** 4 
 COMPOUND   F (1, 54)  =  6.76,  p = 0.0120** 
 EDL*COMPOUND  F (3, 54)  =  1.95,  p = 0.1325     
 
______________________________________________________________ 
aData were analyzed using a two-way ANOVA model with equipotent dose level (EDL) and 
COMPOUND (deltamethrin, permethrin) as the independent variables.  bA post-hoc 
Dunnett’s many-to-one mean contrast test was also performed on the data.  Numbers 
represent the EDL with means in expression significantly different from vehicle controls (p < 
0.05 significance level), 3 = NOAEL, 4 = ED30 and 5 = ED50 for decreases in ambulatory 
motor activity.  ** = significant at p < 0.05 in two-way ANOVA model.  Analysis were 
performed on 2-∆∆CT values (Livak and Schmittgen 2001) 
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Table 3.3.  Statistical analysis of qRT-PCR time course data.a 
 
____________________________________________________________________________________________________________ 
 
Camk1g TRT F (1, 56)  =  4.56, p = 0.0371** 3 hb TRT F (1, 56)  =  2.16, p = 0.1472 n.e. 
 TIME F (3, 56)  =  1.75, p = 0.1665 TIME F (3, 56)  =  1.14, p = 0.3391 
 TRT*TIME F (3, 56)  =  2.07, p = 0.1140 TRT*TIME F (3, 56)  =  0.54, p = 0.6586 
 
Camk1g1 TRT F (1, 56)  =  4.76, p = 0.0334** 3 h TRT F (1, 56)  =  4.65, p = 0.0354** n.e. 
 TIME F (3, 56)  =  3.67, p = 0.0174**  TIME F (3, 56)  =  0.76, p = 0.5225 
 TRT*TIME F (3, 56)  =  3.92, p = 0.0131**  TRT*TIME F (3, 56)  =  0.37, p = 0.7784 
 
Camk1g2  TRT F (1, 56)  =  6.13, p = 0.0164** 6 h TRT F (1, 56)  =  6.89, p = 0.0112** 6 h  
 TIME F (3, 56)  =  5.25, p = 0.0029** TIME F (3, 56)  =  4.73, p = 0.0052** 
 TRT*TIME F (3, 56)  =  4.92, p = 0.0042** TRT*TIME F (3, 56)  =  4.47, p = 0.0069**   
____________________________________________________________________________________________________________ 
aData were analyzed using a Two-way ANOVA model with treatment (TRT) and TIME as the independent factors.  ** = significant at 
p < 0.05. bData were additionally analyzed within time point for each gene using a One-way ANOVA.  Times noted on this table were 
significant at p < 0.05. 
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Figure 3.1.  Exon schematic of rat Camk1g1 and Camk1g2.  A) Intron/exon diagram of rat Camk1g1 and Camk1g2.  Boxes are 
exons while lines are introns.  Camk1g1 contains 13 exons while Camk1g2 contains 12 exons, with the calmodulin-binding domain of 
Camk1g1 (exon 11) absent.  Highlighted boxes correspond to the exon junctions targeted by the qRT-PCR assays.  B) Assay 
schematics for Camk1g, Camk1g1 and Camk1g2 assays, respectively.  Each assay contains a forward primer, reverse primer and a 
probe sequence with fluorophone (P) and quencher (Q).  Upon primer extension the 5’ to 3’ nuclease activity of the AmpliTaq Gold 
DNA polymerase degrades the primer, releases the fluorophore from the quencher and light is emitted which is quantified for 
calculations of mRNA abundance.  Note the probe and reverse primer of the Camk1g1 and Camk1g2 assays are unique while the 
forward primer of each of these two is the same.  Assays are described in detail in Table 3.1.
  
Figure 3.2.  Dose-response for Camk1g1 and Camk1g2 mRNA expression.  Panels A-F 
show dose-response curves for the Camk1g (A-B), Camk1g1 (C-D) and Camk1g2 (E-F) 
qRT-PCR assays in frontal cortex at 6 h following acute exposure to deltamethrin (A,C & E) 
or permethrin (B,D & F).  Data were quantified and analyzed using the 2-∆∆CT method and 
data are expressed as mean 2-∆∆CT ± standard error.  Numbers underlying the points in panels 
A & B demonstrate which equipotent dose level (EDL) groupings each treatment belongs to 
for statistical analyses of these data: 1 = vehicle control, 2 = sub-NOAEL, 3 = threshold, 4 = 
ED30, 5 = ED50 for decreases in motor activity.  Results of statistical analyses of these data 
are given in Table 3.2.  * = treatment group mean is significantly different from vehicle 
control in a Dunnett’s many-to-one mean contrast test (p < 0.05) ** = main effect of 
equipotent dose level with no interaction of EDL & compound in Two way ANOVA (p < 
0.05).  *** = significant interaction of EDL & COMPOUND. 
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Figure 3.3.  Time course for Camk1g1 and Camk1g2 mRNA expression.  Rats were orally 
exposed to either 3 mg/kg deltamethrin (A) or 100 mg/kg permethrin (B) and mRNA 
expression quantified in the frontal cortex at 1,3,6 and 9 h post-exposure.  Data within each 
time point were quantified using the 2-∆∆CT method and data are expressed as mean 2-∆∆CT ± 
standard error.  Red bars correspond to the Camk1g1 specific qRT-PCR assay, green bars to 
the Camk1g2 specific qRT-PCR assay and blue bars to the assay that detects both splice 
variants.  Results of statistical analyses of these data is given in Table 3.3.  * = main effect of 
treatment with no interaction of time & treatment in a two-way ANOVA (p < 0.05).  ** = 
significant interaction of time & treatment (p < 0.05).  Arrows denote time points with means 
in expression significantly different from time-matched vehicle control values in a One-Way 
ANOVA (p < 0.05).  Vehicle treated control data not shown. 
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Figure 3.4.  Rat Camk1g1 and Camk1g2 protein sequences and Camk1g1 protein assay 
development.  A) Alignment of rat Camk1g1 and Camk1g2 protein coding sequences.  
Camk1g1 is the top line and Camk1g2 the bottom line in each doublet.  Highlighting colors 
correspond to the strength of identify between the matched amino acids with red being 
absolute identity and blue being a poor match.  Color bar is in top right corner. Protein 
alignment performed using Swiss Institute for Bioinformatics TCoffee tool.  The antigen 
sequence for the Camk1g1 primary antibody is marked with a blue box.  B)  A single strong 
band at ~ 60 kDa was detected using the Camk1g1 primary antibody.  C)  Signal from 
Camk1g1 increases linearly as a function of total protein loaded from 5-20 µg.  Visualization 
of Western blot bands given in top right corner of panel.  D) Signal from β-tubulin primary 
antibody increased linearly as a function of total protein loaded from 5-20 µg after stripping 
of Camk1g1 primary antibody.  Standard curves in C and E were obtained from the same 
blot. 
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Figure 3.5.  Camk1g1 protein expression following acute pyrethroid exposure.  Rats were 
orally exposed to either 3 mg/kg deltamethrin (A) or 100 mg/kg permethrin (B) and 
Camk1g1 protein expression was quantified in frontal cortex via Western blots at 1,3,6,9,12 
or 24 h post-exposure.  Signal intensities for Camk1g1 expression were normalized within 
sample to β-tubulin and expressed as percent change from untreated control within each set 
of treated and time-matched control samples.  Data are expressed as mean fold-change from 
time matched, vehicle-treated control groups ± S.E. 
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Abstract. 
 
 Pyrethroids are pesticides that interact with voltage-sensitive ion channels and disrupt 
neuronal function.  Acute disruption of neuronal function can result in adverse effects on 
behavior.  In addition, change in neuronal firing patterns, such as those produced by 
pyrethroids, may also lead to changes in activity-regulated gene expression.  Previous 
research demonstrated that permethrin (a Type I pyrethroid) and deltamethrin (a Type II 
pyrethroid) exposure alters gene expression in the rat cortex.  The present study expands 
upon the previous findings by examining the global transcriptional response of rat cortex for 
six different pyrethroids.  Rats were acutely dosed with a Type I pyrethroid (permethrin, 
bifenthrin or tefluthrin), a Type II pyrethroid (deltamethrin, cypermethrin or cyfluthrin) or 
vehicle and cortex was sampled at 3 and 6 h post exposure.  Affymetrix GeneChips® were 
used to obtain global gene expression profiles from the cortical tissue.  Analysis of the 
microarray data demonstrated robust transcriptional responses following exposure to Type II 
pyrethroids.  Type I pyrethroids produced only marginal effects on cortical gene transcription 
some of which were in common with the effect produced by the Type II pyrethroids.  
Comparison of gene expression profiles revealed a suite of genes commonly affected by the 
Type II pyrethroids.  Ingenuity® pathway analysis of these transcriptional changes yielded an 
interconnecting network of gene interactions that is consistent with the excitatory effects of 
these compounds.   
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Introduction. 
 
 Pyrethroids are neurotoxic pesticides used in a variety of agricultural, household, 
veterinary and human health applications (Heudorf & Angerer 2001; Yanez et al. 2002).   
Use of pyrethroids has increased in conjunction with decreased use of insecticides from other 
chemical classes.  There is a potential for human exposures as pyrethroids and pyrethroid 
residues have been detected in urine samples from pesticide applicators, blood samples of 
urban mothers, residential house dust and wipe samples from U.S. child care centers (Leng et 
al. 1997; Whyatt et al. 2003; Colt et al 2004; Weston et al. 2004; Tulve et al. 2006).   
Classically, pyrethroids have been divided into different sub-types based chemical 
structure and the signs of acute poisoning observed in laboratory rodents at near lethal dose 
levels (Verschoyle and Aldridge 1980; Lawrence and Casida 1982).  Pyrethroids containing 
an α-cyano group (Type II) produce a poisoning syndrome characterized by increased 
burrowing and digging behavior that progresses to whole body tremor followed by profuse 
salivation and a sinuous writhing known as choreoathetosis (CS-syndrome, Verschoyle and 
Aldridge 1980).  Pyrethroids that lack an α-cyano group (Type I) produce a poisoning 
syndrome characterized by episodes of aggressive sparing behavior and increased sensitivity 
to external stimuli that progresses to fine tremors followed by course whole body tremors and 
prostration (T-syndrome, Verschoyle and Aldridge 1980).  At lower dose levels, the 
neurotoxic effects of pyrethroids have been detected by a number of neurobehavioral tests.  
Some behavioral endpoints are commonly affected by all pyrethroids (i.e. motor activity, 
Wolansky et al. 2006), while others are affected differently across the pyrethroid class (e.g. 
acoustic startle response and thermoregulation, Crofton and Reiter 1988; Wolansky and 
Harrill 2007).   
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 The primary molecular targets of pyrethroids are voltage-sensitive sodium channels 
(VSSCs).  Pyrethroids delay VSSC deactivation which results in a prolonged entry of Na+ 
into the neuron (Na+ tail current) during periods when unmodified VSSCs are normally 
impermeable (Narahashi 2001).  Abnormal Na+ tail currents can persist for as little as 
milliseconds and as long as hundreds of milliseconds depending upon the structure of the 
pyrethroid and the isoform of VSSC (Vijverberg and Van den Bercken 1990; Smith and 
Soderlund 1998; Choi and Soderlund 2006).  Type II pyrethroids consistently produce more 
prolonged Na+ tail currents than Type I pyrethroids (Vijverberg and Van den Bercken 1990; 
Song et al. 1996; Choi and Soderlund 2006).  The result of increased Na+ permeability 
through VSSCs is repetitive neuronal action potential firing following a stimulus and an 
overall change in neuronal firing rates (Vijverberg and Van den Bercken 1990; Song and 
Narahashi 1996).  Some pyrethroids also affect a number of secondary molecular targets such 
as voltage-sensitive Ca+2 channels, voltage-sensitive Cl- channels (Burr and Ray 2004; Shafer 
and Meyer 2004; Symington and Clark 2007).  Activation of these channels may or may not 
contribute to the manifestation of acute neurotoxicity in vivo or the difference in the acute 
signs of poisoning observed with the two pyrethroid types  (Soderlund et al. 2002; Ray and 
Fry 2006). 
 The accepted mode-of-action for the acute adverse effects of pyrethroids includes 
disruption of voltage-sensitive ion channel function and subsequent increases in neuronal 
excitability which, in turn, leads to behavioral effects observed at the whole organism level 
(Ecobichon 2001; Soderlund et al. 2002; Ray and Fry 2006).  Changes in neuronal 
excitability also triggers changes in gene expression that may result in alterations in neuronal 
function (Fields et al. 1997; Finkbeiner and Greenberg 1998; Fields et al. 2005; Tropea et al. 
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2006).  To date, the effects of acute pyrethroid exposure on activity-dependent gene 
expression in the nervous system has not been extensively studied.  Questions remain 
regarding which genes are altered following pyrethroid exposure, whether or not the same 
sets of genes are affected by different compounds within the pyrethroid class and what 
intracellular signal transduction mechanisms are activated to trigger pyrethroid-induced 
changes in gene expression.  
Previous work using oligonucleotide microarrays demonstrated that acute pyrethroid 
exposure, at doses near the threshold for producing behavioral effects in the rat, altered gene 
expression in the frontal cortex (Harrill et al. submitted).  The gene expression changes 
observed in that study were consistent with pyrethroid-induced increases in neuronal 
excitability in vivo.  In addition, this study demonstrated both differences and similarities in 
the overall transcriptional response elicited by permethrin and deltamethrin, the two 
pyrethroids tested.  The present study expands upon these findings by examining global gene 
expression patterns in the rat frontal cortex across time following acute exposure to six 
pyrethroids: permethrin, bifenthrin and tefluthrin (Type I) or deltamethrin, cypermethrin or 
cyfluthrin (Type II).  Equipotent dose levels were selected based on the behavioral data of 
Wolansky et al. (2006).  Global gene expression profiles from Affymetrix GeneChips® were 
compared across compounds and functional gene regulatory networks were constructed from 
commonly altered genes. 
Methods. 
 
Chemicals.  All pyrethroids examined in this study were of technical grade.  Bifenthrin (BIF: 
98.9 % purity), permethrin (PERM: 92 % purity) and cypermethrin (CYP: 88.0 % purity) 
were donated by FMC Corporation (Philadelphia, PA).  Deltamethrin (DLT: 98.9 % purity) 
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and β-cyfluthrin (CYF: 99.2 % purity) were donated by Bayer Cropscience (Research 
Triangle Park, NC).  Tefluthrin (TEF: 92.6 % purity) was donated by Syngenta Crop 
Protection (Greensboro, NC).  Chemical structures for the six pyrethroids are provided in 
Figure 4.1.  Complete IUPAC nomenclature and isomer ratios of the test material are 
available in Wolansky et al. (2006).  Equipotent dose levels (ED30 for decreased motor 
activity) for each of the pyrethroids were selected based on data from Wolansky et al. (2006) 
(see Figure 4.2).  Pyrethroids were dissolved in corn oil (Sigma-Aldrich, St. Louis, MO) with 
a dosing volume of 1 mL/kg. 
 
Animal care and treatment.  Male Long-Evans rats (58 days of age) were obtained from 
Charles River Laboratories (Wilmington, MA) and housed two per cage in standard 
polycarbonate hanging cages (45 cm X 24 cm X 20 cm) with heat sterilized pine shavings for 
bedding (Beta Chips, Northeastern Products, Inc., Warrensburg, NY).  Animals were 
maintained on 12h:12h photoperiod (lighted hours: 06:00-18:00) and allowed a 5 to 7 day 
period of acclimation to the colony prior to dosing.  Colony rooms were maintained at 22.0 ± 
2.0°C with a relative humidity of 55 ± 20%.  Food (Purina 5001 Rat Chow) and tap water 
were provided ad libitum.  The facility was approved by the American Association for 
Accreditation of Laboratory Animal Care (AAALAC) and all experimental procedures were 
approved in advance by the by the US EPA, National Health and Environmental Effects 
Research Laboratory Animal Care and Use Committee.   
 Rats received a single, oral dose of either 43 mg/kg PERM, 10.7 mg/kg CYP, 3.2 
mg/kg BIF, 3 mg/kg DLT, 2.3 mg/kg TEF, 2.2 mg/kg CYF or corn oil vehicle and allowed to 
recover for either 3 or 6 h.  These doses are an approximate ED30 for decreased motor 
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activity based on the data of Wolansky et al. (2006).  Rats were treated and tissues collected 
in four separate blocks in this study.  Blocks 1 and 2 contained rats treated with Type I 
pyrethroids (PERM, BIF, TEF) or Type II pyrethroids (DLT, CYP, CYF) for 3 h (n = 3 / 
block, n = 6 / treatment).  Blocks 3 and 4 contained rats treated with Type I pyrethroids or 
Type II pyrethroids for 6 h (n = 3 / block, n = 6 / treatment).  Each block also contained time 
matched vehicle controls (n = 3 / block).  Dosing and euthanasia times for pyrethroid and 
vehicle treated rats was counterbalanced across time of day within each block.  All dosing 
occured between 09:00 and 12:00 hours and the last test subject was euthanized before 18:00 
hours.  Rats were removed from the colony suite 1 h prior to dosing and allowed to acclimate 
in a quiet holding room maintained under similar environmental conditions.  Subjects were 
administered a single oral dose of test compounds by gavage and allowed to recover in their 
home cage prior to tissue sampling.  Subjects were then individually removed to an adjoining 
suite with a separate HVAC system for euthanasia by decapitation.  
 Whole brains were rapidly removed and placed on a cold plate (4°C).  The frontal 
cortex was dissected by making a vertical incision at the anterior edge of the optic tract with 
a stainless steel razor, and rapidly frozen on a bed of dry ice.  Cortical samples, without 
striatal tissue, were then bisected into contralateral hemispheres, weighed, frozen in liquid 
nitrogen and stored at -80°C. 
 
RNA extraction.  Cortical samples were homogenized in 1 mL of TRI Reagent (Molecular 
Research Center, Inc., Cincinnati, OH) per 50-100 mg of tissue using a Polytron® PT-K 
homogenizer (Kinematica, Lucerne, Switzerland) and total RNA was isolated per 
manufacturer’s instructions.  Total RNA pellets suspended in DEPC-treated H2O were then 
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subject to DNase I treatment and re-extracted with acid:phenol chloroform, pH = 4.7 
(Ambion Inc., Austin, TX) and chloroform according to manufacturer’s protocol and 
resuspended in DEPC-treated H2O until use.  The total RNA concentration of each sample 
was determined (absorbance @ 260 nm) on a Beckman-Coulter DU® 800 spectrophotometer 
(Fullerton, CA) and adjusted to 1.0 µg/µL prior to sample storage at -80ºC.  The ratio of 
absorbance values at 260 nm and 280 nm (Ab 260/280) was used to assess purity of total 
RNA samples.  All samples used in these studies had Ab 260/280 ratios > 1.83 (data not 
shown).  Preliminary PCR experiments using primers for rat β-actin genomic DNA (outlined 
in Tully et al. 2006) demonstrated that the above protocol adequately prevents genomic DNA 
contamination of total RNA samples (data not shown).  In addition, the RNA integrity of 
each sample was determined using an Agilent 2100 Bioanalyzer and RNA 6000 Series II 
Nano LabChip Kit (Waldbron, Germany) according to manufacturer’s instructions.  All 
samples used in microarray and qRT-PCR experiments had 18S:28S rRNA ratios > 1.8 and 
RNA Integrity Numbers > 8.8 (data not shown).  Following the RNA purity and integrity 
screens, aliquots of each total RNA sample (1 µg/µL for microarray hybridization or 25 
ng/µL for qRT-PCR assays) were stored at -80°C until use. 
 
Microarray sample preparation and data collection.  Affymetrix Rat Genome 230 2.0 
GeneChip® oligonucleotide microarrays (Santa Clara, CA) were used in this experiment.  
First and second strand cDNA synthesis, cRNA amplification, clean-up and biotin-labeling 
of each sample were performed with BioArrayTM single-round RNA amplification and biotin 
labeling system (Enzo Life Sciences, Farmingdale, NY) and Qiagen RNeasy spin columns 
(Spoorstraat, Netherlands), respectively, according to manufacturer’s instructions.  Biotin-
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labeled cRNA was fragmented using Affymetrix 5X fragmentation buffer (200mM Tris 
acetate - pH=8.1, 100 mM KOAc, 150 mM MgOAc). 
 Fragmentation of biotin-labeled cRNA, GeneChip® hybridizations, washes and 
staining were performed according to standard Affymetrix protocols (Affymetrix 2004).  
Hybridizations were performed in an Affymetrix Hybridization Oven 640.  Washes were 
performed on an Affymetrix Fluidics Station 450 using the EukGE-WS2v4-450 fluidics 
script.  GeneChips® were scanned using an Affymetrix GeneChip® 3000 Scanner with the 
GCOS v1.4.0.036 software package.  Target intensity was set to a value of 500 with all other 
scanning parameters set at the factory defaults.  The 3`/5` ratios for GAPDH and β-actin 
internal controls genes were within the range suggested by the manufacturer, indicating that 
RNA was not degraded during processing.   The intensity of hybridization controls (BioB, 
BioC, BioD and Cre) increased linearly on all arrays.   
 
Microarray data analysis.  Gene expression profiles for all samples in the study were 
collapsed across block for data analysis.  Gene expression summaries were calculated with 
RMAExpress© v4.7 (University of California at Berkeley) using the Robust Multiarray 
Average method (RMA, Irizarry et al. 2003).  Paired t-tests between treated samples and 
time-matched controls were performed using Microsoft Excel® to obtain an initial global 
overview of the data.  Treatment-related changes in gene expression were detected using the 
Linear Models for Microarray Data (LIMMA, Smyth 2005) package in the R statistical 
computing environment (v2.6.1).  Each compound was analyzed separately in conjunction 
with time-matched vehicle control values according to contrast matrix outlined in Figure 
4.4A.  The comparisons made for each probe set using LIMMA followed the general model 
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for a two-way analysis of variance (ANOVA) with time and treatment as the independent 
factors (Figure 4.4B).  Treatment-related changes in expression were determined according 
to the flowchart in Figure 4.4C.  Main effects of time and treatment and the interaction 
between time and treatment were considered significant at a false discovery rate adjusted p-
value < 0.10. 
 The Significant Analysis of Function and Expression (SAFE, Barry et al. 2005) 
method was used to identify pathways and functional categories whose genes are 
coordinately regulated in a treatment-related fashion.  SAFE and array annotation were 
loaded from Bioconductor (v2.1, Gentleman et al. 2004).  A comparative SAFE analysis was 
also used to test for enrichment of gene sets with treatment related changes in expression for 
each of the individual pyrethroids (according to LIMMA) across all the other pyrethroids in 
the test panel.  Prior to implementation of the SAFE analyses data were normalized (or re-
centered) to the combined mean of the vehicle treated control groups collapsed across time.  
This normalization was necessary due to the inability of the SAFE method to simultaneously 
analyze two independent variables.  Normalization removed the main effects of time from the 
data (Appendix B, Figure 1).  A multi-factor one-way ANOVA F-statistic was used as the 
local statistic in the SAFE analyses to assess treatment related change in expression within 
the four treatment groups for each pyrethroid.  The global statistic for enrichment was a 
Wilcoxon ranked sum test (Ott 2003).  1000 permutations of the treatment groups were used 
by SAFE to assess the significance of the entire procedure using the Yekutieli and Benjamini 
(1999) method to control the false discovery rate (FDR) and account for multiple 
comparisons.  Ingenuity® pathway analysis software (Ingenuity Inc., Redwood City, CA) 
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was also used to construct interactive gene networks from probe sets altered by pyrethroid 
treatment. 
 
Quantitative real-time RT-PCR.  qRT-PCR was performed using TaqMan® One-Step RT-
PCR Master Mix Reagent Kits and TaqMan® Gene Expression Assays on a ABI 7900HT 
Sequence Detection System (Applied Biosystems, Foster City, CA).  AmpliTaq Gold® DNA 
Polymerase / dNTP mix, MultiscribeTM reverse transcriptase / RNA inhibitor mix and 
TaqMan® Gene expression primer-probe mix specific for the transcript of interest were 
combined according to manufacturer’s specifications (Applied Biosystems, 2005).  The 
reaction mixture was then dispensed into the reaction plate (15 µL / well) and 125 ng of total 
RNA (5 µL) was added.  Each sample was measured in triplicate for each transcript of 
interest and internal reference gene.  Reaction plates were maintained at 5°C during loading 
procedure.  During data collection, reactions were incubated at 48°C for 45 min followed by 
incubation at 95°C for 10 min and 40 cycles of 94°C for 25 sec and 60°C for 1 min.   
 qRT-PCR assays were designed via the Applied Biosystems (ABI) primer / probe 
selection algorithm and bioinformatics pipeline (Applied Biosystems 2006).  The 
amplification efficiency of each assay was examined using a serial dilution of pooled total 
RNA from rat cortex.  Efficiencies were calculated as: Ex = 10(-1/m) – 1, where E is the 
amplification efficiency of target transcript x and m is the slope of threshold cycles vs log 
[total RNA concentration] across the range of dilutions (Applied Biosystems 2004).  Assay 
identification numbers, context sequences, amplicon lengths and calculated amplification 
efficiencies are listed in Appendix B, Table 1. 
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 Six transcripts identified as having treatment related changes in expression were 
examined by qRT-PCR to confirm results of the microarray data.   qRT-PCR data was 
analyzed according to the 2-∆∆CT method as described by (Livak and Schmittgen 2001).  β-
actin expression did not change as a function of time or treatment for either compound (data 
not shown) and was used at the internal reference for all 2-∆∆CT calculations.   
The mean ∆∆CT of vehicle treated controls within each time was used as the 2-∆∆CT calibrator 
for each time-matched treatment group.  A two-way ANOVA was used to statistically 
analyze the qRT-PCR data with time and treatment as independent variables and 2-∆∆CT as the 
dependent variable (p < 0.05 for each contrast).  Transcripts with a significant time*treatment 
interaction were additionally analyzed with a one-way ANOVA at each time point with 
treatment as the independent variable (p < 0.05). 
Results. 
 
 The type II pyrethroids had a much more dramatic effect on gene expression in the 
frontal cortex than Type I pyrethroids.  Figure 4.3 plots the magnitude of fold change from 
control versus the empirical p-value for pair-wise comparisons of treatment and control 
samples for each pyrethroid tested at each time point in the study.  Note that the statistical 
test used in this figure is not adjusted for multiple comparisons or low abundance transcripts 
and was not used in the present study as final indication of significance.  Instead, these 
comparisons were used to examine global trends in the gene expression data.  For all the 
pyrethroids tested, at both 3 h and 6 h post-exposure, the magnitude of fold-change from 
control was less than 4-fold for genes that met an empirical p-value threshold < 0.001 (Figure 
4.3, dotted lines).  At 3 h the Type II pyrethroids deltamethrin (DLT), cypermethrin (CYP) 
and cyfluthrin (CYF) had a larger number of probe sets with empirical p < 0.001 than at 6 h.  
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A majority of these probe sets were upregulated following pyrethroid exposure.  The degree 
of change is much more pronounced for the Type II pyrethroids as compared to the Type I 
pyrethroids.  PERM had a very small number of probe sets with an empirical p < 0.001 in the 
paired t-test.  BIF exposure resulted in alterations in expression mainly at 6 h while TEF 
exposure resulted in alteration in expression mainly at 3 h.  Collectively, these data 
demonstrate that the overall transcriptional response of the rat frontal cortex to Type II 
pyrethroids is qualitatively different from the response produced by the Type I pyrethroids at 
behaviorally equipotent doses.   
 LIMMA analysis of the microarray gene expression data identified a large number of 
probe sets with treatment related changes in expression for the Type II pyrethroids.  No 
significant treatment related effects were observed for the Type I pyrethroids using LIMMA.  
A decision tree for the determination of treatment related effects on expression in the 
LIMMA analysis framework is given in Figure 4.4C.  Unlike the paired t-tests shown in 
Figure 4.3, LIMMA analysis utilizes a false discovery rate multiple comparison correction 
and an adjustment factor for lowly-expressed probe sets.  Figure 4.5 demonstrates three 
distinct patterns of significant treatment related changes in gene expression for the three type 
II compounds: 1) probe sets up- or down- regulated predominantly at 3 h, 2) probe sets up- or 
down- regulated predominantly at 6 h and 3) probe sets up or down-regulated across both 
time points in the study.  The first pattern describes the most dramatic changes in gene 
expression for each of the Type II compounds.  CYP exposure yielded the least number of 
probe sets with treatment related changes in expression (n = 149) followed by DLT (n = 399) 
and CYF (n = 3742).  In the case of CYF a large number of the identified gene expression 
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changes (~80 %) were small in magnitude with < 1.25-fold changes from control at either 
time point.   
 Comparison of the probe sets with treatment related changes in expression for DLT, 
CYP and CYF, respectively, revealed a group of probe sets commonly affected by the Type 
II compounds (Figure 4.6A).  Comparative enrichment analysis (SAFE algorithm, Barry et 
al. 2005) provided a quantitative measure of similarity between the gene expression profiles 
of the different pyrethroids in the test panel (Table 4.1).  Queried lists of probe sets were 
based on LIMMA analysis of individual Type II compounds in the test panel and zones of 
similarity in the Venn diagram comparison from Figure 4.6A.  Significant enrichment of the 
group of probe sets identified as being affected by either DLT (n = 399) or CYP (n = 149) 
was observed in all three Type II compounds in the study (Table 4.1).  In contrast the large 
list of treatment affected probe sets identified for CYF (n = 3742) was not significantly 
enriched for the other Type II compounds.  Gene lists based on the DLT-CYP, DLT-CYF 
and CYP-CYF unions of the Venn diagram (Figure 4.6A) were also significantly enriched for 
the other Type II compound not involved in forming the union.   
 The LIMMA analysis did not detect significant alterations in gene expression for the 
Type I pyrethroids.  This is in contrast to the empirical t-tests illustrated in Figure 4.3 that 
identified a group probe sets as being altered by PERM, BIF and TEF.  A heatmap 
visualization of probe sets commonly altered by the Type II pyrethroids demonstrates that 
some of the genes within this union are changed by Type I pyrethroids, albeit at lower fold-
change magnitudes than observed with the Type II’s (Figure 4.6B, arrows and bracket).  
Results of the comparative SAFE enrichment procedures also demonstrates a similarity in the 
overall response of the Type I pyrethroids to the Type II pyrethroids (Table 4.1).  Probe sets 
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with treatment related effects for DLT were enriched for PERM.  Likewise, probe sets with 
treatment related effects for DLT and CYP were enriched for BIF.  These data demonstrate a 
degree of similarity is present in the overall transcriptional response for PERM, BIF, DLT 
and CYP.  The large group of probe sets with treatment related effects for CYF was enriched 
in the TEF treated group but not the PERM and BIF treated groups, demonstrating that the 
overall transcriptional response of TEF is more similar to CYF than CYP or DLT.  All of the 
gene lists defined from the common overlaps of the Type II pyrethroids had significant 
enrichment in all of the Type I compounds tested.   
 Lists of genes commonly altered by any combination of at least two Type II 
pyrethroids in the microarray data sets are given in Table 4.2.  The most pronounced 
response to the Type II pyrethroids was the induction of a variety immediate early genes 
encoding transcription factors (Junb, c-fos, Egr2, Nr4a1, Klf4 and Klf10), phosphatases 
(Dusp1, Dusp5 and Dusp6) and cellular effectors (Arc).  Some glucocorticoid responsive 
gene transcripts were also induced (Rasd1, Gpd1 and Sgk).  In addition, all three of the Type 
II pyrethroids induced the expression of a small group of receptors Cxcr4, Il6r, Vipr1 and 
Tnfrsf11b.  Complete lists of probe sets regulated by each of the Type II pyrethroids in 
available in the electronic appendices for the present study.  
 Six transcripts were selected for confirmation of treatment-related changes in 
expression for all six pyrethroids in the test panel using qRT-PCR: Nr4a1, Arc, Gpd1, Nedd9, 
Camk1g and Egr1.  The first four are located in the DLT-CYP-CYF union in Figure 4.6A.  
Camk1g, and Egr1 are located in the DLT-CYF, and CYP-CYF unions, respectively.  A 
summary of statistical analyses of qRT-PCR data for these genes is given in Appendix B, 
Table 2.  Expression of Nr4a1 mRNA was increased following exposure to all six 
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pyrethroids in the test panel.  Nr4a1 induction was of much greater magnitude for the Type II 
pyrethroids (4 to 6-fold at 3 h) than the Type I pyrethroids (< 3-fold at 3 h).  The expression 
pattern of Arc mRNA was similar to the expression patterns observed for Nr4a1 for all 
pyrethroids except lower in magnitude.  Arc mRNA expression was increased with all the 
Type II pyrethroids on the order of 3 to 4-fold at 3 h.  In contrast, Arc expression was 
increased only 1.5-fold at 3 h for the Type I pyrethroids.  Gpd1 mRNA expression was 
increased for all of the Type II pyrethroids with the largest responses observed for DLT, CYF 
and CYP respectively.  Only PERM had a significant effect on Gpd1 expression and this 
effect was very low in magnitude (<1.2-fold).  Camk1g mRNA expression was affected most 
dramatically by DLT at 6 h.  A smaller increase in Camk1g expression (~1.3-fold) was 
observed across both time points in the study for CYP and CYF (main effect of time, see 
Appendix B, Table 2) however no main effects of treatment were observed at p < 0.05.  
Nedd9 mRNA expression was increased at 3 h for DLT and CYP only, consistent with its 
location in the comparison in Figure 4.6A.  The Type I pyrethroids had no effects on Camk1g 
or Nedd9 expression.  Egr1 mRNA expression was increased following exposure to all three 
Type II pyrethroids similar to the trends in expression observed for the other immediate early 
genes Nr4a1 and Arc.  TEF was the only Type I with significant effects on Egr1 mRNA 
expression.  Overall, gene expression patterns measured by qRT-PCR had good concordance 
with the microarray data. 
 Two methods were implemented to identify biologically meaningful associations 
between the transcripts regulated by the two Type II pyrethroids: SAFE analysis (Barry et al. 
2005) and Ingenuity® pathway analysis.  SAFE analysis of Gene Ontology ‘molecular 
function’ (GOMF), ‘biological process’ (GOBP) and ‘cellular component’ (GOCC) 
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categories from Bioconductor v1.8 did not detect significant enrichment for any of the 
pyrethroids in the test panel using the Yekutieli and Benjamini (1999) false discovery rate 
correction at a threshold of p < 0.1 (data not shown).  However, the overlapping GOMF 
categories ‘MAP kinase tyrosine/serine/threonine phosphatase activity’ (GO:0017017) and 
‘MAP kinase phosphatase activity’ (GO:0044440) had an empirical p < 0.01 for all of the 
Type II pyrethroids in the panel.  This is consistent with the numerous phosphatases and 
kinases demonstrated to be upregulated after Type II exposure (Table 4.2).   
 Input of genes commonly regulated by all of the Type II pyrethroids into the 
Ingenuity® pathway analysis software package yielded a complex interconnected network of 
protein interactions (Figure 4.8C).  This network is comprised primarily of inducible 
transcription factors and protein phosphatases upregulated following Type II pyrethroid 
exposure and a variety of interconnected kinase complexes, growth factors and transcription 
factors that are constitutively expressed in neurons and not transcriptionally regulated by 
pyrethroids in the present study (Figure 4.8A-B).  Dissection of this interconnected network 
into its component parts demonstrates that the phosphatases and kinases upregulated by the 
Type II pyrethroids primarily act upstream of the constitutively expressed interconnecting 
kinase complexes (Figure 4.8D).  Furthermore, the constitutively expressed kinase 
complexes and transcription factors (NFκB, STAT, CREB) act primarily upstream of the 
pyrethroid inducible transcription factors (Figure 4.8E).  Other pyrethroid upregulated genes 
(Ier2, Gadd45b, Nedd9, Per1 and Per2) are downstream of interconnecting transcription 
factors and growth factors.  The peptide receptor Vipr1 acts upstream of NFκB while the 
chemokine receptor Cxcr4 has a variety of upstream and downstream interactions with the 
constitutive kinase complexes (Figure 4.8F).  Figure 4.8G-H illustrates the protein 
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interactions between the constitutive kinase complexes and the transcription factors or 
growth factors present in the Ingenuity® network, respectively.  The constitutive 
transcription factors are downstream of the kinase complexes (Figure 4.8G, orange arrows) 
while the kinase complexes are downstream of the growth factors (Figure 4.8H, orange 
arrows). 
Discussion.   
 
 The present study demonstrates that Type I and Type II pyrethroids do not produce 
equivalent effects on gene transcription in the rat frontal cortex following behaviorally 
equipotent doses.  The expression of a large number of transcripts was affected by the Type 
II pyrethroids with maximal changes in expression on the order of 4-fold from control.  The 
mRNA expression patterns produced by the Type II pyrethroids have features common to 
DLT, CYP and CYF as well as features unique to each of the respective compounds. The 
observed gene expression changes are consistent with pyrethroids producing increased 
excitability of cortical circuits in vivo.  Ingenuity® pathway analysis modeling yielded a 
complex network of interconnecting gene expression changes consistent with increases in 
neuronal excitability by the Type II pyrethroids.  In addition, visual inspection of the 
microarray gene expression data and comparative enrichment analysis indicated that some 
components of the common Type II transcriptional response were also present in the Type I 
treatment groups, albeit at lower magnitudes of change.  This hypothesis was supported by 
qRT-PCR analysis of a sub-set of pyrethroid regulated mRNAs.   
 A principal finding from this study is that Type I and Type II pyrethroids 
administered at dose levels that produce equivalent effects on an apical behavior (i.e. motor 
activity) cause dramatically different effects on global gene expression in the rat frontal 
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cortex.  A large number of gene expression changes were detected with the Type II 
pyrethroids DLT, CYP and CYF using the LIMMA analysis framework (Figure 4.5).  In 
contrast, LIMMA did not detect any gene expression changes with the Type I pyrethroids 
PERM, BIF and TEF even though empirical pair-wise contrast tests indicated that a small 
number of low-magnitude gene expression changes occurred following Type I pyrethroid 
exposure (Figure 4.3).  These data are consistent with the differential effects of the two 
pyrethroid types on voltage-sensitive sodium channel function.  Type I pyrethroids produce 
abnormal Na+ tail currents with time constants of decay much shorter than those produced by 
Type II pyrethroids (Song et al. 1996; Tabarean and Narahashi 1998; Narahashi 2000; Choi 
and Soderlund 2006).  The longer duration Na+ tail currents produced by Type II pyrethroids 
maintain neurons in a more hyperexcitable state than Type I pyrethroids (Ecobichon 2001; 
Ray and Fry 2006).  Furthermore, Type II pyrethroids produce longer trains of repetitive 
firing following stimulus than the Type I pyrethroids (Vijverberg and Van den Bercken 
1990).  The present data suggest that Type II pyrethroids produce a greater degree of 
neuronal excitation in the cortex than the Type I pyrethroids at the administered doses 
examined which would in turn produce more dramatic changes in the expression of genes 
regulated by neuronal activity.   
 The differences in gene expression profiles between the two pyrethroids types may 
also reflect differential activation of secondary molecular targets sites that control gene 
transcription.  For example, Ca+2 is an intracellular second messenger capable of triggering 
de novo gene transcription (Schulman and Roberts 2003).  Symington and Clark (2007) have 
demonstrated an increase in Ca+2 influx into rat brain synaptosomes following both 
deltamethrin (Type I) and cismethrin (Type II).  Cismethrin-stimulated Ca+2 influx was 
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dependent upon Na+ channel mediated depolarization while deltamethrin-stimulated Ca+2 
influx was Na+ channel independent.  In addition, the concentration-response curve for 
deltamethrin-stimulated Ca+2 influx is to the left of that for cismethrin, indicating a smaller 
concentration of the Type II pyrethroid is required to produce the response.  It is possible that 
at the dose levels used in the present study, the Type II pyrethroids are more potent activators 
of a secondary molecular target(s) that mediate gene transcription than the Type I 
pyrethroids.  These actions could be independent of both pyrethroid effects at VSSCs and the 
behavioral response (i.e. decreased motor activity), which may explain why the doses used 
here produce the same magnitude of behavioral change for the two pyrethroid types but do 
not produce the same magnitude of gene expression changes. 
  An additional alternative is that pharmacokinetic differences in the distribution or 
metabolism of Type I and Type II pyrethroids may be contributing to the divergent effects on 
global gene expression observed here.  Comparison of pharmacokinetic (PK) data available 
in the literature for DLT and PERM do not support this conclusion (PK models for CYP, 
CYF, BIF and TEF in the rat are not presently available).  Both DLT and PERM accumulate 
in the frontal cortex following an acute oral dose (Anadon 1991; Anadon 1996).  
Furthermore, brain concentrations of both Type I and Type II pyrethroids correlate with 
changes in behavior at high doses (Gray et al. 1980; Rickard and Brodie 1985) and doses 
compatible with those used in this study (Scolon et al. in preparation).  Lastly, pyrethroids 
all have different efficacies for interacting with different VSSC isoforms (Soderlund et al. 
2000; Choi and Soderlund 2006).  In in vitro studies of neuronal function, different 
pyrethroid types produce disparate effects on the excitable properties of the same neuronal 
cell populations and different neuronal subtypes respond differently to the same pyrethroid 
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(Tatebayashi and Narahashi 1994; Tabarean and Narahashi 1998; Grosse et al. 2002; Meyer 
and Shafer 2006; Meyer et al. 2007).  Therefore, since different VSSC isoforms and neuronal 
subtypes are heterogeneously expressed throughout central nervous system tissues, the 
unique effects of the individual pyrethroid types on channel function may be the critical 
factor contributing to the differential gene expression patterns. 
 The transcriptional response of the frontal cortex to the Type II pyrethroids DLT, 
CYP and CYF contains some genes that are commonly regulated by multiple Type II 
pyrethroids in the test panel and some genes that are uniquely regulated by the individual 
Type II pyrethroids (Figure 4.6A).  These data support that all three of the Type II 
pyrethroids in the test panel elicit similar changes in the expression of a sub-set of genes 
while also producing changes in expression unique to the different Type II compounds.  The 
comparative SAFE enrichment analysis also supported this conclusion and demonstrates that 
the transcription response of DLT and CYP is the most similar.  Differences in chemical 
structure between the three Type II pyrethroids in the panel may be responsible for mediating 
the differences in the global transcriptional response of DLT, CYP and CYF.  Structurally, 
DLT and CYP differ only in the identity of halogen groups on the cyclopropane carboxylic 
acid moiety of the compounds: bromines for DLT and chlorines for CYP (Figure 4.1).  CYF 
differs from CYP only by the addition of a fluorine group to the aromatic alcohol moiety 
(Figure 4.1).  These small differences in chemical structure can have impacts on the duration 
of VSSC modification and adverse outcomes on the behavioral level (Verschoyle and 
Aldridge 1980; Choi and Soderlund 2006).  Differences in stereoisomer ratios between the 
Type II pyrethroids may also explain the divergences observed in global gene expression 
profiles.  The preparation of DLT used is composed exclusively of the ‘more toxic’ cis-(αR) 
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stereoisomer whereas CYP and CYF are heterogenous mixtures of cis- and trans- α-S and α-
R stereoisomers (Soderlund 1985; Ray 2001; Soderlund et al. 2002).  Definitive conclusions 
regarding the impact of chemical modifications or stereochemistry on pyrethroid induced 
gene expression can not be made without systematic comparison of isomerically pure 
preparations of the test compounds.  However, the present data clearly demonstrate that there 
is a specific suite of genes commonly regulated by Type II pyrethroid compounds regardless 
of isomeric composition.   
 The mechanistic relationship(s) between acute pyrethroid action at ion channels and 
the genes altered by Type II pyrethroids is currently unclear.  However, the present data are 
consistent with the previous findings (Harrill et al. submitted).  Both studies failed to detect 
any changes in gene expression corresponding to the primary molecular targets of 
pyrethroids (i.e. VSSCs, Ca+2 channels, Cl- channels).  On the other hand, some of the 
transcripts within the suite of genes commonly regulated by the Type II pyrethroids are 
known to be upregulated in response to excitatory stimulation.  This supports the hypothesis 
that the Type II pyrethroids DLT, CYP and CYF produce neuronal excitation within the 
frontal cortex in the present study.  The expression of the immediate early (IEG) transcription 
factors c-fos, JunB, Egr1and Nr4a1 have been shown to be upregulated by a variety of 
excitatory stimuli (Hazel et al. 1991; Morgan and Curran 1991; Fields et al. 1997; Hughes et 
al. 1999; Patra et al. 2004) and are also upregulated by Type II pyrethroids in the present 
study.  In addition, the expression of the phosphatases Dusp1, Dusp5 and Dusp6 and the 
cytoskeletal protein Arc that are upregulated by DLT, CYP and CYF in the present study are 
also induced following neuronal excitation (Gass et al. 1996; Muda et al. 1996; Hevroni et al. 
1998; Kodama et al. 2005; Guzowski et al. 2006; Machado et al. 2008).  Another component 
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of the common Type II response are the genes Rasd1 and Gpd1 which are both regulated by 
activation of intracellular glucocorticoid receptors by the hypothalamic-pituitary-adrenal axis 
(Baughman et al. 1997; de Kloet et al. 1998; Brogan et al. 2001).  The upregulation of Gpd1 
indicates that transcriptional responses of glial cells may be included in the overall global 
expression profiles for pyrethroids in the frontal cortex, given that this protein is expressed 
exclusively in oligodendrocytes (Leveille et al. 1980).  In addition, Sgk has been shown to be 
upregulated following both glucocorticoid receptor activation and activation of post-synaptic 
excitatory glutamate receptors (Lee et al. 2003; Webster et al. 2003) which supports a role 
for both neuronal excitation and glucocorticoid stimulation in the transcriptional response of 
the frontal cortex to pyrethroids.  These data are consistent with previous studies that 
demonstrate induction of activity-regulated genes and increases in circulating corticosterone 
following acute pyrethroid exposure (Hassouna et al. 1996; de Boer et al. 1998; Wu and Liu 
2003).  Even though the mechanistic linked between pyrethroid action at the ion channel and 
the present gene expression is unknown, these data do provide insight into some of the 
intracellular signaling pathways that may be stimulated by acute pyrethroid action in vivo. 
 Ingenuity® pathway analysis of genes commonly affected by the Type II pyrethroids 
yielded an interconnected network of protein interactions that is also consistent with the 
induction of hyperexcitability by pyrethroids in the frontal cortex.  This network is comprised 
of the IEG transcription factors, phosphatases and effector proteins commonly upregulated 
by the Type II pyrethroids as well as constitutively expressed kinase and transcription factor 
complexes (Figure 4.8C). Systematic deconstruction of this interactive network supports a 
model of acute pyrethroid action that includes stimulation of constitutive kinase signaling 
cascades and subsequent activation of constitutive transcription factors followed by de novo 
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expression of IEG phosphatases and kinases that deactivate the excitatory signaling 
pathways, effector proteins that may impact cellular function and IEG transcription factors 
that can regulate subsequent changes in the expression of additional effector proteins (Figure 
4.9).  Increased neuronal excitation results in the activation of Akt, Jnk, MAPK, p38 MAP, 
MEK and Pkc (Rosen et al. 1994; Vanhoutte et al. 1999; Perkinton et al. 2002; Brager et al. 
2003; Chen et al. 2003; Vaillant et al. 2003; Corvol et al. 2005; Pezet et al. 2005) which are 
the connecting nodes of the Ingenuity® network (Figure 4.8C).  Dusp1, Dusp5, Dusp6 and 
Ptpn1 may then act to dephosphorylate and deactivate these kinases, and to turn off the 
excitatory stimulus in a transcription dependent feedback loop.  The activated kinase 
complexes are also upstream of de novo expression of the IEG transcription factors induced 
by the Type II pyrethroids.  The model supports a role for the constitutive transcription 
factors STAT, CREB and NFκB in connecting the excitatory responses of the kinase networks 
to the pyrethroid induced de novo gene expression changes.  These three proteins are 
downstream of the putatively activated kinase complexes and upstream of the transcriptional 
responses elicited by the Type II pyrethroids (Figure 4.8D and 4.8E, Wooten 1999; Davis et 
al. 2000; Kaltschmidt et al. 2002). Ingenuity® also incorporated the growth factors Fgf, Pdgf 
and Tgfβ into the network based on upstream effects on the inducible components of the 
Type II pyrethroid response.  However, there are no data available that support a role for 
these genes in the biological activity of pyrethroids in vivo.  At this time, the effect of de 
novo gene expression induced by pyrethroids on downstream cellular functions is unclear.  
Additional studies are needed to investigate the activation of the signaling pathways 
putatively identified in the present study in response to pyrethroids. 
 165 
Several lines of evidence within that current study suggest that components of the 
transcriptional response commonly elicited by the Type II pyrethroids (Table 4.2, far right 
column) was also be present in the Type I treatment groups, even though LIMMA analysis 
did not detect them.  First, pair-wise comparisons of PERM, BIF and TEF treated groups to 
vehicle controls indicated that the expression of a small group of probe sets was in fact 
changed (Figure 4.3).  Second, visual inspection of the expression profiles for genes 
commonly affected by the Type II pyrethroids demonstrated that a small sub-set of genes had 
qualitatively similar changes in expression between pyrethroid types, although the response 
produced by the Type I’s was lower in magnitude (Figure 4.6B, brackets).  Lastly, 
comparative SAFE enrichment analysis (Table 4.1) demonstrated that gene lists derived from 
the overlapping portions of the Type II transcriptional responses were significantly enriched 
in the PERM, BIF and TEF treatment groups.  Similarities in the transcriptional response to 
Type I and II pyrethroids has been previously reported (Harrill et al. submitted).  These 
observations support that the multiple-test correction employed by LIMMA may have been 
too conservative for the purpose of detecting the small number of low-magnitude gene 
expression changes observed in the Type I treatment groups.  Alternatively, the use of motor 
function data (Wolansky et al. 2006) to define equipotent dose levels may have 
overestimated the potency of Type I pyrethroids at the neuronal membrane.  This latter point 
is consistent with the smaller effects observed with the Type I pyrethroids in this study.  
Dose-response data on gene expression for Type I pyrethroids using higher administered 
doses would test this hypothesis. 
Quantitative RT-PCR analysis performed on a group of transcripts commonly 
regulated by multiple Type II pyrethroids in the microarray experiment are consistent with 
 166 
the expression patterns observed in the microarray study and also support that a small 
number activity-regulated genes are regulated in response to the Type I pyrethroids.  Arc and 
Nr4a1 IEG expression was significantly changed by all six pyrethroids in the test panel 
(Figure 4.7).  Egr1 and Gpd1 mRNA was upregulated by all the Type II pyrethroids and by 
PERM and TEF respectively.  Nedd9 expression was upregulated by DLT and CYP while 
Camk1g was significantly increased only by DLT.  The changes in Arc and Nr4a1 mRNA 
expression for the Type I pyrethroids were of smaller magnitude than those observed with the 
Type II pyrethroids and is consistent with a  lesser degree of neuronal activation in the cortex 
for the doses PERM, BIF and TEF used here as compared to DLT, CYP and CYF.  In a 
previous study (Harrill et al. submitted) a dose of 100 mg/kg PERM produced increases in 
Egr1, Gpd1 and Camk1g comparable to the 3 mg/kg dose of DLT used in the present study.  
The 100 mg/kg PERM dose examined was slightly more efficacious for decreasing 
ambulatory motor activity than the 3 mg/kg DLT dose (ED50 vs. ED30, Wolansky et al. 
2006).  This is consistent with the hypothesis stated above that suggests higher doses of Type 
I pyrethroids will produce similar effects to the Type II pyrethroids observed in the present 
study.  These data do not support that the frontal cortex is insensitive to the effects of Type I 
pyrethroids in terms of de novo gene transcription.   
          The lack of effect of Type I pyrethroids on Camk1g mRNA is inconsistent with 
previous studies (Harrill et al., submitted, Harrill and Crofton, in preparation).  In those 
studies an ED30 dose of DLT and either an ED30 or ED50 doses of PERM (based on 
Wolansky et al. (2006) motor activity data) were sufficient to produce an upregulation of 
Camk1g mRNA.  In addition, in these previous studies, the Camk1g mRNA response to 
PERM was less robust that that observed with DLT.  In the present study, an ED30 dose of 
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DLT again resulted in an increase in Camk1g mRNA expression, whereas an ED30 dose of 
PERM caused no effect.  The reason for this disparity is unclear.  The PERM used in the 
present study was taken from the same lot of technical grade product as used in the two 
previous studies.  Therefore, differences in isomer composition and purity can not account 
for the disparate results.  Alternatively, differences in the metabolic rates for PERM between 
the cohorts of animals used across studies may account for the difference.  The rats used in 
the present study may have had a greater capacity for metabolizing PERM than the rats used 
in the previous studies, therefore resulting in a lower target tissue concentration at a 
comparable administered dose level and no appreciable increase in Camk1g mRNA.  
 Collectively, across studies the data indicate that Camk1g mRNA expression is 
affected by pyrethroids with DLT being the most potent for producing this effect.  Camk1g 
mRNA expression in cortical neurons is responsive to changes in neuronal firing patterns and 
internal Ca+2 trafficking (Xiang et al. 2007).  The greater relative potency of DLT for 
increasing in Camk1g mRNA expression may be due to the longer duration Na+ tail currents, 
and consequently greater increase in neuronal excitability, produced by DLT as compared to 
other pyrethroids (Vijverberg and Van den Bercken 1990; Choi and Soderlund 2006).  
Alternatively, DLT may activate a secondary molecular target that controls Camk1g 
expression, such as a voltage-sensitive Ca+2 channel, at lower concentrations than other 
pyrethroids (Symington and Clark 2007).  Further work is needed to substantiate these 
hypothesis as a formal link between pyrethroid action at the neuronal membrane, increased 
internal Ca+2 concentrations and increased Camk1g mRNA expression has not been 
established. 
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 In conclusion, the present data demonstrate that the Type II pyrethroids produce more 
pronounced changes in activity-regulated gene expression than Type I pyrethroids in the 
frontal cortex of rats orally exposed to behaviorally equipotent doses.  The data also provide 
predictions for some intracellular signaling pathways that may be affected directly 
downstream of pyrethroids actions at the neuronal membrane.   
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Table 4.1.  Enrichment scores for gene-of-interest lists derived from Venn Diagram 
comparison. 
 
    ________Type II_____ ________Type I______  
    n   DLT   CYP   CYF PERM   BIF   TEF 
 
DLT-Limma  399    n/a 0.0001 0.0009 0.0345 0.0314 0.1433 
CYP-Limma  149 0.0001    n/a 0.0022 0.0689 0.0030 0.0854 
CYF-Limma 3742 0.1246 0.3499    n/a 0.0874 0.1632 0.0046 
DLT-CYP Union   91    n/a    n/a 0.0003 0.0345 0.0060 0.0258 
DLT-CYF Union  216    n/a 0.0001    n/a 0.0345 0.0311 0.0258 
CYP-CYF Union   85 0.0001    n/a    n/a 0.0348 0.0031 0.0258 
DLT-CYP-CYF Union  71    n/a    n/a    n/a 0.0345 0.0060 0.0107 
________________________________________________________________________ 
Gene lists derived from the LIMMA analysis Venn Diagram (Figure 4.6a) were analyzed for 
enrichment by SAFE analysis across all six compounds in the study.  Prior to analysis 
microarray expression values were re-centered to the combined mean of 3 h and 6 h controls 
to eliminate main effects of time (Appendix B, Figure 1).  The local statistic for the SAFE 
analysis is based on a multi-factor ANOVA of mean centered expression values.  Global 
statistics are based on a Wilcoxon rank sum test.  The threshold for significant enrichment 
was set at an FDR < 0.05 (highlighted in bold).  n/a = not analyzed: compounds upon which 
a particular gene-of-interest list is based were not tested for enrichment for that list. 
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Table 4.2.  Genes changed by Type II pyrethroid exposure._________________________________________________________ 
   DLT-CYP        DLT-CYF    CYP-CYF    DLT-CYP-CYF 
      Union           Union       Union           Union_________  
Transcription / Nuclear Factors  
 Vgll4 Cebpb, Tsc22d3, Ets2, Egr1, Tcfcp212 Klf10, Junb, Nab2, c-fos,  
  Mybbp1a, Madh3,   Nr4a1, Id1, Hes1, Klf4, 
  Mcyn  Egr2 
Phosphatases  
 Acpl2 Ptpru  Dusp1, Dusp5, Dusp6,  
    Ptpn1 
Kinases 
 Map2k3 Camk1g, Mertk, Pdk4,  Sgk, Snf1lk, Sbk, Trib1  
  Pim3, Uae1   
Cytoskeletal/Structural Proteins  
  Cryab, Pxn, Pkp2  Arc, Nedd9, Lims2 
Metabolic Proteins 
  Fmo2, Fmo3, Lfng,  Gpd1, Gfpt2, Hs3st1 
  Xdh, Sult1a1, Hyal2 
  Usp54 
Ligands / Receptors 
 Nppc Sstr2, Chrm4, Adipor2  Cxcr4, Il6r, Vipr1, 
    Tnfrsf11b 
Extracellular Matrix Proteins  
 Vwa1, Prss11, Lcn7  
 Fst, Angpt14  
Ion Channels / Ion Transport  
 Gjb6, Cacng2  
Transporters 
  Slc21a14, Slc2a1, Slc25a25,    
  Slc39a1 
____________________________________________________________________________________________________________ 
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Table 4.2. continued__________________________________________________________________________________________ 
Cellular Stress Response 
  Hspb1 Bcl2l1, Ndrg1,   
   Rbm3 
Adaptor Proteins a 
 Homer1 Ralgds, Mgl1, Errfi1,  Irs2, Gadd45b 
  Lrg1, Rin3, Fkbp51, 
  Slc9a3r2, Cdkn1a, 
  Cnksr3, Nfkbia, Bag3,  
  Arhgap7   
Other / Unknown Functions  
 Ctrl,  Smpdl3b, Arrdc2, Degs,  Rnf39, Xkr6, Per1, Per2,  
 LOC681858, Clec14a, Prr5, Srxn1,  Ier2, Plekhf1, Rasd1, Ier5 
 LOC367746,  Nid67. LOC684871,  Ier5l  
 LOC500592  LOC690516, LOC683687, 
  RGD1311086, RGD1308276 
  RGD1359349, RGD1311086, 
  RGD1304790 
Predicted Protein Sequences 
 Cttnbp2nl, Rasgrp3, Pnpla2, Sesn1, Midn, Ephb3,  Dnajb5, Tiparp, Klf2,  
 Rasgeflc Cbr3, Mkl1, Asah3l, Spsb1 RGD1560818 Zfp189, Rkhd3, Axud1, 
  B3galt5, Cables1, Map3k6  Spry4 
  Bcl6, Cd163, Asph, Rundc1, 
  Pla2g3, Usp43, Cdc42ep4, 
  Pwwp2, Mrc1, 
  RGD1310714, RGD1561512, 
  RGD1559797, RGD1306323 
Number of ESTs 
       8                   39          9                 12___________ 
aColumns were defined from different zones of similarity shown in Figure 4.6A.  bProteins that directly associate with and affect the 
function of another protein without phosphorylation or dephosphorylation.  
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Figure 4.1.  Chemical structures of pyrethroids. 
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Figure 4.2.  Pyrethroid effects on motor activity.  Data replotted from Wolansky et al. 
(2006).  Ambulatory motor activity expressed as percent change from vehicle treated control 
± standard error (y-axis) versus administered dose of pyrethroids (x-axis).  Type II 
pyrethroids plotted in gray, Type I pyrethroids plotted in black.  The calculated ED30 for 
decreased motor activity for each compound is given in the inset.  These are the administered 
doses used in the present study. 
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Figure 4.3.  Volcano plots of pair-wise comparisons of microarray data.  Each panel plots 
the empirical p-value from a pair-wise t-test of treated groups to their corresponding time-
matched vehicle controls groups (y-axes) versus fold change from control (x-axis).  Type II 
pyrethroids are in the upper panels while Type I pyrethroids are in the lower panels.  3 h 
treatment groups are in rows 1 and 3.  6 h treatment groups are in rows 2 and 4.  Dashed lines 
represent an empirical p-value threshold of p < 0.001.  All probe sets present on the 
Affymetrix Rat 230_2 array are shown in each panel. 
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Figure 4.4.  Linear Models for Microarray Data (LIMMA) analysis scheme.  (A) Condition 
matrix for each of the compounds examined in the study.  Two treatments (control and 
pyrethroid) and two times (3 h and 6 h) comprise the 2-by-2 matrix.  (B) Contrasts made in 
the LIMMA analysis for each probe set.  Treatment groups involved in each contrast are 
listed in brackets.  The structure is identical to a two-way ANOVA model. (C) Flowchart for 
the determination of treatment related changes in expression by LIMMA analysis.  Decisions 
for each contrast are made based on a significance threshold of p < 0.1 for Yekutieli-
Benjamini (1999) adjusted p-values.  Gene expression values for each pyrethroid were 
examined individually within this framework. 
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Figure 4.5.  Results of LIMMA analysis for Type II pyrethroids.  Each panel shows gene 
expression changes as a function of fold-change from control (y-axes) across time (x-axes) 
for probe sets with treatment related changes in expression for DLT (blue tabbed panels), 
CYP (red tabbed panels) and CYF (orange tabbed panels).  Branches within the diagram 
correspond to the decisions regarding each contrast outline in the flowchart in Figure 4.4C.  
Tabs with black numbers in the top two or last row of the diagram represent the number of 
probe sets that met the particular condition.  Probe sets with > 1.25-fold changes in 
expression for either the 3 h or 6 h condition are shown in blue and correspond to the blue 
numbers in each panel.  Probe sets with no fold changes in expression >1.25 for either the 3 h 
or 6 h condition are shown in gray and correspond to the gray numbers in each panel.
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Figure 4.6.  Comparison of gene expression changes across compounds.  (A) Venn diagram comparing treatment related changes in 
gene expression for the Type II pyrethroids deltamethrin, cypermethrin and cyfluthrin. (B) Heatmap displaying patterns of gene 
expression changes for the 71 probe sets commonly regulated by the Type II pyrethroids.  Columns are individual probe sets.  Rows 
are treatment groups.  Areas of apparent similarity between the Type II and Type I compounds are marked with arrows and brackets.  
Tile coloring is based on the mean fold change from control for each of the treatment conditions.
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Figure 4.7.  qRT-PCR results.  Each panel shows changes in gene expression measured with 
TaqMan® qRT-PCR for Nr4a1, Arc, Gpd1, Camk1g, Nedd9 and Egr1.  Each gene of interest 
was examined for each pyrethroid in the test panel.  Data are expressed as 2-∆∆CT values ± 
standard error (y-axes) across time (x-axes) as described in the Methods section.  Colored 
boxes beside each gene name correspond to the area of the Venn Diagram in Figure 4.6A in 
which each transcript is found.  Compound abbreviations listed under each gene symbol 
denote that a significant effect of treatment was observed for that individual pyrethroid (p < 
0.05).  Statistical analyses of these data are described in the Methods section and results are 
given in Appendix B, Tables 2. 
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Figure 4.8.  Ingenuity® pathway analysis of genes commonly affected by Type II 
pyrethroids.  The 71 probe sets commonly affected by all the Type II pyrethroids in the 
microarray data was input into the Ingenuity® pathway analysis software package and yielded 
the interconnected network shown in panel C.  (A) List of the pyrethroid-sensitive genes 
present in the network.  Coloring of these elements is based on the expression pattern observed 
with deltamethrin: red = upregulated, blue = downregulated.  (B) List of connecting nodes 
present in the network.  (D-F) Systematic deconstruction of the interaction network in Figure 
C.  Associations between the connecting nodes of the full network removed for clarity in 
panels D-F.  The network is separated into an inducible phosphatase/kinase component (D), an 
inducible transcription factor component (E) and other regulated proteins component (F).  Note 
in panel D that inducible phosphatases act upstream of the constitutive kinases (arrows pointed 
to the right) and in panel E constitutive kinases and transcription factors act upstream of 
inducible transcription factors (arrows radiating inward).  (G-H) The interconnections of the 
constitutive kinase complexes are given in the absence of pyrethroid-responsive genes for 
clarity.  Interconnections between kinase complexes and transcription factors (orange arrows 
pointing out) and kinase complexes and growth factors (orange arrows pointing in) are given in 
panels G and H.     
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Figure 4.9.  Schematic of putative pyrethroid gene regulatory network.  Putative 
intracellular signaling cascades impacted by pyrethroids as indicted by Ingenuity® analysis.  
A = activation, TR = transcription, TL = translation, D = deactivation, M = translocation / 
movement. 
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 The present research project was undertaken to address a fundamental data gap in the 
toxicological profile of pyrethroid insecticides: i.e. changes in gene expression that occur 
downstream of the pharmacological interaction of these agents with voltage-sensitive ion 
channels.  The acute neurotoxic effects of pyrethroids manifest at the whole organism level 
as a result of pharmacological disruption of neuronal firing (Narahashi 2001; Soderlund et al. 
2002; Ray et al. 2005).  A vast literature in the fields of molecular biology and neuroscience 
demonstrate that increased neuronal excitability produce changes in gene expression.  These 
changes in gene expression are thought to mediate adaptive responses of neurons to 
excitatory stimuli in both adult and developing animals (Finkbeiner and Greenberg 1998; 
Zhang and Poo 2001; Wong and Ghosh 2002; Zito and Svoboda 2002; Miller and Kaplan 
2003; Uesaka et al. 2006; Uesaka et al. 2005; Kullman and Lamsa 2007).  Yet, the effects of 
pyrethroids on neuronal gene expression downstream of actions at the neuronal membrane 
had not been characterized.   
 The overall goal of the present research was to test the hypothesis that pyrethroids 
cause changes in the expression of activity-regulated gene transcripts in the central nervous 
system in dose ranges surrounding the threshold for acute neurotoxic effects.  The present 
studies: 1) identified activity-regulated gene expression changes following acute pyrethroid 
exposure, 2) identified some intracellular signaling pathways that may be activated by 
pyrethroids, and 3) demonstrated that neuronal branching morphogenesis is affected by 
pyrethroid exposure in vitro.  The latter finding may represent a novel neurotoxic effect of 
pyrethroids.  
 The gene expression studies conducted in Chapters 2 and 4 of this work identified a 
suite of activity-regulated genes as being sensitive to pyrethroids including c-fos, Arc, Nr4a1, 
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Egr1, Dusp1, Dusp5, Dusp6 and Camk1g.  The majority of these findings are novel to the 
field of pyrethroid research and consistent with the neuronal hyperexcitability produced by 
pyrethroids.  These changes in gene expression occur at or below doses that produce minimal 
effects on neurobehavior in the whole animal (Bloom et al 1983; Crofton and Reiter 1984; 
Peele and Crofton 1987; McDaniel and Moser 1996; Wolansky et al. 2006).  The activity-
regulated transcripts identified as being responsive to pyrethroids are a ‘molecular tool’ 
useful in addressing a critical gap in the field of pyrethroid research; do different pyrethroids 
activate the same neuronal circuits at doses that produce minimal effects on neurobehavior?   
 The neurobehavioral endpoints affected by pyrethroids are apical measures of 
nervous system function and can be affected by a wide variety of chemicals with diverse 
toxicological mechanisms (Davis 1986; Moser and MacPhail 1990; Crofton et al. 1991; 
Crofton and MacPhail 1996).  It is possible that at moderately effective dose levels, Type I 
and Type II pyrethroids activate different neuronal circuits or different neuronal sub-types to 
elicit the same overall effect on apical neurobehavioral endpoints.  In support of this, in vitro 
studies have demonstrated that different pyrethroid types produce disparate effects on the 
same neuronal cell populations and that neurons with different cellular phenotypes respond 
differently to the same pyrethroid (Tatebayashi and Narahashi 1994; Tabarean and Narahashi 
1998; Stucky and Lewin 1999; Grosse et al. 2002; Wu and Pan 2004; Meyer and Shafer 
2006; Meyer et al. 2008).  In addition, the present data from Chapter 4 demonstrate that 
activity-regulated gene expression in the rat cortex is less intense following Type I pyrethroid 
exposure as compared to Type II pyrethroids at low doses that produce the same quantitative 
effect on motor function.  The pyrethroid-regulated gene signatures defined in the present 
study may be used as cellular ‘markers-of-activation’ to compare the excitatory effects of 
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pyrethroids, both across brain regions and across different compounds.  Data on activation of 
specific neuronal circuits in the lower end of the pyrethroid-dose effect range would aid in 
the mechanistic grouping of different pyrethroids in the context of a cumulative risk 
assessment framework (EPA 2002).     
 The mapping of activated neuronal circuits with immediate early genes has been used 
to study both behavior in untreated animals and neurotoxicity produced by a variety of 
compounds (Vendrell et al. 1991; Vendrell et al. 1992; Andre et al. 1998; Guzowski et al. 
1999; Storey et al. 2002; Caravajel et al. 2005).  Guzowski et al. (2005) demonstrated the 
utility of fluorescent in situ hybridization (FISH) in identifying neurons activated by an 
excitatory stimuli using an immediate early mRNA as the marker of effect.  The immediate 
early genes identified in the present study could be used as markers of effect with the FISH 
method to examine the neuronal circuitry activated by pyrethroids in an acute dosing model.  
Future experiments could include a multi-factorial design that examines pyrethroid-induced 
neuronal activation at several doses surrounding the threshold for acute behavioral effects, 
several sampling times that match the onset and peak of neurobehavioral effects and several 
different pyrethroids for comparison of effects across the chemical class.  Serial sectioning of 
whole brains would be used to provide a comprehensive map of neuronal cell bodies 
activated by pyrethroids throughout the different brain regions at different times and doses.  
The commercial availability of fluorophores that excite at different wavelengths also allows 
for multicolor FISH.  Different colored flourophores could be used to label the immediate 
early gene marker and other mRNA species specific to neurons with different molecular 
phenotypes (such as those coding for specific neurotransmitter receptors or ion channels).  
This would allow determinations of whether different neuronal populations within the brain 
 193 
are activated by different pyrethroids or at different pyrethroid doses.  The type of approach 
described here would address potential mechanistic differences in the Type I and Type II 
action at the cellular level. 
 From a molecular biology standpoint, the data on pyrethroid-regulated gene 
expression in the present study support a model for the intracellular effects of these 
compounds at the protein level.  This putative signaling network includes the activation of 
constitutive kinase pathways (PI3K/Akt, Jnk, p38 MAPK, ERK/MEK, Pkc), subsequent 
activation of CREB, NFκB and STAT transcription factors and finally induction of immediate 
early gene phosphatases, transcription factors and effectors.  These pyrethroid induced genes 
terminate stimulation of the kinase pathways, mediate subsequent gene transcription events 
and may augment downstream neuronal functions, respectively (see Chapter 4, Figure 4.9).  
The pyrethroid effects on immediate early gene expression are empirically measured in the 
present studies, however the activation of the constitutive kinase complexes and transcription 
factors in this network are speculative at this point.  Future experiments examining the 
phosophorylation states, kinase activities and transcriptional activities of these proteins in 
response to pyrethroids are required to validate the proposed intracellular signaling network.   
 Predictions regarding the role of immediate early gene expression and the putative 
intracellular signaling networks as it relates to pyrethroid neurotoxicity are difficult.  Some of 
genes upregulated by pyrethroids in the present studies (Arc, Egr1), as well as some 
components of the predicted pyrethroid signaling network (MAPK, p38 MAPK, Jnk, CREB, 
NFκB) are essential to the process of long-term potentiation and memory consolidation in the 
brain (Bozon et al. 2003; Li et al. 2005; Miyamoto 2006; O’Mahoney et al. 2006; Plath et al. 
2006; Liu et al. 2007; Toyoda et al. 2007).  Subsequently, abnormal activation of these 
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pathways by pyrethroids may interfere with memory formation and cognitive recall.  In 
support of this, a limited number of in vivo studies report effects of acute pyrethroid exposure 
on learned behavior in rats using operant response tasks (Bloom et al. 1983; Peele and 
Crofton 1987; Stein et al. 1987).  A consistent decrease in operant response rates was 
observed for numerous pyrethroids and indicates that these compounds either interfere with 
cognitive recall of a learned response or, alternatively, decrease motivation for completing a 
reward-driven task.  If protein phosphorylation and activation studies confirm the putative 
findings from the gene array pathway analysis, then investigation of low dose pyrethroid-
induced effects on working memory (learning) and reference memory (retention) with 
classical behavioral test paradigms (Eckerman and Bushnell 1992) and correlation of those 
effects with changes in biochemical endpoints would be a sensible follow-up study. 
Of all the findings in the present study, the observation that pyrethroids can affect 
neuronal branching morphogenesis in vitro has the highest potential impact on human health 
and the field of pyrethroid toxicology.  The basis for testing whether or not pyrethroids 
affected this developmental process came from functional category level analysis of the 
microarray data presented in Chapter 2 of this work.  The in vitro model used herein revealed 
that pyrethroids increased neurite branching but not length.  This finding is novel and in 
contrast to the few available reports of pyrethroid effects on neuronal morphology (Nandi et 
al. 2006; Tran et al. 2006; Weeks and Perez 2006).  The present data predict that pyrethroids 
may affect neuronal branching in vivo in both the adult and developing nervous system.  
Repeated abuse of the stimulant drugs cocaine and amphetamine have been shown to 
produce increased dendritic branching in the adult cortex, which has been putatively linked to 
impairment of cognitive function and development of addiction (Robinson and Kolb 1999; 
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Robinson et al. 2001).  Repeated exposures to pyrethroids may cause the same types of 
effects.  In addition, neurons undergo extensive dendritic branching prior to the formation of 
synaptic contacts in the developing nervous system (Wong and Ghosh 2002; Jan and Jan 
2003; Libersat and Duch 2004; McAllister et al. 2004).  Pyrethroids also have the potential to 
affect this developmental process, based on the present in vitro findings.   
The potential for pyrethroids to act as developmental neurotoxicants has been 
recently reviewed (Shafer et al. 2005).  To date, the database on pyrethroid developmental 
neurotoxicology includes investigations of acetylcholine receptor density, neurotransmitter 
levels and motor behavior in adult rats and mice exposed during gestational or early post-
natal life (Eriksson and Nordberg 1990; Eriksson and Fredriksson 1991; Ahlbom et al. 1994; 
Talts et al. 1998a; Lazarini et al. 2001).  The present data argue that changes in neuronal 
microstructure and network connectivity should also be examined in laboratory animal 
models exposed to pyrethroids during the critical period of neuronal growth and branching. 
Gene expression data provides a number of attractive candidate molecules that may 
mediate the pyrethroid effects on branching morphogenesis.  These include Camk1g, Cxcl12 
and its cognate receptor Cxcr4, Notch and β-catenin all of which control some aspects of 
neuronal branching (Redmond et al. 2000; Yu and Malenka 2003; Pujol et al. 2005; Wayman 
et al. 2006; Takemoto-Kimura et al. 2007).  An immediate future direction would be to 
confirm the effects on branching morphology observed in vitro in an in vivo model.  A 
morphological examination of neuronal dendritic fields following pyrethroid exposure in 
both early life and in adulthood would serve to confirm or refute the present observations.  If 
pyrethroids are shown to impact neuronal branching in vivo, then the gene candidates 
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identified in the present studies could be used as starting point to examining the molecular 
mechanisms that control this response 
In summary, the present research provides important findings regarding the effects of 
pyrethroids on gene expression in the brain, an area of pyrethroid research that had not been 
extensively studied previously.  The results of these studies supported the hypothetical model 
of pyrethroid effects on gene expression outlined prior to experimentation.  In addition, these 
data demonstrated that different pyrethroids induce changes in a similar sub-set of activity 
regulated genes and facilitated predictions regarding the activation of intracellular signaling 
cascades and functional effects in neurons downstream of the pharmacological actions of 
pyrethroids at the neuronal membrane.  Finally, one of the functional effects predicted by the 
gene expression studies was confirmed in an in vitro model of neuronal morphogenesis. 
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Mean coefficients of variation for GCOSv1.2 normalized expression summaries 
 
 1-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71-80% 81-90% 91-100% 
 
          
n 3105 3104 3104 3104 3104 3104 3104 3104 3104 3105 
 
          
Control 66.52 57.09 40.99 32.80 28.50 26.69 25.29 24.84 24.33 21.21 
Permethrin           
1 mg/kg 63.15 55.64 41.30 33.61 29.65 29.05 28.67 28.48 28.24 24.44 
10 mg/kg 63.61 55.24 40.35 32.25 27.69 25.73 25.08 24.45 23.72 21.13 
100 mg/kg 61.74 55.51 41.06 33.35 28.94 27.03 26.02 25.35 24.78 22.55 
Deltamethrin           
0.3 mg/kg 61.29 52.91 37.26 28.68 24.00 21.44 19.17 17.85 16.91 14.91 
1.0 mg/kg 61.36 54.54 39.81 31.28 27.01 24.69 23.65 23.00 22.55 19.61 
3.0 mg/kg 63.26 55.61 39.18 32.80 25.77 23.49 21.79 20.53 19.52 17.03 
 
          
Mean coefficients of variation for RMA normalized expression summaries 
 
 1-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71-80% 81-90% 91-100% 
n 3105 3104 3104 3104 3104 3104 3104 3104 3104 3105 
           
Control 7.08 9.99 11.95 13.65 15.05 16.59 18.07 18.45 19.21 16.86 
Permethrin           
1 mg/kg 7.39 10.53 12.77 15.25 17.36 20.03 22.71 23.35 23.80 20.53 
10 mg/kg 6.99 9.68 11.66 13.69 15.40 17.47 19.42 20.21 20.72 18.08 
100 mg/kg 7.01 10.10 12.27 14.41 16.52 18.68 20.99 21.76 22.43 19.46 
Deltamethrin           
0.3 mg/kg 6.08 8.40 9.96 11.42 12.55 13.45 14.33 14.51 14.89 12.84 
1.0 mg/kg 6.66 9.49 11.49 13.34 14.95 16.71 18.55 19.16 19.75 17.70 
3.0 mg/kg 6.53 8.99 10.84 13.65 13.94 15.37 16.58 17.09 17.27 15.29 
 
Appendix A, Table 1.  Comparison of mean coefficients of variation (CV) between GCOSv1.2 and RMA microarray expression 
summaries.  For each expression summary calculation method, all 31,042 probe sets present on the Affymetrix Rat 230 2.0 GeneChip® array were sorted 
based on the mean expression summary within the control group and divided into equally sized percentile ranges in ascending order.  CV’s were calculated for 
each individual probe set within each dose group.  The mean CV for each percentile range was then calculated across probe sets for each dose group.  Expression 
summaries calculated using RMA consistently reduces the variability of the expression summaries across the entire data set when compared to GCOSv1.2.  A 
dramatic decrease in variability is observed in the lower 50% of the data set. 
 
 204
Appendix A, Table 2.  Taqman® qRT-PCR assay information. 
 
  Gene                               Amplicon           Amplification 
Symbol Assay I.D. Reference Sequence      Assay Position*    Length Efficiency (%) 
 
β-actin Rn00667869_m1 CTTCCTTCCTGGGTATGGAATCCTG 4 - 5     exon junction 91 95.2  
Gpd1 Rn00573596_m1 GGGCCTCGTGGACAAGTTTCCCTTG 7 - 8     exon junction 79 92.4  
Fkpb51 Rn01768371_m1 GAGCAGGATGCCAAGGAAGAGGCCA 10 - 11   exon junction 74 91.8 
Camk1g Rn00788224_m1 CATTTCTGAGTCAGCCAAGGACTTT 8 - 9     exon junction 71 96.0  
Hsp27 Rn00583001_g1 TCACCCGGAAATACACGCTCCCTCC 2 - 3     exon junction 136 94.4 
Ddc Rn01401187_m1 TCCGGCTAAAGGGCTCCAACCAGTT 13 - 14   exon junction 102 92.5 
BDNF Rn02531967_s1 AAATTCTTGCTGTGGTCTCTTTTTG exon VIII** 142 97.5  
Rassf5 Rn00571287_m1 GGAGACGTAGAGTGGGATGCCTTTT 5 - 6     exon junction 75 92.4 
c-fos Rn02105433_s1 CTTCAGCGTCCATGTTCATTGTCAT exon 4 160 96.0 
Egr1 Rn00561138_m1 ACGAGCACCTGACCACAGAGTCCTT 1 - 2     exon junction  64 98.0 
_________________________________________________________________________________________________________________________________ 
*taken from Applied Biosystems web-site. 
**determined from Liu et al. Brain Research 1067(1), 1-12 (2006)  
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Appendix A, Figure 1.  Identification of dose-responsive probe sets by linear regression or 
penalized linear (SAM) regression.  Panels A and B are histograms of the number of probe 
sets identified as dose-responsive using either a linear regression (blue bars) or a penalized 
linear regression in SAM (yellow bars) for deltamethrin and permethrin, respectively.  Decile 
bins were defined by ranking probe sets by the mean raw expression summary score across 
all treatment conditions from lowest to highest and dividing the probe sets into equal groups 
(n = 3104 for deciles 2-8 and 3105 for deciles 1 and 10).  Probe sets within each decile that 
were determined to be dose-responsive with each method were counted and plotted in the 
panels.  Note that less probe sets were detected as significantly dose-responsive in the lower 
decile ranges using penalized regression while the number of probe sets identified as dose-
responsive in the upper deciles was similar between the two methods
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Appendix B, Table 1.  Taqman® qRT-PCR assay information. 
 
  Gene                               Amplicon           Amplification 
Symbol Assay I.D. Reference Sequence      Assay Position*    Length Efficiency (%) 
 
β-actin Rn00667869_m1 CTTCCTTCCTGGGTATGGAATCCTG 4 - 5     exon junction 91 95.2  
Gpd1 Rn00573596_m1 GGGCCTCGTGGACAAGTTTCCCTTG 7 - 8     exon junction 79 92.4  
Camk1g Rn00788224_m1 CATTTCTGAGTCAGCCAAGGACTTT 8 - 9     exon junction 71 96.0  
Egr1 Rn00561138_m1 ACGAGCACCTGACCACAGAGTCCTT 1 - 2     exon junction  64 98.0 
Arc Rn00571208_g1 GCCCCCAGCAGTGATTCATACCAGT 1 - 2     exon junction 119 98.8 
Nr4a1 Rn00577766_m1 CGGGAGCCGGCCGGAGATGCCCTGT 1 - 2     exon junction  108 91.1 
Nedd9 Rn01435420_m1 ATCATCAGCTGAGTCAGTTCCAGCT 6 - 7     exon junction 89 90.8 
 
*taken from Applied Biosystems web-site. 
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Appendix B, Table 2. Statistical Analysis of qRT-PCR Data 
  Deltamethrin 
  Two-Way ANOVA 3 h pair-wise 6 h pair-wise 
  F p-value F p-value F p-value 
Nr4a1 TRT 15.15 0.0005 104.81 0.0001 0 0.9476 
 TIME 39.2 0.0001     
 TRT*TIME 40.53 0.0001     
  
      
Arc TRT 9.11 0.0050 46.31 0.0001 0 0.9558 
 TIME 25.16 0.0001     
 TRT*TIME 24.4 0.0001     
  
      
Egr1 TRT 0.28 0.5972 6.45 0.0219 1.36 0.2608 
 TIME 6.58 0.0152     
 TRT*TIME 0.69 0.4115     
  
      
Camk1g TRT 3.95 0.0553 0.16 0.6915 20.68 0.0003 
 TIME 12.98 0.0011     
 TRT*TIME 9.31 0.0046     
  
      
Nedd9 TRT 2.71 0.1094 6.74 0.0195 0.46 0.5060 
 TIME 1.52 0.2267     
 TRT*TIME 5.03 0.0319     
  
      
Gpd1 TRT 6.36 0.0168 154.19 0.0001 21.21 0.0003 
 TIME 127.98 0.0001     
 TRT*TIME 16.71 0.0003     
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Appendix B, Table 2 continued. 
  
Cyfluthrin 
  
Two-Way ANOVA 3 h pair-wise 6 h pair-wise 
  
F p-value F p-value F p-value 
Nr4a1 TRT 9.51 0.0042 31.54 0.0001 0.59 0.4538 
 TIME 18.26 0.0002     
 TRT*TIME 26.17 0.0001     
  
      
Arc TRT 9.23 0.0047 31.77 0.0001 0.44 0.5178 
 TIME 17.85 0.0002     
 TRT*TIME 24.87 0.0001     
  
      
Egr1 TRT 3.48 0.0712 12.13 0.0031 0.01 0.9240 
 TIME 8.02 0.0079     
 TRT*TIME 7.37 0.0106     
  
      
Camk1g TRT 0.14 0.7088 2.2 0.1574 3.91 0.0655 
 TIME 5.15 0.0301     
 TRT*TIME 0.09 0.7627     
  
      
Nedd9 TRT 1.24 0.2734 1.97 0.1794 0.49 0.4934 
 TIME 0.25 0.6173     
 TRT*TIME 2.22 0.1458     
  
      
Gpd3 TRT 3.06 0.0897 36.26 0.0001 2.3 0.1488 
 TIME 27.14 0.0001     
 TRT*TIME 8.92 0.0054     
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Appendix B, Table 2 continued. 
  Cypermethrin 
  Two-Way ANOVA 3 h pair-wise 6 h pair-wise 
  F p-value F p-value F p-value 
Nr4a1 TRT 28.15 0.0001 76.3 0.0001 2.27 0.1511 
 TIME 44.66 0.0001     
 TRT*TIME 68.03 0.0001     
  
      
Arc TRT 13.77 0.0008 30.48 0.0001 2.8 0.1135 
 TIME 19.03 0.0001     
 TRT*TIME 32.77 0.0001     
  
      
Egr1 TRT 10.11 0.0033 29.5 0.0001 0.23 0.6368 
 TIME 15.88 0.0004     
 TRT*TIME 20.95 0.0001     
  
      
Camk1g TRT 0.37 0.5458 3.81 0.0688 2.76 0.1162 
 TIME 6.52 0.0156     
 TRT*TIME 0.38 0.5424     
  
      
Nedd9 TRT 3.79 0.0604 10 0.0060 0.31 0.5853 
 TIME 3.52 0.0697     
 TRT*TIME 7.04 0.0123     
  
      
Gpd3 TRT 0.65 0.4267 17.2 0.0008 1.08 0.3142 
 TIME 11.09 0.0022     
 TRT*TIME 2.8 0.1041     
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Appendix B, Table 2 continued. 
  
Permethrin 
  
Two-Way ANOVA 3 h pair-wise 6 h pair-wise 
  
F p-value F p-value F p-value 
Nr4a1 TRT 0.39 0.5384 16.18 0.0010 3.5 0.0799 
 TIME 17.52 0.0002     
 TRT*TIME 2.48 0.1254     
  
      
Arc TRT 0.04 0.8506 3.76 0.0702 1.36 0.2615 
 TIME 4.95 0.0333     
 TRT*TIME 0.46 0.5018     
  
      
Egr1 TRT 0.13 0.7229 0.54 0.4738 1.83 0.1952 
 TIME 2.26 0.1425     
 TRT*TIME 0.3 0.5875     
  
      
Camk1g TRT 0.18 0.6772 0.07 0.7892 0.33 0.5719 
 TIME 0.02 0.8843     
 TRT*TIME 0.33 0.5712     
  
      
Nedd9 TRT 0.19 0.6693 0.01 0.9251 0.34 0.5660 
 TIME 0.26 0.6121     
 TRT*TIME 0.15 0.6990     
  
      
Gpd3 TRT 0.42 0.5199 4.53 0.0493 0.41 0.5294 
 TIME 0.19 0.6696     
 TRT*TIME 2.45 0.1271     
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Appendix B, Table 2 continued. 
  
Tefluthrin 
  
Two-Way ANOVA 3 h pair-wise 6 h pair-wise 
  
F p-value F p-value F p-value 
Nr4a1 TRT 3.29 0.0792 8.42 0.0104 2.91 0.1075 
 TIME 2.36 0.1346     
 TRT*TIME 11.31 0.0020     
  
      
Arc TRT 3.15 0.0855 5.25 0.0358 4.27 0.0555 
 TIME 1.03 0.3183     
 TRT*TIME 9.02 0.0052     
  
      
Egr1 TRT 3.91 0.0567 4.98 0.0402 2.71 0.1195 
 TIME 1.19 0.2841     
 TRT*TIME 7.61 0.0095     
  
      
Camk1g TRT 0.89 0.3519 2.72 0.1184 0.01 0.9127 
 TIME 1.36 0.2517     
 TRT*TIME 1.73 0.1982     
  
      
Nedd9 TRT 1.68 0.2036 3.08 0.0986 0.13 0.7237 
 TIME 1.33 0.2571     
 TRT*TIME 2.56 0.1195     
  
      
Gpd3 TRT 0.01 0.9324 3.02 0.1014 0.26 0.6196 
 TIME 1.72 0.1985     
 TRT*TIME 0.17 0.6840     
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Appendix B, Table 2 continued. 
  
Bifenthrin 
  
Two-Way ANOVA 3 h pair-wise 6 h pair-wise 
  
F p-value F p-value F p-value 
Nr4a1 TRT 4.15 0.0501 10 0.0060 2.37 0.1428 
 TIME 4.85 0.0349     
 TRT*TIME 12.37 0.0013     
  
      
Arc TRT 2.64 0.1137 3.63 0.0750 5.52 0.0320 
 TIME 0.02 0.8755     
 TRT*TIME 8.92 0.0054     
  
      
Egr1 TRT 1.89 0.1788 0.29 0.6005 5.76 0.0289 
 TIME 1.12 0.2983     
 TRT*TIME 3.61 0.0666     
  
      
Camk1g TRT 0.06 0.8051 0.01 0.9104 0.28 0.6066 
 TIME 0.23 0.6370     
 TRT*TIME 0.11 0.7437     
  
      
Nedd9 TRT 0 0.9710 0.53 0.4780 1.64 0.2180 
 TIME 1.82 0.1871     
 TRT*TIME 0.03 0.8572     
  
      
Gpd3 TRT 0.05 0.8202 0.91 0.3552 0.1 0.7555 
 TIME 0.53 0.4701     
 TRT*TIME 0.03 0.8635     
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Appendix B, Figure 1.  Dimensional reduction of microarray data: effect of mean 
centering on measures of significance.  Panels in the first column of the figure plot raw 
expression summary values for a probe set that has a significant interaction of time and 
treatment in a two-way ANOVA model (Nfkbia, top row), a probe set that has a 
significant main effect of treatment and no interaction of time and treatment 
(2610029k21, middle row) and a probe set with a significant main effect of time and no 
interaction of time and treatment (Ly86, bottom row).  Significant effects observed with 
Nfkbia and 2610029k21 are exemplary of effects considering ‘interesting’ in the present 
study.  Effects of time with no treatment are not of interest.  Panels in the middle column 
are box plots of the expression summaries for each condition in the study before mean 
normalization for Nfkbia, 2610026K21 and Ly68.  Significance values for analysis of the 
four groups with a One-Way ANOVA are listed above the panels.  Note that all three of 
the genes are significant in the one-way ANOVA.  Panels in the far right column are box 
plots of the expression summaries for each condition in the study after mean 
normalization.  Note that the significant effect for Ly68 (bottom right corner panel) in the 
one-way ANOVA model is eliminated.  Also, the two genes with treatment effects in the 
two-way ANOVA still have a significant model p-value in one-way ANOVA.  Numbers 
in italicized type over each box plox are coefficients of variation of the data in each 
group.  The C.V.s do not change following mean normalization.  Mean normalized data 
was used in the SAFE enrichment analyses throughout the present study.   
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